The ELDERMET biobank: Isolation and characterization of  the intestinal microbiota from elderly Irish subjects by Lakshminarayanan, Bhuvaneswari
Title The ELDERMET biobank: Isolation and characterization of  the
intestinal microbiota from elderly Irish subjects
Author(s) Lakshminarayanan, Bhuvaneswari
Publication date 2014
Original citation Lakshminarayanan, B. 2014. The ELDERMET biobank: Isolation and
characterization of  the intestinal microbiota from elderly Irish subjects.
PhD Thesis, University College Cork.
Type of publication Doctoral thesis
Rights © 2014, Bhuvaneswari Lakshminarayanan
http://creativecommons.org/licenses/by-nc-nd/3.0/
Embargo information No embargo required
Item downloaded
from
http://hdl.handle.net/10468/1709
Downloaded on 2017-02-12T10:50:53Z
i  
The ELDERMET Biobank: Isolation and Characterization of     
Intestinal Microbiota from Elderly Irish Subjects 
 
A Thesis Presented to the National University of Ireland for the Degree of 
Doctor of Philosophy 
  
By 
Bhuvaneswari Lakshminarayanan 
 
March 2014 
 
Research supervisors: Prof. Paul Ross, Prof. Paul O’Toole 
and Prof. Catherine Stanton  
 
 
 
 
 
Teagasc Food Research Centre, Moorepark, Fermoy, Co. Cork, Ireland 
 
 
 
 
 
 
 
 
Department of Microbiology, University College Cork, Ireland 
 
 
 
ii  
Table of Contents 
 
ABSTRACT            i 
LIST OF PUBLICATIONS         iV 
GLOSSARY OF TERMS           V 
INDEX OF TABLES         Vii 
INDEX OF FIGURES          iX 
SUPPORTING INFORMATION Xi 
 
CHAPTER 1 
COMPOSITIONAL DYNAMICS OF THE HUMAN INTESTINAL MICROBIOTA WITH AGEING: 
IMPLICATIONS FOR HEALTH                                                                                                          1 
1.1  Abstract ................................................................................................................................... 2 
1.2  Introduction............................................................................................................................. 3 
1.3 Changes and succession of human gut microbiota from infancy to elderly                              3 
1.4 Pathogenesis and alterations in the gut microbiome during intestinal dysbiosis ................... 7 
1.5 Influence of diet on the gut microbiota ................................................................................. 16 
1.6 Analysis of microbiota diversity in the gut ........................................................................... 19 
1.7 Effect of antibiotic therapy on the intestinal microbiota of elderly subjects ........................ 24 
1.8 Modulation of elderly gut microbiota using probiotics, prebiotics and synbiotics ............... 27 
1.9 Conclusions ............................................................................................................................ 31 
1.10 Acknowledgements ................................................................................................................ 32 
1.11 References.............................................................................................................................. 33 
CHAPTER 2 
(A) CORRELATION OF rRNA GENE AMPLICON PYROSEQUENCING AND BACTERIAL 
CULTURE FOR MICROBIAL COMPOSITIONAL ANALYSIS OF FAECAL SAMPLES FROM 
ELDERLY IRISH SUBJECTS ...................................................................................................... 49 
2.1 Abstract ................................................................................................................................. 50 
2.2 Introduction........................................................................................................................... 51 
2.3 Materials and Methods.......................................................................................................... 54 
2.4 Results ................................................................................................................................... 58 
2.5 Discussion .............................................................................................................................. 60 
2.6 Acknowledgements ................................................................................................................ 62 
2.7 References.............................................................................................................................. 63 
 
(B) ALTERATIONS IN INTESTINAL MICROBIOTA OF ELDERLY IRISH SUBJECTS POST-
ANTIBIOTIC THERAPY .............................................................................................................. 69 
2.8 Synopsis ................................................................................................................................. 70 
2.9 Introduction........................................................................................................................... 71 
2.10 Materials and Methods.......................................................................................................... 73 
2.11 Results ................................................................................................................................... 76 
2.12 Discussion .............................................................................................................................. 81 
2.13 Acknowledgements ................................................................................................................ 83 
2.14 References.............................................................................................................................. 84 
 
 
iii  
CHAPTER 3 
TEMPORAL STABILITY OF CULTURABLE BIFIDOBACTERIUM SPP., LACTOBACILLUS SPP. 
AND ENTEROBACTERIACEAE IN ELDERLY IRISH SUBJECTS                                          105 
3.1 Abstract ............................................................................................................................... 106 
3.2 Introduction......................................................................................................................... 107 
3.3 Materials and Methods........................................................................................................ 110 
3.4      Results and Discussion ........................................................................................................ 112 
3.5 Conclusions .......................................................................................................................... 120 
3.6 Acknowledgements .............................................................................................................. 121 
3.7 References............................................................................................................................ 122 
CHAPTER 4 
ISOLATION AND CHARACTERIZATION OF BACTERIOCIN-PRODUCING BACTERIA FROM 
THE INTESTINAL MICROBIOTA OF ELDERLY IRISH SUBJECTS  ................................. 139 
4.1 Abstract ............................................................................................................................... 140 
4.2 Introduction......................................................................................................................... 141 
4.3 Materials and Methods........................................................................................................ 143 
4.4 Results  ................................................................................................................................ 148 
4.5 Discussion ............................................................................................................................ 153 
4.6 Acknowledgments................................................................................................................ 158 
4.7 References............................................................................................................................ 159 
CHAPTER 5 
PREVALENCE AND CHARACTERIZATION OF CLOSTRIDIUM PERFRINGENS FROM THE 
FAECAL MICROBIOTA OF ELDERLY IRISH SUBJECTS ................................................... 173 
5.1 Abstract ............................................................................................................................... 174 
5.2 Introduction......................................................................................................................... 175 
5.3 Materials and Methods........................................................................................................ 177 
5.4      Results and Discussion ........................................................................................................ 183 
5.5 Acknowledgements .............................................................................................................. 190 
5.6 References............................................................................................................................ 191 
CHAPTER 6 
ISOLATION AND MOLECULAR CHARACTERIZATION OF CIPROFLOXACIN RESISTANT 
LACTIC ACID BACTERIA FROM ELDERLY IRISH SUBJECTS ........................................ 203 
6.1 Abstract ............................................................................................................................... 204 
6.2 Introduction......................................................................................................................... 205 
6.3 Materials and Methods........................................................................................................ 208 
6.4 Results and Discussion ........................................................................................................ 211 
6.5 Acknowledgements ............................................................................................................... 215 
6.6 References ............................................................................................................................ 216 
 
DISCUSSION AND OVERALL CONCLUSIONS...................................................................... 223 
REFERENCES ............................................................................................................................. 233 
ACKNOWLEDGEMENTS .......................................................................................................... 236 
 
 
 
 
iv  
 
 
 
 
 
 
 
 
 
 
 
 
ABSTRACT 
 
 
 
 
 
v  
The human gastrointestinal (GI) tract is colonized by a dense and diverse bacterial 
community, the commensal microbiota, which plays an important role in the overall health of 
individuals. This study was an investigation of selected intestinal microbiota, mainly the 
Bifidobacterium and Lactobacilli communities of elderly Irish subjects, using both traditional 
culture-dependent and next generation sequencing technologies. The degree of correlation 
between measurements from both methods (Chapter 2a) suggested that a single method is 
capable of profiling intestinal Bifidobacterium spp., Lactobacillus spp. and 
Enterobacteriaceae populations. However, both methods have advantages that justify their 
use in tandem. 
Antibiotic administration has been associated with profound disturbances of the GI 
microbiota. Chapter 2b evaluates the impact of antibiotic therapy on the composition of the 
intestinal microbiota of a cross-section of elderly Irish subjects, using both culture-dependent 
(plating) and culture-independent (compositional) approaches. Culturable bifidobacterial 
population in antibiotic-treated group decreased 7-fold when compared with the antibiotic-
untreated group and the culturable lactobacilli numbers increased 2.6-fold in antibiotic-
treated subjects. Exploring the impact of antibiotic types revealed that the nucleic acid 
synthesis inhibitors had the most dramatic effect on the levels of Bifidobacterium spp., 
showing a 23-fold decrease. In contrast the cell envelope antibiotics increased the levels of 
Lactobacillus spp. by 10-fold. Therefore, while antibiotics remain an essential medical tool, 
more targeted antimicrobial therapies should be explored to prevent intestinal dysbiosis. 
The temporal stability of the gut microbiota is of importance to host health and consequently 
maintenance of the balance of this bacterial community is desirable. For this reason, the 
stability of culturable Bifidobacterium spp., Lactobacillus spp. and Enterobacteriaceae in 
faecal samples from 65 elderly subjects was monitored over a 6 month period (Chapter 3). 
Unexpectedly antibiotic administration did not result in major perturbations in the counts of 
the 3 bacterial groups. Regular probiotic consumption resulted in a significant increase in 
Bifidobacterium spp. counts by month 6, while there were no alterations in the other 2 
bacterial groups studied. Overall, the studied bacterial groups remained relatively stable over 
a 6 month period; reinforcing a previous study by the ELDERMET team.  
Chapter 4 investigated the isolation of bacteriocin-producing LAB of human intestinal origin 
that may be evaluated for probiotic use. A number of previously characterized bacteriocins, 
including ABP-118 and salivaricin B (from Lactobacillus salivarius), enterocin B 
vi  
(Enterococcus faecium), lactacin B (L. acidophilus), gassericin T and a variant of gassericin 
A (L. gasseri) were identified. Interestingly, two antimicrobial-producing species, not 
generally associated with intestinally derived microorganisms were also isolated: 
Lactococcus lactis producing nisin Z and Streptococcus mutans producing mutacin II. The 
results presented are important due to growing evidence indicating bacteriocin production as 
a potential probiotic trait by virtue of strain dominance and/or pathogen inhibition in the 
mammalian intestine. 
While ELDERMET aimed to enumerate bifidobacteria, lactobacilli and Enterobacteriaceae 
from faecal samples of elderly subjects, the fortuitous isolation of the clinically significant C. 
perfringens at high levels, on medium selective for bifidobacteria, from a sub-set of these 
elderly subjects motivated this spin-off study (Chapter 5). Of 368 faecal samples analysed 
during this study, 28 samples (7.6% of samples from 19 subjects), yielded colonies that were 
atypical of Bifidobacterium spp. on the Bifidobacterium selective medium, which were 
confirmed as C. perfringens using 16S rRNA sequencing. Microbiota profiling revealed some 
significant compositional changes across both the family and genus taxonomic levels 
between the C. perfringens positive and negative data-sets. The isolation frequency of C. 
perfringens from subjects in long-stay residential care with a shedding level in excess of 10
6 
cfu/gram faeces suggest that such a high viable count may be indicative of a less healthy 
microbiota in the intestine of elderly people residing in longstay residential care. 
The selection pressure applied on the bacterial population during antibiotic usage is the 
driving force for the emergence of antibiotic resistant bacteria. Investigation of lactic acid 
bacteria (LAB) isolated from over one hundred faecal samples for their resistance against the 
clinically important antibiotics, ciprofloxacin and amoxicillin (Chapter 6) identified 21 LAB 
isolates with increased ciprofloxacin resistance. The parC and gyrA genes of the quinolone 
resistance determining region (QRDR) for the isolates with increased ciprofloxacin 
resistance, showed no typical mutations in the amino acid codons encoding gyrA. However, a 
single amino acid change in the parC gene was determined. Identification of antibiotic 
resistant isolates opens up the possibility of using such probiotics to offset the problems 
caused by antibiotics to the gut microbiota. 
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CHAPTER 1 
 
 
 
 
 
 
COMPOSITIONAL DYNAMICS OF THE HUMAN MICROBIOTA 
WITH AGEING: IMPLICATIONS FOR HUMAN HEALTH 
 
 
 
 
 
 
 
 
A draft of this chapter has been accepted in  
Journal of Nutrition, Health and Ageing 
B. Lakshminarayanan, C. Stanton, P.W. O’Toole and R.P. Ross 
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1.1 Abstract 
 
The human gut contains trillions of microbes which form an essential part of the complex 
ecosystem of the host. This microbiota is relatively stable throughout adult life, but may fluctuate 
over time with aging and disease. The gut microbiota serves a number of functions including roles 
in energy provision, nutrition and also in the maintenance of host health such as protection against 
pathogens. This review summarizes the age-related changes in the microbiota of the gastrointestinal 
tract (GIT) and the link between the gut microbiota in health and disease. Understanding the 
composition and function of the gut microbiota along with the changes it undergoes overtime 
should aid the design of novel therapeutic strategies to counteract such alterations. These strategies 
include probiotic and prebiotic preparations as well as targeted nutrients, designed to enrich the gut 
microbiota of the aging population. 
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1.2 Introduction 
The human gut is home to a complex ecological system harboring trillions of bacteria which vary 
according to their location in the gastrointestinal tract (GIT). This ecological niche provides an 
excellent site for complex interactions between the host and its microbial inhabitants. Molecular 
methods indicate that there are approximately 1,100 prevalent bacterial species in the intestine with 
as many as 10
12
-10
14 
microorganisms present, of which 70-80% remain uncultured (1, 2, 3, 4, 5, 6). 
In its entirety, the human intestinal microbiota is estimated to contain 150-fold more genes than its 
own host’s genome (7). The mutualistic relationship between the gut microbiota and the human host 
contributes to the maintenance of health and well-being in a number of ways. These include 
protecting the host against colonization of pathogenic bacteria, metabolizing complex 
carbohydrates, producing bioactive peptides and lipids, synthesizing vitamins and hormones and 
stimulating the immune system (8, 9, 10, 11). Reduced proportions of protective bacteria such as 
lactobacilli and bifidobacteria in the gut have been linked to the severity of disorders such as 
inflammatory bowel diseases or colonic inflammation (12, 13). This review summarizes the age-
related changes that occur in the human GIT and makes the link between the bacterial communities 
and human health in an effort to understand the relationship between the two. 
1.3 Changes and succession of human gut microbiota from infancy to elderly 
The establishment of a stable microbial population involves complex processes such as bacterial 
succession and host-microbe interactions (14, 15). The colonization of the microbial population in 
the human gut begins immediately after birth, and results in an unstable composition in infants, 
which then undergoes marked changes until it develops into a relatively stable community in the 
adult (15, 16). The initial bacterial population of an infant depends on a number of factors including 
mode of delivery, feeding type, antibiotic usage and the surrounding environment (17, 18). The 
microbiota of infants delivered by Caesarean (C-) section have been reported to harbour relatively 
4  
lower numbers of bifidobacteria and higher numbers of Clostridium difficile and Escherichia coli 
than infants delivered vaginally (17). Colonization is also delayed in infants delivered by C-section 
when compared to vaginally delivered infants. Not surprisingly, bacteria involved in the initial 
colonization of the gut of vaginally delivered infants were predominated by lactobacilli and 
Prevotella species which have been shown to reflect their mother’s faecal and vaginal bacteria (19). 
Antibiotic administration has also been shown to influence the intestinal colonization in infants, 
whereby antibiotic treated infants have lower numbers of enterococci and lactic acid bacteria (17). 
The diet of a new born is one of the major factors affecting the intestinal colonization and studies 
using molecular techniques showed that the gut microbiota of the breast-fed infants is 
predominantly comprised of E. coli, streptococci and bifidobacteria and the gut microbiota of 
formula-fed babies is predominantly comprised of Bacteroides, clostridia and enterobacteria (17, 
20). Changes to the intestinal microbiota then occur after the introduction of solid food leading to a 
remarkably complex and stable gut microbial population (20). The impact of diet on the gut 
microbiota of European children (1-6 years of age) consuming a Western diet was compared to the 
gut microbiota of children from a rural African village consuming a diet rich in fibre (21). The 
Western diet was associated with reduced microbiota diversity, higher proportions of Firmicutes 
and Proteobacteria and lower proportions of Bacteroidetes and Actinobacteria compared with the 
African diet. 
After several years of development into the typical adult microbiota, the species composition of the 
bacterial community remains relatively stable (14) but can be transiently altered by some extrinsic 
factors (4, 22, 23). While both anaerobic and aerobic bacteria inhabit the GIT (3), the majority of 
genera are composed of anaerobic bacteria such as bifidobacteria, lactobacilli, clostridia, and 
Bacteroides (2). Recent 16S rRNA gene compositional studies had shown that the diversity of the 
healthy adult intestinal microbiota was mostly distributed among the phyla Firmicutes and 
Bacteroidetes followed by Actinobacteria, Proteobacteria and others (24, 25, 26).  
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The composition of the intestinal microbiota in elderly subjects changes from that of healthy adults 
due to factors related to aging, including nutritional behaviour, lifestyle modification, mobility, 
dentition, stress and reduced intestinal functionality (27, 28). Alterations in the gut morphology and 
physiology also occur during the aging process. These include difficulty in swallowing, decreased 
gastrointestinal motility, prolongation of gastric emptying and decline in splanchnic blood flow (28, 
29). The microbial composition in elderly subjects was typically characterized by a decreased 
diversity of bacterial species, including the levels of beneficial bacteria (30, 31). Assessment of the 
gut microbiota of the elderly revealed lower levels of bifidobacteria and lactobacilli and higher 
levels of Enterobacteriaceae and clostridia when compared to younger adults (32, 33). This age 
related breakdown in the balance between the beneficial and detrimental bacteria has been 
associated with an increase in many intestinal inflammatory disorders. Indeed, a healthy intestinal 
microbial population supports human longevity. A recent Italian study supports the hypothesis that 
complex remodeling of metabolism and gut microbiota functionality are the key regulatory 
processes that marks longevity in humans (34). 
Changes in the intestinal microbiota of the elderly may derive from dietary changes, changes in 
immune response, hospitalization, prolonged intestinal transit times, lack of physical activity, 
recurrent infections, and frequent use of antibiotics and other medications (31, 35, 36, 37, 38). The 
most dramatic changes in the composition of the intestinal microbiota in the elderly include 
reduction in numbers and species diversity of Bacteroides and biﬁdobacteria, and increased 
abundance of Ruminococcus, enterobacteria and lactobacilli (30, 32, 39, 40). Interestingly, a high 
level of total presumptive aerobes were recorded in the gut microbiota of elderly when compared to 
the younger adult (41). Isolation of potential pathogens such as Clostridium perfringens and C. 
difficile (causative agent of C. difficile associated diarrhoea (CDAD)) from elderly subjects has also 
been reported (33, 42). 
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The gut microbiota of the elderly has been reported to show different microbial composition and 
greater inter-individual variations compared to younger adults (31, 43). A Finnish study showed 
that members of Firmicutes, Bacteroidetes and Actinobacteria were reported to be more abundant 
in the intestinal microbiota of younger adults compared to the elderly (44). Similarly, Claesson et al 
have also reported that the Firmicutes/Bacteroidetes ratio was lower in elderly people when 
compared to young adults (31). However, Biagi et al did not find significant differences among 
the Firmicutes/Bacteroidetes ratios of Italian centenarians, elderly and young adults (36). 
Age related changes in the intestinal microbial composition have also been shown to be 
location/geography-dependent (45). The intestinal abundance of Clostridium cluster XIVa has been 
reported to decrease in elderly Japanese, Italian and Finnish people (44, 45, 46), whereas an inverse 
trend was noted in elderly German people (45). An increase in the relative abundance of 
Bacteroides group was also observed in the Austrian elderly (47), whereas decreased proportions of 
Bacteroides group were reported in elderly Italian people (45). Benno et al reported that elderly 
Asian subjects had lower levels of bifidobacteria and higher levels of lactobacilli and 
Enterobacteriaceae (48). 
One of the well documented aging effects is the decrease in the prevalence of Faecalibacterium 
prausnitzii, a member of Clostridium cluster IV, as found in the elderly Austrian and Italian 
subjects (36, 45, 47). Analysis of the faecal microbiota of IBD patients previously showed reduced 
numbers of Faecalibacterium prausnitzii (49, 50). A decrease in the Faecalibacterium population is 
also associated with hospitalization and antibiotic therapy (35). The gut ecosystem is dynamic. In 
order to fully understand the human biology in respect to the human microbiota, it is crucial to 
understand the impact of the gut microbiota on the host health. Summarization of the earlier studies 
on elderly has reported a large inter individual variations among older subjects (2, 31, 36). Any 
deviation in the diversity of the intestinal microbiota profile seems to be one of the indicators of 
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aging process and have been reported to be associated with inflammatory disorders. Overall, the 
maintenance of microbial homeostasis in the GI tract is essential for healthy ageing.  
1.4 Pathogenesis and alterations in the gut microbiome during intestinal dysbiosis 
The gut microbiota plays an important role in both human health and disease (51) and a vital role in 
the maturation of host immunity and defence against enteropathogens (52, 53, 54, 55). The stability 
that coexist between the host and the gut microbiota has a profound impact on the human health 
status, in ageing and longevity; as alteration of the intestinal microbiota composition (sometimes 
referred to as “dysbiosis”) (56) is associated with pathogenesis of many diseases, including liver 
disease (57), Inflammatory Bowel Disease (IBD) (58), cancer (59, 60), malnutrition (61, 62), 
diabetes (25) imbalance in the regulation of body weight (63, 64) and several chronic conditions 
including obesity, frailty, sarcopenia and cognitive impairment among others. In addition, changes 
in the diet and lifestyles are also involved in disease manifestation. The changes of gut microbial 
communities during these diseased states are discussed in detail. 
Bowel Diseases 
The absence or low levels of bifidobacteria in the intestine of the elderly may have health 
consequences for the host, such as affecting the immune system or colonization resistance in the 
bowel (39). Irritable Bowel Syndrome (IBS) is an intestinal disorder that is characterized by 
recurrent intestinal pain, diarrhoea and / or constipation with other non-colonic symptoms, which 
includes features such as constant backache, urinary symptoms, non-cardiac chest pain and 
fibromyalgia (65, 66). Abdominal bloating, passage of mucus and faecal urgency are the most 
common features by IBS and are often rated as the worst symptoms by IBS patients (66). Several 
studies have implicated the role of the gut microbiota in immune changes in IBS (67, 68, 69, 70, 
71). 
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Crohn’s disease (CD) and Ulcerative Colitis (UC), are collectively known as chronic inflammatory 
bowel diseases (IBD) of the GIT. Diagnostic methods are the same as for other age groups. It would 
be of benefit to elderly IBD patients to receive proper diagnosis as misdiagnosis in the initial stages 
of IBD are more common, which can explained by the higher prevalence of number of clinical 
conditions that may mimic IBD, particularly ischemic colitis or colitis associated with diverticular 
disease (66, 72). The IBD pathogenesis includes impairment of mucosal barrier function, superficial 
or deep ulcers, rectal bleeding, higher rates of anaemia, electrolyte disturbance and malnutrition, 
which are more common in older patients compared to patients younger than 65 years (73) . 
Crohn’s disease can involve any part of the gastrointestinal tract from the mouth to the anus; 
however, the colon seems to be most affected in the elderly (74). Severity of recurrence after 
surgery is usually common in CD. Depending on the localization and disease extent, the clinical 
picture can be variable and the patients may present with abdominal pain, tiredness, fever, anemia, 
weight loss and symptoms of bowel obstruction (74). Although the initial mortality rate in elderly 
CD patients is similar to that in younger patients, the elderly do show a higher mortality rate few 
years after the onset of CD (72). Ulcerative colitis generally affects the rectum and colon to a 
varying extent, and can be cured by surgery. The pathogenesis involves impairment of mucosal 
barrier function and superficial or deep ulcers. Common features include bloody diarrhea, passage 
of mucous, abdominal pain and sometimes fever (74). Pouchitis is a common complication 
occurring in mostly in the first 10 years of disease (74). 
In general, a large reduction in the microbial diversity was reported in patients with CD, including a 
decline in proportions of Bacteroidetes and Firmicutes (49, 58, 75). Similarly, studies observed the 
disruption of the commensal microbiota in UC, including a decreased proportion of bifidobacteria 
(76), reduction in the proportions of members belonging to the phyla Bacteroidetes and Firmicutes 
(58), decreased levels of F. prausnitzii (50), along with increased Peptostreptococcus species 
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numbers compared to healthy individuals (76) and the occurrence of C. difficile during relapse of 
UC (77). 
Antibiotic-associated diarrhoea (AAD) occurs in 5-30% of patients receiving antibiotic therapy 
(78). The common risk factors include hospitalization, health of the host and exposure to pathogens, 
such as toxigenic C. difficile, a spore-forming gram-positive toxigenic anaerobic bacterium that is 
commonly associated with patients in hospitals and long-term care facilities (42). The overgrowth 
of this bacterial species in the intestinal tract disrupts the normal microbiota leading to 
gastrointestinal illness, decreased digestion, infections including sepsis, perforation of the colon, 
pseudo membranous colitis and sometimes death (79, 80, 81, 82). 
Colon Cancer 
The most common bowel cancer is colon or colo-rectal cancer (CRC),which is the second largest 
cause of cancer deaths in Western countries (83). Colorectal cancer (CRC) is a major source of 
morbidity and mortality in the elderly population with advancing age (84). More likely both colon 
and rectal cancer in the older adults are diagnosed at an advanced stage, which may contribute to a 
decreased survival among this population (85). The standard treatment for advanced colorectal 
cancer includes chemotherapy or combination of therapies, during which the patients experience 
diarrhoea, vomiting, especially neurotoxicity, which can cause functional decline and poorer quality 
of life (86). It has been suggested that both dietary supplements and intestinal bacteria may play a 
role in the initiation of colon cancer through production of carcinogens (87). Results from a human 
study indicated that Bacteroides species (B. vulgatus and B. stercoris) are associated with a higher 
risk of colon cancer (87) and especially with a high-fat diet; mainly because fat stimulates bile flow, 
which in turn is thought to stimulate the growth of Bacteroides species. Other studies have 
supported a similar finding with members of Bacteroides species being shown to convert bile to 
metabolites and fecapentaenes, which are considered co-carcinogenic or mutagenic (88). Studies 
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have observed changes in the bacterial species of individuals that are associated with CRC. Scanlan 
et al. observed that colon cancer patients exhibit a significantly increased diversity and reduced 
stability of clostridia compared to healthy individuals (89). Interestingly, Sobhani et al 
demonstrated (using qPCR) that all the bacterial species belonging to the Bacteroides/Prevotella 
group were more abundant in colon rectal cancer patients than in normal individuals (90). 
Obesity 
The prevalence of obesity is increasing in all age groups. In general, obese individuals with a BMI 
≥ 30 are considered to have a higher mortality risk than do those who are considered overweight 
(BMI: 25.0–29.9) (91). In older adults, obesity can cause serious medical complications, which can 
lead to considerable cardiovascular morbidity, osteoarthritis, hypertension and impaired quality of 
life (91, 92). Increased BMI is associated with an increased risk of knee osteoarthritis and higher 
rates of certain types of cancers including breast, colon, renal and cervical in older population (91). 
Obesity increases the risk of frailty, sarcopenia in older adults (92). Obesity is also a recognized 
contributing factor to urinary incontinence in older population, especially in older women (93). 
Increased abdominal obesity in older people can cause metabolic changes which lead to insulin 
resistance, a key risk factor in the development of type II diabetes (92). Aging causes a progressive 
decrease in renal function and obesity is a significant risk factor for end-stage renal disease (92). 
Increased chest wall stiffness in obese adults may contribute to difficulty in breathing (93). 
On the whole, obesity is a complex and increasingly alarming health issue in humans so it is not 
surprising that obesity-related gut microbiota studies have received a lot of attention in recent years. 
Ley and co-workers characterized the faecal microbiota of 12 obese individuals consuming low 
calorie diets and observed significantly higher proportions of Firmicutes than Bacteroidetes when 
compared to the faecal microbiota of lean individuals (63). This was in agreement with the findings 
by Turnbaugh et al, where they observed individuals with high BMI have decreased proportion of 
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Bacteroidetes compared to lean individuals (64). In contrast, a study by Schwiertz et al showed that 
the obese individuals showed higher proportions of Bacteroidetes compared to lean counterparts. 
They also observed that the concentrations of SCFAs were higher in the obese individuals than the 
lean individuals. The study concluded that rather than the Firmicutes/Bacteroidetes ratio, the 
metabolism of SCFAs might play a considerable role in the development of obesity (94). However, 
these specific changes remain controversial as other studies found no evidence that the proportions 
of Bacteroidetes and Firmicutes are associated with obesity (95, 96). 
Diabetes 
Type-2 diabetes is a metabolic disease associated with insulin resistance and compositional changes 
in the intestinal microbiota. Aging is associated with a reduced ability to metabolize glucose from 
food, which makes type-2 diabetes one of the most prevalent conditions in elderly (97). It is 
considered as the sixth-leading cause of death among the aged population, as it associated with 
increased risk of multiple medical conditions in older adults including cardiovascular events, fatal 
hypoglycemia, dementia and Alzheimer’s disease (98, 99). Hypoglycemia is linked to cognitive 
impairment and incidence of dementia among older population (100). Age related insulin resistance 
appears to be associated with oral and dental issues, sarcopenia, under nutrition due to altered taste 
and smell, swallowing difficulties, hearing impairment (100). 
Larsen and co-workers observed that the proportion of Firmicutes and Clostridium species were 
significantly reduced in diabetic patients compared to non-diabetic subjects (25). In addition, the 
Bacteroidetes/Firmicutes ratio and the ratio of the Bacteroides-Prevotella group to C. coccoides-
Escherichia rectale group demonstrated a positive correlation with plasma glucose concentration 
(25). Recently, a study highlighted that diabetic individuals were characterized by a decrease in the 
abundance of butyrate-producing bacteria and an increase in several opportunistic pathogens, as 
well as an increase in functions relating to oxidative stress response and sulphate reduction (101). 
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Other diseases 
Intestinal permeability and increased bacterial translocation (migration of bacteria from the 
intestinal lumen to mesenteric lymph nodes or other extra-intestinal sites) especially by E. coli, 
Klebsiella, enterococci and other streptococci species are a common complication in patients with 
cirrhosis(102).Other frequent complications observed in these patients include spontaneous 
bacterial peritonitis (an infection of ascitic fluid), urinary tract infections, respiratory tract sepsis 
(pneumonia and spontaneous bacterial empyema) and bacteraemia (102, 103). 
Celiac disease is a chronic inflammatory disorder of the small intestine, where patients show 
permanent intolerance to cereal gluten proteins. The only therapy is adherence to a strict lifelong 
gluten-free diet. Recent studies on healthy adults consuming a gluten-free diet (GFD) have shown 
reductions in beneﬁcial gut bacteria populations (including bifidobacteria and lactobacilli) and 
corresponding alterations in host immunity (104). Similar results were seen in a preliminary study, 
where subjects on a GFD showed decreased populations of beneficial bacteria, while populations of 
E. coli and total Enterobacteriaceae increased. In addition, production of pro-inflammatory 
cytokines and chemokines (TNFα, IFNγ and IL-8) and anti-inflammatory cytokines (IL-10) were 
remarkably reduced as a consequence of the GFD (105). 
Using a combination of flow cytometry, 16S rRNA hybridization and DNA-staining, Vaahtovuo 
and colleagues compared the composition of the intestinal microbiota of patients with early 
rheumatoid arthritis (RA) and fibromyalgia (FM). The RA patients had significantly lower levels of 
bifidobacteria, members of the Bacteroides-Porphyromonas-Prevotella group, B. fragilis subgroup 
and Eubacterium rectale–C. coccoides group when compared to patients with FM (106). 
Although it is clear from the studies described above that the intestinal microbiota are likely to be 
involved in various diseases but is difficult to draw definite conclusions on the role of any particular 
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bacterial groups. Further well-designed studies are required to examine the disease progression and 
outline the link between the gut microbiota and various health measures. 
Geriatric syndromes 
It has been suggested that decreased levels of SCFA production by the gut microbiota of older 
people may contribute to the onset of some distinctive conditions such as frailty, malnutrition, 
diabetes and sarcopenia (107). Frailty can be generally defined as state of decreasing reserves to 
functions in the elderly such as mobility, physical fitness, comorbidity, hearing, weight loss and 
vision and stress factors (108). Frailty in older men is associated with poor health conditions, less 
cognitive function and greater mortality (109). It is typically a multisystem impairment and its 
prevalence advances with age. Serum levels of IL-6 and CRP have shown to be elevated in the 
community-dwelling frail older adults (110).  
Cognitive decline occurs at varying degrees in older adults (111). The basic cognitive functions 
most affected by age are attention and memory. The other factors associated with cognitive aging 
include hypertension, diabetes mellitus, and dietary factors such as vitamin D deficiency (112, 113). 
The study conducted by Barnes et al included women aged 65 and above being assessed for 
cognitive function of a 15 year period. About 9 % maintained optimal cognitive function, 58 % 
showed minor decline and 33 % experienced major decline. The group with optimal cognitive 
function was shown to have access to a positive social network, lack of diabetes, lack of 
hypertension and have moderate alcohol consumption (113). Maintaining a balanced diet, regular 
exercising have been considered as protective factors for cognitive decline related to aging (112). 
Sarcopenia is an important syndrome characterized by progressive loss of skeletal muscle mass and 
strength, which occurs as a consequence of aging and is usually associated with decreased motility 
and poor physical inactivity (114). IL-6 is shown to be strongly associated with adverse physiologic 
effects such as sarcopenia, loss of weight and increased susceptibility to infections (110). 
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Nutritional supplementation in particular dietary protein intake is relevant for the maintenance of 
this condition (114).  
Immune disorders 
The survival of the host against the effects of pathogenic microbes depends on the protective 
immune system. Aging is a complex process that negatively impacts the functionality of the 
immune system resulting in a low-grade inflammatory status often referred to as inflamm-aging 
(115). This causes a persistent inflammation of the intestinal mucosa, increased susceptibility to 
diseases such as type-2 diabetes, sarcopenia, arthritis, osteoporosis and Alzheimer’s diseases (116). 
The high prevalence of cardiovascular risk factors and morbidity increases with age and 
significantly contributes to the higher circulating levels of proinflammatory cytokines in older 
people (117). Increased levels of proinflammatory cytokines including interleukin-6 (IL-6) and C-
reactive protein (CRP) can influence Alzheimer’s disease and mortality in the elderly (118). It has 
been shown that higher production of IL-10 has a significant influence in the attainment of 
longevity (119). Immunosenescence (deterioration of the immune system) may lead to significant 
biological changes in the elderly population (115, 120, 121), which are detailed in Table 1. 
The aging process also affects innate immunity, with a reduction in the levels of natural killer (NK) 
cells and phagocytes making the elderly more prone to infections (122, 123). In this respect, the 
composition of the commensal microbiota may be disrupted which may favour the growth of 
opportunistic pathogens (pathobionts) (124). Aging has been shown to be associated with reduced 
antigen-specific IgA antibody responses (125), involuntary weight loss (126), diminished ability to 
generate high affinity antibodies after immunization (120), reduced secretion of IL-7, an essential 
cytokine for development of lymphocyte responses and altered composition/type of lymphocytes in 
the spleen and lymph nodes (121). 
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In healthy human intestine, a fine homeostatic balance exists between the immune cells and the gut 
microbes (127). The interaction of an altered microbiota could contribute to maintaining a low-
grade, systemic inflammation (128). The aged gut microbiota enriched in facultative anaerobes 
including streptococci, staphylococci, enterococci, and enterobacteria (often classified as 
pathobionts) and depleted in immune modulatory species belonging to the Clostridium clusters IV 
and XIVa are hypothesized to contribute to the development of an overall pro-inflammatory profile 
(107). 
In this context, in a recent study a comparison of aged microbiota between community-dwelling and 
long-stay individuals showed that the microbiota of people in a long-stay care environment had a 
high proportion of Bacteroidetes, whereas individuals living in the community had a high level 
of Firmicutes (37). Levels of clinical markers such as IL-6 and IL-8 and C-reactive protein (CRP) 
were significantly high in long-stay subjects than in community dwellers expressing the status of 
systemic inflammation In addition, metabolome data suggested that changes in gut microbial 
populations are responsible for an altered production of short-chain fatty acids, which was more 
pronounced in community group than in long-stay subjects. Taken together, the major trends in the 
microbiota that separated healthy community subjects from less healthy long-term care correlated 
with increased frailty, inflammation and other clinical markers (37).  
Fermentation of non-digestible prebiotic substances by certain anaerobic bacteria accounts for the 
production of short chain fatty acids (SCFA), in particular butyrate, acetate and propionate. In aged 
people, reduction of butyrate levels was correlated with decreased amounts of F. prausnitzii, and 
bacteria belonging to the E. rectale/Roseburia group, which are butyrate producers. Therefore, the 
decrease of anti-inﬂammatory SCFA-producing bacteria may lead to an easier entry of pathogens 
into the intestinal mucosa, especially Enterobacteriaceae, which has been positively correlated with 
the serum levels of two proinflammatory cytokines in old Italian people (36). It has also been 
demonstrated that the level of Bifidobacterium species is negatively correlated with the serum levels 
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of the pro-inflammatory cytokine TNF-α and the regulatory cytokine IL-10, indicating that the 
modulation of the faecal Bifidobacterium microbial population may represent a mean of influencing 
the inflammatory responses (129). Although, it seems plausible that the intestinal microbiota play 
an important role in regulating the inflammatory and immune responses, more studies are required 
for a better understanding of the intricate relationship between the human gut microbiota and the 
gut immune cells in the elderly.  
1.5 Influence of diet on the gut microbiota  
Dietary habits are considered as one of the major factors that influence the intestinal microbiota 
composition in human studies (21, 37) and animal models (130) and this review provides a link on 
the changes in the gut microbiome of elderly and other subjects based on diet. The study by De 
Filippo et al indicated that both the composition and the fermentation pattern of the gut microbes 
were influenced by diets rich in dietary fibre. The African children had significantly higher levels of 
Actinobacteria and Bacteroidetes, which possess enzymes that encode for hydrolysis of complex 
polysaccharides. Furthermore, higher abundance of Enterobacteriaceae, Prevotella and 
Xylanibacter species that possess enzymes required for cellulose hydrolysis were found in the 
African children which were absent from the European population (21). The authors postulated that 
the microbiota of the rural African population allow them to maximize energy extraction from the 
consumed fibre rich diet.  
A more recent molecular study by our ELDERMET consortium compared the dietary pattern and 
faecal microbiota of elderly community-dwelling subjects (consuming diet rich in fibre but low in 
fat) and elderly subjects in long-term residential care (consuming diet low in fibre but rich in fat). 
Those in long-term care had a less diverse microbiota with a higher proportion of the phylum 
Bacteroidetes, while the microbiota of community subjects exhibited a far greater level of diversity 
with a higher proportion of phylum Firmicutes. The microbiota of the community-dwelling subjects 
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had an abundance of bacteria from the genus Prevotella, similar to the rural Burkina Faso children 
(21), confirming the association between carbohydrate rich diet and the genus Prevotella (37). 
Notably, the microbiota of elderly in long-term care was significantly less diverse and a loss of the 
community-associated microbiota correlated with increased frailty and progression of disease in 
older people and hence indicates the relationship between diet, gut microbiota and the health status 
among the elderly (37). 
In the same context, van Tongeren and colleagues assessed the faecal microbiota composition of 23 
elderly volunteers (median age of 86 years) living in the same environment and receiving similar 
diet. Based on the Groningen Frailty Indicator, the subjects were stratified into two groups, 13 
subjects with low frailty score and 10 subjects with high frailty score. More differences in faecal 
microbiota composition were observed between elderly subjects with low and high frailty scores. 
Statistically significant reduction was seen in the number of lactobacilli (26-fold), F. prausnitzii (4-
fold) and Bacteroides/Prevotella group (3-fold) were seen in the high frailty volunteers. In contrast, 
members of Enterobacteriaceae showed a 10-fold increase in high frailty group (131). 
Diet and dietary patterns fluctuate over time, especially in older life, and can be modulated by 
mobility, appetite, taste and smell. Malnutrition is considered as one of the major factors leading to 
reduced immune responses in all ages of people (132). Both amino acid and protein deficiencies has 
been associated with impaired cellular immunity and decreased antibody response respectively 
(132). Gastric atrophy or Helicobacter pylori infection in the elderly has been associated with the 
malabsorption of vitamin B12 (133). A nutritionally-imbalanced diet may result in reduced 
mastication and taste sensation (134), coupled with dysphagia (135). Constipation, a common 
problem with advancing age, may be associated with inappropriate diet, depression, decreased 
physical activity resulting from chronic diseases and multiple medications (136, 137). Constipation 
maybe readily improved by laxative intake or by non-pharmological measures including increased 
fluid and fibre intake, consumption of legumes, fruits and vegetables (137). 
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Diet appears to be the main environmental modifier for microbiota composition. It has been shown 
by Wu et al that dietary protein and animal fat favour the growth of Bacteroides while carbohydrate 
is associated with increase in Prevotella (138). Diets rich in fat result in a phylogenetic shift in the 
intestinal microbiome associated with obesity (139). Diets low in vegetables but rich in fat and 
processed meat have been shown to be associated with the increase the faecal excretion of N-nitroso 
compounds, a promoter of colon cancer (140). A low fibre diet and low levels of calcium and 
selenium may also relate to the incidence of colonic diseases (141). 
Diet influences metabolism of the bacterial species and specific items in the diet may have selective 
effects in the microbiota, which may be important for host health, irrespective of their age. It is been 
suggested that reducing the intake of food items rich in sulphur containing amino acids (such as 
cheese and eggs) from the diet of UC patients resulted in substantial therapeutic benefits (142). The 
ingestion of sulphur-rich food encourages the production of sulphide, which can damage the colonic 
mucosa by inhibiting butyrate oxidation- this is a characteristic defect in UC patients (142). Dietary 
protein may also reach the colon undigested and is then fermented by the gut microbiota to produce 
end products including ammonia, indoles, cresol and phenols, which favour the growth of malignant 
cells and may play a role in the etiology of bladder and bowel cancer (143). In contrast, a high-fibre 
diet was shown to lower urinary phenol and cresol concentrations in humans (144). 
Kruis et al observed that a high-sugar diet (165 grams/day) prolonged the gut transit time and 
significantly increased the fermentative colonic bacterial activity and concentration of intestinal bile 
acids in the human colon (145). De Palma and co-workers observed that GFD could contribute to a 
reduction in pro-inﬂammatory signals (TNF-α, interferon-γ, IL-10 and IL-8) which was associated 
with modiﬁcations in the microbiota composition. These include decreased levels of bifidobacteria 
and lactobacilli and increased levels of E. coli (104).  
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1.6 Analysis of microbiota diversity in the gut 
The complexity of the microbial communities in the human gut makes their study challenging. 
Traditionally, the composition of the gut microbiota was analysed using culture based techniques. 
Molecular approaches have opened a new window to explore and understand the composition of the 
intestinal microbiota (146). 
Metagenomic approaches for analyzing the gut microbiota 
Until a decade ago, research on the intestinal microbiota relied on the use of culture dependent 
methodologies. Triggered by a growing awareness that only certain microbial species can be 
cultured under standard laboratory conditions, various molecular methods have been evaluated 
depending on the rationale of the scientific study. These include Polymerase Chain Reaction (PCR) 
(147), real-time PCR or quantitative PCR (qPCR) (148, 149), Fluorescent in situ hybridization 
(FISH) (45, 150),  DNA microarrays (151), dot-blot hybridization (152) and metagenomics . 
Various functional microbiomic approaches, such as metabolomics, metaproteomics and 
metatranscriptomics has allowed an in-depth analysis of the microbial communities and their 
metabolic outputs/consequences (153, 154, 155, 156). 
The most employed and accepted molecular marker gene for bacterial classification and 
identification is the 16S ribosomal RNA gene, which is conserved in all eubacteria, and is of 
reasonable size (approximately 1.5 kb) for comparative sequence analysis. The diversity of the 
gastrointestinal microbiota can be thoroughly characterized using a full-length 16s rRNA 
sequencing (Sanger sequencing) method. The PCR technique is a widely used technique, which 
involves the amplification of the target DNA sequence using oligonucleotide primers. The 
amplified DNA fragments can then be visualized using agarose gel electrophoresis (157). The 
technique where the DNA amplicon resulting from the PCR reaction can be digested using 
restriction enzymes resulting in fragments of different sizes is referred as Restriction Fragment 
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Length Polymorphism (RFLP). This approach has been used to measure variations within the 
microbial communities among individuals (158).  
Real-time or qPCR is another molecular biology tool, where the targeted DNA molecule of specific 
bacteria present in a bacterial community is simultaneously amplified and quantified. It is also the 
method of choice for rapid determination of bacterial number for microbiome sampling. 
Quantification is done using fluorescence-labelled group or species specific probes or DNA binding 
dye (ethidium bromide) (159). The fluorescence or dye intensity is proportional to the concentration 
of the target DNA, which depends on the prevalence of the target bacterial species. Molecular 
fingerprinting techniques that combine PCR-amplification of 16S rRNA gene and separation of 
amplicons using Denaturing Gradient Gel Electrophoresis (PCR-DGGE) have been successfully 
proven to analyse variations in the microbial community (160), while dot blot hybridization 
employs labelled oligonucleotide probes targeting the 16S rRNA gene, to measure the abundance of 
particular taxa (159). Using specific fluorescence probes (in situ hybridization) or primers (qPCR), 
quantitative analysis of the bacterial population can be achieved. FISH has been widely used to 
target different bacterial groups. A study by Mueller et al analysed the faecal microbiota using a set 
of group and species specific 16s rRNA targeted probes by FISH coupled to flow cytometry (45). 
Fluorescein-labelled oligonucleotide probes that target the 16S rRNA genes are frequently used for 
FISH analysis. Each probe is specific to a particular group of bacteria. The advantage of flow 
cytometry includes its high-speed process and accuracy and that there is no requirement for DNA 
extraction or amplification. The bacterial cells are fixed in a liquid and hybridized with fluorescein 
labelled antibodies or probes or stained with DNA-binding dye. Another promising quantitative 
technique that is used to study the bacterial composition is real-time PCR, which exhibits an 
increased numeric accuracy in comparison with the FISH technique (161).   
Temporal temperature gradient gel electrophoresis (TTGE), temperature gradient gel 
electrophoresis (TGGE) and DGGE are related methods that have been widely used to determine 
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the identity of bacterial species present in the complex intestinal microbial communities without the 
need for sequence information (14, 162). The amplicons become denatured according to their GC 
content during gel migration. In TGGE and DGGE, a temperature gradient and denaturing gradient 
of urea and formamide are used, respectively for separation of DNA fragments (163). More 
recently, microarray technology is being used to study the diversity of microbial ecosystems. DNA 
microarray technology is a multiplex technology consisting of an arrayed series of thousands of 
probes which determine relative abundance of nucleic acid sequences in the target. This quantitative 
technique has been used to investigate the profile of the infant gut microbiota  (164) and the genes 
involved in carbohydrate metabolism (165). 
In general, DNA sequencing is the most powerful method for the identification of gut microbial 
composition (2) and has transcended all other techniques. The technology has developed further 
using next generation sequencing to study complex microbial communities (7). High throughput 
sequencing technologies (also known as next generation sequencing) includes three platforms that 
are presently widespread: the Roche/454, Illumina and SOLid (Applied Biosystems) (166, 167). 
The Roche-454 platform is based on pyrosequencing chemistry, which provides 100 fold higher 
throughput than Sanger sequencing targeting amplicons of the highly variable regions of the 16s 
rRNA gene (e.g. V2, V3, V4 or V6 regions) using bar-coded primers (168). Pyrosequencing has 
revealed in-depth information on the ecological impact of antimicrobial agents on the human 
intestinal microbiota (169). In a relatively new 454 pyrosequencing technique, parallel sequencing 
of a large number of templates can be performed without need for cloning. The illumina sequencing 
platform has been applied to metagenomic analysis, which produces read length of 100 bases 
(HiSeq system) to 150 bases (MiSeq system) (168, 170). The new technologies are evolving all the 
time and are helping to open new areas of research, including the investigation and characterization 
of microbial diversity and identification of variation in the complex genomes.  
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Conventional methods and molecular methodologies 
Historically, culture-based approaches have provided significant contributions towards the 
understanding of gut microbiology. The advantages of culture dependent methods include reduced 
cost, enumeration of the bacterial populations and the possibility of performing various biochemical 
and physiological tests on the isolated strains (e.g. assessing antimicrobial production, inhibitory 
spectrum, antibiotic susceptibility testing and ability to utilize different substrates). However, these 
culture-dependent methods have several drawbacks in that they are laborious, time-consuming and 
technically challenging (171). Reasons for such cultivation problems include inherent limitations 
related to issues with the growth of the bacterial species, the selectivity of the media and stress 
factors (159). In addition, the nutritional interdependence of different species present in the human 
intestine makes the quantification by culture technique an inaccurate reflection of the available 
population. Nevertheless, traditional methods may not decline in usage in the future, as there is a 
need for the in-depth study of the physiology of particular bacterial isolates, which cannot be 
achieved without pure bacterial cultures.  
To circumvent the limitations associated with culturing, molecular methodologies have accelerated 
progress by enabling the rapid simultaneous analysis of the complex intestinal microbiome (171, 
172). Undoubtedly, one of the major advantages of these methods is its independence of variations 
in the growth conditions of the microbes. These techniques allow a high throughput approach to 
samples processing and exhibit various levels of discriminatory power from phylum to species 
level. As mentioned, the 16S rRNA gene is the predominant basis for phylogenetic determination; 
however, the ribosomal sequences may not be divergent enough to allow robust discrimination of 
species of the same genus (173). Most PCR-based methods, however, fail to reveal the ratio 
between the live and dead bacteria, as the amplification is dependent on intact nucleic acid rather 
than viable cells  (174). The method may induce bias in relation to the primers used. It should also 
be emphasized that the results achieved with these molecular approaches are significantly 
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influenced by the efficacy of the protocol for the extraction of the genetic material from samples, as 
even a DNA contaminant may serve as a PCR template (175).  
The major issue when using DGGE or TGGE is that the species diversity may be underestimated; in 
that a single band can represent more than one strain due to incomplete separation of amplicons 
(176). Disadvantages of FISH are its low sensitivity and that only few probes can be used per 
analysis (177). In addition to low sensitivity, flow cytometry analysis is limited mostly to liquid 
samples. qPCR has provided insight to the microbial community by amplifying and simultaneously 
targeting DNA molecule of  specific bacterial group (25). One of the major limitations of qPCR 
using bacterial 16S rRNA is the presence of multiple copies of 16s rRNA in their genome resulting 
in either under or over estimation of the targeted taxa concentration. Also, the numbers of microbes 
quantified do not represent only viable microbiota as the primers and probes amplify DNA of all the 
cells present which can lead to an inaccurate viable count. In addition, there can be a question of 
specificity in relation to the primers and probes used. Although the technological improvement in 
the sequencing field has made a huge impact on microbial genetics, it still has its limitations. One of 
the major limitations of the available metagenomic approaches is that the composition of the 
predominant bacterial community is host specific (14). Also, it is an expensive approach and quiet 
challenging as the analysis of the complex data generated is far from easy and so requires extensive 
bioinformatics skills for the relevant representation of the complete microbiome (178). Comparative 
analysis of both culture dependent and culture independent techniques is presented in Table 2. 
Technologies continue to improve and the culture independent methods are particularly useful to 
establish the composition of the gut microbiota by identifying bacterial species that are present in 
the GI tract at relatively low abundance and difficult to culture. The shift from culture dependent 
methods to these molecular approaches has resulted in rapid growth in the field of GIT microbiota 
research. 
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1.7 Effect of antibiotic therapy on the intestinal microbiota of elderly subjects 
While the development of antibiotics has lengthened the lifespan of humans, their use has led to a 
pervasive impact on the gut microbiota for a long period of time, sometimes up to one or two years, 
depending on the antibiotics used (179). Antibiotic therapy for the main part drastically alters the 
composition of the microbiota and can provide a pathway for the proliferation of pathogens. The 
intensity of the impact on the commensal bacteria depends on the antibiotic type, dosage, route and 
duration of therapy (180). 
Assessing the temporal changes in the gut microbiota due to administration of broad spectrum 
antibiotics is one of the emerging fields of research and is a target for highly sophisticated 
molecular techniques. Several studies have demonstrated the long-term ecological impact on the gut 
microbiota of antibiotic therapy (181, 182). Dethlefsen et al demonstrated that a short course of the 
antibiotic ciprofloxacin (member of the Fluoroquinolones) reduced the diversity and abundance of 
the intestinal microbiota with significant effect on about one-third of the bacterial taxa (26). 
Although the majority of the bacterial community returned to the pretreatment state within a period 
of four weeks, failure of several other species to recover demonstrated the permanent damage and 
changes caused by antibiotic therapy (26). In another study, the impact of the same antibiotic on 3 
individuals was assessed over a 10 month period. The study highlighted that the microbiota 
response varied across the subjects with reduced diversity among the microbial population in all 
subjects. This diversity was restored following the completion of antibiotic treatment to the point 
that they had stabilized by end of the study (183). Using molecular approaches, Donskey et al have 
also demonstrated the disturbances in the gut population due to administration of different 
antibiotics (184). The study indicated that the anaerobic microbiota was minimally affected by 
ciprofloxacin but markedly reduced by clindamycin therapy. 
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It is important to understand the need for antibiotics in the elderly, in particular those living in long-
term care facilities, as these vulnerable people are more prone to bacterial infections due to 
immunosenescence and compromised health. In the process of eliminating the pathogenic microbes, 
the antibiotic therapies extend their effect to the gut microbiota as a whole, leading to unintentional 
dysbiosis. Several studies have looked at the impact of antibiotics on the intestinal microbiota in the 
elderly. Antibiotic therapy decreased the proportion of Desulfovibrio and Faecalibacterium species 
(35) along with increasing levels of Lactobacillus species (185). Recently, Claesson et al 
investigated the overall impact of antibiotic administration on the gut microbial composition of the 
elderly and revealed that antibiotic therapy reduced proportions of Firmicutes and Proteobacteria 
and increased the proportion of Bacteroidetes (31). Bartosch et al also reported a 2.5-fold decrease 
in the Bifidobacterium species in elderly hospitalized subjects receiving antibiotics compared to 
those not on antibiotics (35). 
As a consequence of the potential damaging effect of the antibiotics, a number of investigations 
have focused on the introduction of antimicrobials over classical antibiotics that can cause less 
collateral damage. One such potent narrow spectrum antimicrobial peptide is Thuricin CD, a 
recently identified bacteriocin produced by Bacillus thuringiensis, which is specifically active 
against C. difficile (186). The efficacy of broad spectrum antimicrobials, such as vancomycin, 
metronidazole, lacticin 3147 and the Thuricin CD bacteriocin, on the gut microbiota composition, in 
particular C. difficile was demonstrated in a human distal colon model (187). The introduction of 
broad spectrum antibiotics resulted in a major disturbance in the overall population with a dramatic 
proportional increase in Proteobacteria and Enterobacteriaceae and a decrease in the numbers of 
Bacteroidetes and Firmicutes. In contrast, the introduction of the Thuricin CD bacteriocin caused 
no significant alterations in the relative proportions of the dominant microbial population but had 
potent anti-C.difficile activity.  
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Another major concern with the use of antibiotics is the emergence of antibiotic resistant bacteria, 
and the potential transfer of antibiotic resistance genes to pathogenic bacteria (182, 188). Bacterial 
resistance to antimicrobial agents can be either intrinsic (inherent or natural) or acquired. The 
microbes develop intrinsic resistance by altering the target sites to avoid binding of the antibiotic or 
by decreasing the permeability of their cell walls and/or developing efflux pumps to pump out the 
antibiotic. In acquired resistance, the microbes acquire genes to produce different enzymes, such as 
beta-lactamases which deactivate the beta-lactam ring of penicillin. Treating the rapidly emerging 
antibiotic resistant bacteria, especially the hospital acquired microbes, is becoming more 
challenging (189). S  lund et al demonstrated that all Enterococcus species isolated immediately 
after treatment with clarithromycin had high level resistance to the antibiotic due to the presence of 
the ermB gene. It was also observed that resistant enterococci persisted for one to three years even 
after treatment in 3 patients (190). 
The frequency and severity of infectious diseases are higher in older people compared to younger 
individuals (189). In this respect, antibiotic administration is the cause of profound disturbances in 
the indigenous bacterial population which undoubtedly lead to compromised colonization 
resistance, causing adverse effects including AAD (191), unintentional state of dysbiosis (56), risk 
of CDAD especially in elderly hospitalized patients (42, 192, 193), bowel dysfunction (194), 
intestinal malabsorption (195), nephrotoxicity, ototoxicity, seizures, skin rashes, nauseas, 
abdominal cramps, renal dysfunction and acute liver injury (196, 197). The mechanism of action 
and the adverse effects of different antibiotics are presented in Tables 3 and 4, respectively.  The 
benefits of antibiotic usage is straight-forward, nevertheless negative impacts like the promotion of 
antibiotic resistance and disruption of the ecology within the gut are quiet common. Antibiotic 
alternatives are an active area of research in terms of developing new approaches. The use of 
prebiotics and/or probiotics could be a promising effect in restoring impaired functions or 
enhancing desirable functions of the microbiota.  
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1.8 Modulation of the elderly human gut microbiota using probiotics, prebiotics and synbiotics 
The increased prevalence of diseases and disorders associated with the gut microbial imbalance due 
to factors such as dietary habits, lifestyle and drug usage can be modulated through supplementation 
with probiotics, prebiotics or synbiotics. 
Probiotics 
Probiotics, a term derived from the Greek meaning ‘for life’, are defined as “live microorganisms, 
which, when consumed in adequate amounts, confer a health benefit on the host” (198). The most 
promising probiotics include organisms of the genera Lactobacillus, Bifidobacterium, Lactococcus, 
Streptococcus and non-pathogenic yeasts. Probiotic strains should be natural inhabitants of the host 
species and have some of the following properties, technologically suitable for industrial processes, 
acid-fast and bile-fast, viable, adhere to the gut epithelial tissue, modulate immune responses (199, 
200), regulate cytokine secretion and produce antimicrobial substances such as bacteriocins (201, 
202). A number of mechanisms have contributed to the health benefits of probiotic bacteria, 
including production of SCFAs, vitamins, bioactive peptides, bacterial-host signalling molecules, 
antimicrobial substances and triggering the immune response (200, 203). 
Prebiotics 
The term prebiotic was first introduced by Gibson and Roberfroid in 1995 and are defined as “a 
non-digestible food ingredient that beneficially affects the host by selectively stimulating the 
growth and/or activity of one or limited number of bacteria in the colon, and thus improves the 
health of the host” (204). Prebiotic usage avoids the drawbacks of using probiotic bacteria, such as 
maintaining viability during storage or en route to the intestine (204). Prebiotics of proven efficacy 
and commercially available are lactulose, galacto-oligosaccharides (GOS), fructo-oligosaccharides 
(FOS) and inulin, of which the last two are the most studied and well recognized (204). These 
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carbohydrates, when fermented by gut bacteria can serve as energy sources for the intestinal 
epithelial cells. Through stimulation of bacterial growth and fermentation, prebiotics can influence 
many aspects of bowel functionality (205). 
Health benefits of probiotics and prebiotics in elderly 
Probiotic intervention is a promising dietary approach for exerting health benefits such as 
prevention of ADD (206, 207), restoring the intestinal population in IBS patients (208) and 
enhancement of intestinal immunity (209, 210, 211). Probiotics have been considered as a 
promising approach to modify the gut microbiota and its overall functions for decades (212). Sood 
and colleagues reported that the probiotic preparation VSL#3 reduced UC symptom severity in 
some patients and induced remission in patients with mild-to-moderately active UC (213). 
Lactobacilli and bifidobacteria are well known for their beneficial effects as probiotics in human 
health and can cause significant improvements in providing longevity and alleviation of age related 
disorders. As a key member of the intestinal microbiota, bifidobacteria were shown to inhibit the 
growth of enteric pathogens and may prevent gastroenteritis in humans (214). Supplementation with 
Bifidobacterium strains have been shown to increase the levels of health-promoting bacteria in the 
elderly (215, 216). Some strains of the genus Bifidobacterium exhibit powerful anti-inflammatory 
properties by restoring appropriate cytokine production (217). Certain members of the genus 
Bifidobacterium have been involved in functional foods, conferring health-promoting effects, in 
particular reduction of chronic inflammatory diseases including UC and Pouchitis, reducing 
symptoms of allergy and lactose intolerance (218). A Finnish study has shown an increase in the 
frequency of bowel movements in elderly nursing home residents with natural food supplies 
containing the two probiotic strains, B. longum and B. lactis (219). Intervention studies with B. 
lactis HN019 have also shown positive effects on the immune system of the elderly, such as 
increased phagocytic activity and number of NK cells (209, 220).  
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A more recent study demonstrated that one-month consumption of a probiotic biscuit, containing 
mixture of two probiotic strains, B. longum Bar33 and L. helveticus Bar13 was effective in not only 
restoring some of the age-related dysbiosis of the intestinal microbiota but also reverted the age-
related increase in the opportunistic pathogens Clostridium cluster XI, C. difficile, C. perfringens, 
E. faecium and Campylobacter (221). Probiotic supplements containing lactic acid bacteria such as 
L. rhamnosus and L. acidophilus has been shown to alleviate constipation in aging people (222, 
223). A randomized control study also demonstrated that dietary supplementation with L. casei DN-
114001 in elderly subjects for three weeks showed potential for a 20% reduction in the duration of 
‘‘winter infections’’ (gastrointestinal or respiratory) compared to the controls (224). 
Elderly people may be regarded as immune compromised due to their decreased ability to fight 
infections- this is one of the main targets for researchers to develop strategies that can boost their 
immunity level (225). Probiotic intervention is a potential nutritional approach to modulate immune 
functions in the elderly population. The probiotic strains Lactobacillus rhamnosus HN001 and B. 
lactis HN019 have improved innate immune functions in elderly subjects (226, 227). Recent studies 
have demonstrated that the consumption of probiotic cheese containing L. rhamnosus HN001 and L. 
acidophilus NCFM by elderly volunteers resulted in significantly enhanced innate immune function 
(228) and modified subpopulations of faecal lactobacilli and C. difficile (229). Some probiotics are 
able to increase the activity of NK cells (230) especially in those habitual smokers affected by 
decreased NK cell activity (231). Other studies addressing the use of specific probiotic strains and 
their involvement in improving the host health are shown in Table 5. 
Prebiotics have been shown to exert beneficial effects on host health by minimizing the disruption 
to the baseline gut bacterial community. Guigoz et al reported an increase in levels of faecal 
bifidobacteria accompanied by a significant rise in total lymphocyte counts in a group of frail 
elderly subjects treated with the prebiotic FOS for three weeks (232). Kleessen et al found that the 
intake of unabsorbed carbohydrates such as inulin improved constipation in elderly and 
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significantly increased the bifidobacterial population (233). Consumption of the prebiotic mixture 
trans-galacto-oligosaccharide (B-GOS) showed a beneficial effect, by significantly increasing the 
level of bifidobacteria and the immune response in healthy elderly volunteers (234). Similarly, a 
four week ingestion of short chain fructo-oligosaccharides (scFOS) significantly increased the 
levels of faecal bifidobacteria in healthy elderly volunteers (235). A progressive increase in inulin 
ingestion from 20 grams (g)/day (d) to 40 g/d for 19 days in an in vivo study significantly increased 
the population of bifidobacteria without altering the total bacterial counts in elderly female subjects 
suffering from constipation (233). Inulin has also been used as an aid to treat UC and to inhibit C. 
difficile infections (236). 
Synbiotic therapy is proving promising in the management of some health conditions. The use of 
synbiotic supplementation (combination of B. longum and fructo-oligosaccharides/inulin) in a 
placebo-controlled study was shown to reduce inflammation in patients with active UC (237). 
Similarly, their use in the treatment of CD has been documented, where the patients receiving 
synbiotics exhibited reduced CD activity (238).The consumption of the synbiotic combination with 
L. acidophilus NCFM and lactitol had an effect on the microbiota composition (239) further 
reinforcing the effects on microbiota reported previously for this combination(240). Bartosch et al 
have demonstrated that consumption of synbiotics modified the composition of intestinal 
biﬁdobacterial populations in healthy elderly volunteers(241). A similar synbiotic preparation has 
been used to increase the levels of bifidobacteria and lactobacilli (242). Supplementation with 
pre/pro/synbiotics has been proven to promote species diversity and increase resilience of microbial 
communities to challenges including various pathological conditions and antibiotic therapy. 
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1.9 Conclusions 
The human gut is made up of a complex consortium of microorganisms that perform multiple 
important functions, including governing the health of the host by acting as a barrier against 
pathogens and improving the host immune system. With rapidly developing metagenomic methods, 
an in depth understanding of the physiological and metabolic activities of the intestinal microbes is 
being uncovered. Several factors promote shifts in the microbial diversity during aging, such as the 
use of antibiotics, dietary supplements and life style, resulting in susceptibility to infections and 
diseases. Studies hold promise that administration of functional foods containing probiotics and/or 
prebiotics on its own or in combination (synbiotics) as possible approaches to restore homeostasis 
between the gut microbiota and immune system of the elderly. However, there is very little 
evidence for long term colonization with probiotics suggesting that their effects are transient and 
occur at times following consumption. Future research and applications should help serve not only 
to investigate the complex diversity of the microbial community, but also to focus on the functional 
properties ensuring health benefits for the host. 
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Table 1 Age-related immune changes 
 
Affected cell type Change Reference 
Phagocytes Reduced in number of cells (122, 243) 
B-lymphocytes Reduced antibody production (120, 123) 
Lymphokines Declined production of IL-2 (120) 
Antigens* Declined proliferation of T-cells (121, 123) 
Memory cells Decreased functionality (120) 
Cytokines profile Increased production of proinflammatory cytokines  (243) 
*response to stimulation of antigens 
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Table 2 Comparative analysis of culture dependent and independent techniques 
 
Techniques             Advantages            Disadvantages 
Culture dependent 
methods 
 
 
 
 
 
 
 
 
 
 
 
 
 
Culture 
independent 
methods 
 
 Inexpensive, limited 
equipment is required 
 Organisms are 
available for  further 
analysis 
 Possible to obtain 
knowledge about 
physiological or 
functional properties 
of strains 
 Can identify novel 
species 
 
 
 More sensitive – can 
detect less abundant 
and uncultivable 
organisms 
 Many samples can be 
analysed 
simultaneously 
 Can target specific 
bacterial groups 
(FISH, qPCR, 
microarray) 
 Samples can be frozen 
for later analysis 
 Bias of selective enrichment media 
as no appropriate defined media is 
available for culturing most GI 
organisms 
 Restricted to detection of only 
culturable organisms 
 Time consuming and labour intensive 
 Samples require immediate 
processing 
 
 
 
 
 
 Bias in the selection of primers and 
oligonucleotide probes and 
differences in  
extraction efficiency  
 Expensive 
 Extensive bioinformatics analysis is 
required for example-454 
pyrosequencing requires training and 
experience for interpretation of 
results 
 Cannot identify novel groups of 
bacteria (qPCR, FISH) 
 Both living and dead cells are 
quantified 
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Table 3 Mode of action of antibiotics commonly prescribed to the elderly 
 
Antibiotic Interferes with  Target site  References 
Pencillins, cephalosporins, 
carbapenems and glycopeptides 
Cell wall synthesis Peptidoglycan layer (244) 
Fluoroquinolone 
Rifampicin 
Nucleic acid 
synthesis  
 
DNA gyrase enzyme 
RNA polymerase 
(245) 
(246) 
Macrolides  Protein synthesis Ribosomal subunits (245) 
Sulfonamides 
Aminoglycosides 
Folic acid synthesis 
Elongation process 
Folic acid 
Peptidoglycan layer 
(247) 
(248) 
 
 
 
 
 
 
Table 4 Side effects of antibiotic therapy in the elderly 
 
Antibiotic  Side effects 
Beta-lactams: penicillins, cephalosporins and carbapenems Bronchitis, diarrhoea and rashes 
Fluoroquinolones: ciprofloxacin, ofloxacin andgatifloxacin Nausea, vomiting and seizures 
Rifampicin Drug interactions 
Macrolides: erythromycin, clarithromycin and azithromycin Gastrointestinal intolerance 
Trimethoprim-Sulfamethoxazole Rashes and drug induced fever 
Aminoglycosides: amikacin, streptomycin and kanamycin Nephrotoxicity and ototoxicity 
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Table 5 Effect of probiotic therapy on human health 
 
 
 
 
Probiotic strain or probiotic mix Therapeutic effect Reference 
   
L. casei DG Prevents recurrence of diverticular 
disease of the colon 
 
(249) 
L. rhamnosus GG, Saccharomyces 
boulardii and probiotic mixtures 
 
Reduces the development of AAD (250) 
L. johnsonii La1 (NCC533) Improves immune system and reduces 
duration of infection 
 
(251) 
L. casei DN 114001, L. bulgaricus 
and Streptococcus thermophilus 
Reduces the incidence of AAD and 
CDAD 
 
(252) 
L. acidophilus SDC 2012 and 
L. acidophilus SDC 2013 
Reduces abdominal discomfort in 
patients with IBS 
 
(253) 
L. casei DN 114001 Improves antibody responses to influenza 
vaccination 
 
(254) 
L. bulgaricus Increases NK cell activity and reduces 
risk of common cold 
 
(255) 
L. acidophilus 145 and 
Bifidobacterium sp.420 
Prevents recurrence of diverticular 
disease of colon 
 
(256) 
L. casei DN 114001 Reduces duration of respiratory infection 
 
(257) 
Bifidobacterium longum BB536 Increases NK cell activity and 
neutrophilic function 
(258) 
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CHAPTER 2A 
 
 
 
 
Correlation of rRNA gene amplicon pyrosequencing and 
bacterial culture for microbial compositional analysis of faecal 
samples from elderly Irish subjects 
Bhuvaneswari Lakshminarayanan Chapter 4A contribution: 
 
 Participated in the microbiological analysis including media preparation, isolation and 
microbial enumeration  
 
 Analysed all data in relation to 16S compositional sequencing analysis with the aid of the 
staff bioinformatician  
 
 Collaborated with the authors to write the manuscript relating to the analysis of the 
microbial composition through culture dependent method  
 
 
This chapter has been published in  
Journal of Applied Microbiology 
O. O’Sullivan, M. Coakley, B. Lakshminarayanan, M.J. Claesson, C. Stanton, P.W. 
O’Toole and R.P. Ross (2011) 
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2.1 Abstract  
Aims 
The aim of this investigation was to establish the degree of correlation between measurements from 
culture-dependent microbiological techniques and from next generation sequencing technologies.  
Methods and Results  
Data generated by both techniques were collected from faecal samples from 185 elderly Irish people 
involved in the on-going ELDERMET study (http://eldermet.ucc.ie). The results for three groups of 
intestinal bacteria were compared. Bifidobacterium spp., Lactobacillus spp. and Enterobacteriaceae 
were enumerated on selective media through culture dependent techniques, whereas proportions of 
these bacteria were determined through sequencing technology against the background of other 
bacteria. The Spearman’s rank correlation coefficient determined a good correlation between results 
from culture-dependent microbiology and culture independent techniques for all three bacterial 
groups assessed (correlation coefficients for Bifidobacterium spp., Lactobacillus spp. and 
Enterobacteriaceae were 0.380, 0.366 and 0.437, respectively).  
Conclusion 
Correlation between the two methods implies that a single method is capable of profiling intestinal 
Bifidobacterium, Lactobacillus and Enterobacteriaceae populations. However, both methods have 
advantages that justify their use in tandem. 
Significance and Impact of Study 
This is the first extensive study to compare bacterial counts from culture-dependent microbiological 
techniques and from next generation sequencing technologies.  
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2.2 Introduction 
The human gastrointestinal tract harbours a complex microbial ecosystem consisting of a  large 
number of bacteria (Eckburg et al. 2005; Qin et al. 2010; Tiihonen et al. 2010) that have been 
shown to contribute to various aspects of human health, including immunity, nutrition, digestion 
and even well-being (Curtis 2007; Sekirov et al. 2010; Cryan and O'Mahony 2011). From its 
establishment in infancy, the human intestinal microbiota is thought to undergo a period of stability 
in adulthood until it again changes in old age (Mitsuoka 1992; Hopkins and Macfarlane 2002; 
Hopkins et al. 2002; Silvi et al. 2003; Makivuokko et al. 2010; O'Toole and Claesson 2010). The 
ELDERMET consortium, founded in 2008 (http://eldermet.ucc.ie) was established to investigate the 
composition of the intestinal microbiota specific to the elderly Irish population, with a view to 
developing functional foods for this societal group. Initial results have revealed a core gut 
microbiome rich in Bacteroidetes and Firmicutes with large inter-individual variability but intra-
individual temporal stability (Claesson et al. 2011). Additionally the core elderly microbiota has 
been demonstrated to have a distinct pattern from its younger counterparts (Claesson et al. 2009; 
Claesson et al. 2010).  
Culture based techniques have been routinely used to monitor bacterial populations and to 
determine the bacterial composition of faeces as an indicator of the composition of the intestinal 
microbiota. The term “plate count anomaly” was introduced in 1985 (Staley and Konopka 1985) to 
describe the difference (sometimes in orders
 
of magnitude) between the numbers of cells from 
natural environments
 
that form colonies on agar media and those from direct cell counts under the 
microscope. Molecular techniques based on the analysis of 16S rRNA genes directly amplified from 
faecal DNA have estimated that less than 25 % of the faecal bacterial populations have been 
cultured to date (Suau et al. 1999). Estimations of the total culturable gut bacteria range 10-50 %  
therefore, despite constant evolution and improvement of culturing techniques, the full spectrum of 
the bacteria in any given environment cannot be accurately established (O'Toole and Claesson 
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2010). There have been improvements in culture independent techniques such as fluorescence in 
situ hybridisation (FISH), quantitative real-time PCR (qPCR), phylogenetic microarrays and direct 
sequencing of 16S rRNA which aim to solve this “plate count anomaly” through the identification 
of so-called uncultivable bacteria (Tyson and Banfield 2005; Mardis 2008; Petrosino et al. 2009). 
However, culture independent methods are not without their limitations (e.g. choice of target gene, 
detection of live/dead cells, choice of primers and availability of accurate databases) (Juste et al. 
2008).  
For the ELDERMET study, it was proposed that culture independent techniques would be used in 
concert with culture dependent techniques (Mardis 2008) and in this study the results from 185 
elderly subjects were compared to examine the correlation between culture dependent and culture 
independent approaches. Culture dependent techniques were employed whereby a selective medium 
was used to determine the total numbers of Bifidobacterium spp., Lactobacillus spp. and 
Enterobacteriaceae in fresh faecal samples from elderly Irish subjects. The counts determined in this 
way were then compared to relative abundance measurements of Bifidobacterium spp., 
Lactobacillus spp. and Enterobacteriaceae determined by 16S rRNA amplicon pyrosequencing. We 
decided to focus on these microorganisms because bifidobacteria and lactobacilli are natural 
inhabitants of the healthy human intestinal microbiota and there is mounting evidence 
demonstrating the role of these bacteria as potential probiotics (Gill et al. 2001; Klaenhammer et al. 
2008; Turroni et al. 2008; O'Flaherty and Klaenhammer 2010; Aureli et al. 2011). Additionally, 
fluctuations in the levels of bifidobacteria and lactobacilli have been reported in the elderly intestine 
or faeces (Mitsuoka 1992; Hopkins and Macfarlane 2002; Woodmansey 2007), particularly during 
antibiotic usage where their numbers rapidly decline.  Members of the family Enterobacteriaceae 
constitute an important part of the human intestinal microbiota (Qin et al. 2010) and while many 
have been demonstrated to be important factors in gut health (Lupp et al. 2007; Garrett et al. 2010) 
some also represent important pathogenic species (e.g. Salmonella spp. and Escherichia coli). 
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Determination of a correlation between the culture dependent and culture independent techniques 
would render both methods equally efficient at detecting levels of Bifidobacterium spp., 
Lactobacillus spp. and Enterobacteriaceae in the intestinal microbiota. However, the ability of 
culture dependent techniques to target and isolate bacteria with probiotics potential from the 
intestinal tract and the ability of culture independent methods to profile the entire intestinal 
microbiota (both culturable and uncultivable) justifies using both in parallel. 
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2.3 Materials and Methods  
 
Subject Recruitment and Sample Collection 
One hundred and eighty-five subjects aged 65 yr and older were recruited and examined at 
ELDERMET Clinics at two local hospitals (Cork University Hospital and St. Finbarr's Hospital, 
Cork). Informed consent was obtained from all subjects or in cases of cognitive impairment, from 
next of kin, in accordance with the local Clinical Research Ethics Committee guidelines. This study 
was approved by the Clinical Research Ethics Committee of the Cork Teaching Hospitals.  
Sequencing and Bioinformatics 
DNA was extracted from faecal samples according to a standard protocol (Qiagen, West Sussex, 
UK) using Qiagen QIAamp DNA Stool Mini Kit. Universal 16S rRNA primers, designed to 
amplify from highly conserved regions corresponding to those flanking the V4 region (region and 
primers selection based on previous study (Claesson et al. 2009)), i.e. the forward primer F1 (5’-
AYTGGGYDTAAAGNG) and a combination of four reverse primers R1 (5’-
TACCRGGGTHTCTAATCC), R2 (5’-TACCAGAGTATCTAATTC), R3 (5’-
CTACDSRGGTMTCTAATC) and R4 (5’-TACNVGGGTATCTAATC) (RDP's Pyrosequencing 
Pipeline: http://pyro.cme.msu.edu/) were used for Taq-based PCR amplification. Standard PCR 
reaction conditions were employed for reactions with Taq polymerase – 2 mM MgCl2, 200 nM 
each primer, 200 µM dNTPs. The PCR conditions were 94°C for 50 seconds (initialization and 
denaturing) followed by 40°C for 30 seconds (annealing), 72°C for 60 seconds in 35 cycles 
(extension), and a final elongation step at 72°C for 5 minutes. Two negative control reactions 
containing all components, but water instead of template, were performed alongside all test 
reactions, and were routinely free of PCR product, demonstrating lack of contamination with post-
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PCR product. The optimal annealing temperature for the primers, which included 454 adapters and 
barcode sequences, was empirically determined by gradient PCR using control reactions with 
initially purified bacterial genomic DNA, and validated on faecal microbial community DNA (data 
not shown). Subsequently the V4 region of the 16S rRNA gene was amplified and sequenced on a 
454 Genome Sequencer FLX platform (Roche Diagnostics) according to 454 protocols as 
previously described (Claesson et al. 2009).  Twenty five subjects were sequenced per sequencing 
run generating, on average, 41000 raw sequence reads per person.  Raw sequencing reads were 
quality trimmed using a locally installed version of the Ribosomal Database Project (RDP) 
Pyrosequencing Pipeline applying the following criteria (Cole et al. 2009): (i) exact matches to 
primer sequences and barcode tags, (ii) no ambiguous bases (Ns), and (iii) read-lengths no shorter 
than 150 bp. Trimmed fasta sequences were then analyzed by BLAST (Altschul et al. 1990) against 
a previously published 16S rRNA gene sequence-specific database (Urich et al. 2008) using default 
parameters. The resulting BLAST output was parsed using MEGAN (Huson et al. 2007). MEGAN 
assigns reads to NCBI taxonomies by employing the Lowest Common Ancestor algorithm. Bit 
scores were used from within MEGAN for filtering the results prior to tree construction and 
summarization.  A bit-score of 86 was selected, as previously used for 16S rRNA gene sequence 
data (Urich et al. 2008). Total number of pyrosequencing reads assigned to taxa in the 185 
individuals ranged from 10368 to 26071.  Counts for total bifidobacteria (genus level), lactobacilli 
(genus level) and Enterobacteriaceae (family level) were extracted from the MEGAN output of each 
subject. 
Isolation and enumeration of Bifidobacterium spp. through bacteriological culture  
The faecal sample for microbiological analysis was collected by the ELDERMET subject into a 
sterile container and stored at 4
o
C until delivery to the laboratory; storage times varied from 3 to 
193 hr and were on average 28 hr.  One gram of the faecal sample was placed in a small Seward 
stomacher bag (VWR, Dublin, Ireland) and mixed well with 9 gram maximum recovery diluents 
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(MRD, Oxoid Ltd, Basingstoke, Hampshire, UK), prior to diluting further through ten-fold 
dilutions. To enumerate total culturable bifidobacteria, dilutions of the faeces were spread-plated 
(100 l) onto de Man, Rogosa, Sharpe (MRS, Difco Laboratories, Detroit, MI, USA) agar 
supplemented with 0.05% (wt/vol) L-cysteine hydrochloride (Oxoid Ltd., Basingstoke, Hampshire, 
UK) (denoted mMRS agar) supplemented with 100 µg/ml mupirocin (Oxoid), 50 Units nystatin 
(Sigma) and 1.5 % (wt/vol) agar (Oxoid). The agar plates were incubated anaerobically (anaerobic
 
jars with Anaerocult A gas packs, Merck, Darmstadt, Germany) at 37°C for 72 hr. Bacterial counts 
were recorded as colony forming units (CFU) per gram of faeces and data were expressed as log 
CFU gram
-1
 faeces.   
 Isolation and enumeration of Lactobacillus spp. through bacteriological culture  
To enumerate total culturable lactobacilli, the required dilutions of the faeces were spread-plated 
onto Lactobacillus selective agar (LBS, Becton Dickinson Co, Cockeysville, USA) with 50 Units 
nystatin. Agar plates were incubated anaerobically at 37°C for 5 days. Bacterial counts were 
recorded as described previously. 
Isolation and enumeration of Enterobacteriaceae through bacteriological culture  
To enumerate total culturable Enterobacteriaceae, the required dilutions of the faeces were pour-
plated onto Violet Red Bile Glucose Agar (VRBG agar, Merck, Darmstadt, Germany). Agar plates 
were incubated semi-aerobically at 37°C overnight. Bacterial counts were recorded as described 
earlier. 
Confirmation of bacterial strain identity 
Bacterial isolates from the Bifidobacterium-selective and Lactobacillus-selective media were 
identified through sequencing. Putative lactobacilli and putative bifidobacteria were selected from a 
number of ELDERMET subjects. Lactobacilli were confirmed using the CO1 and CO2 universal 
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primers under conditions previously outlined (Simpson et al. 2003).  The BIF-specific and 23S_bif 
primers were used to amplify the Bifidobacterium 16S and ITS spacer sequences, as previously 
outlined (Turroni et al. 2009). Sequence analysis was then carried out by Beckman Coulter (Essex, 
UK) with the CO1 and CO2 primers (for Lactobacillus (Simpson et al. 2003)) and the bif-sec and 
23S-bif primers (for Bifidobacterium (Turroni et al. 2009)). Sequences obtained were used to 
identify the isolates using the NCBI BLAST database (http://blast.ncbi.nlm.nih.gov).   
Statistical Methods 
Statistical analyses were performed using Minitab Release 15.1.1.0 (Minitab Inc. 2007). The 
Spearman’s rank correlation coefficient was used to estimate the relationship between the variables. 
Statistical significance was accepted at P<0.05. 
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2.4 Results  
Bifidobacterium numbers enumerated by bacteriological culture ranged from <3.0 log CFU gram
-1
 
faeces (limit of detection) to 10.7
 
log CFU gram
-1 
faeces, .The selective medium used to enumerate 
bifidobacteria proved effective, because when a selection of isolates (n=39) were identified by full 
length 16S rRNA gene sequencing, all were identified as Bifidobacterium spp. (data not shown). 
Other bacteria can grow on this medium but they can be distinguished, based on colony size on the 
selective medium (Simpson et al. 2004) or by microscopic examination (unpublished data). 
Bifidobacterium numbers established by pyrosequencing were expressed as a relative number of the 
total reads assigned to taxa (number of actual bifidobacteria reads counted ranged from 0 to 2153). 
These relative numbers ranged from 0 to 0.08 (mean = 0.005) for the 185 ELDERMET subjects 
whose faecal microbiota amplicons were sequenced. Based on Spearman’s rank correlation 
coefficient (0.38) there was a significant correlation between data from pyrosequencing and the 
bacteriological culture (Figure 1a, P<0.001, Table 1).  
Lactobacillus populations enumerated using bacteriological culture ranged from <3.0 log CFU 
gram
-1 
faeces
 
(limit of detection) to 9.74 log CFU gram
-1
 faeces. The selective medium used to 
recover and enumerate lactobacilli proved effective as, when a selection of isolates (n=37) were 
identified through 16S rRNA gene sequencing all were identified as Lactobacillus spp. (data not 
shown). Using pyrosequencing, the levels of Lactobacillus spp. detected ranged from 0 to 0.01 
(mean=0.0006; total reads of lactobacilli ranged from 0 to 1699). Using the Spearman’s rank 
correlation coefficient (0.366) there was a significant correlation between the counts obtained from 
the pyrosequencing method and the counts from bacteriological culture (Figure 1b, P<0.001, Table 
1).  
Enterobacteriaceae numbers established by culture techniques ranged from <2.0 log CFU gram
-1
 
faeces (limit of detection) to 10.0 log CFU gram
-1
 faeces. The relative quantities of 
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Enterobacteriaceae detected using pyrosequencing ranged from 0.0 to 0.11 (mean = 0.003; total 
reads of Enterobacteriaceae ranged from 0 to 4449). Based on the Spearman’s rank correlation 
coefficient (0.437) there was a significant correlation between the counts obtained from the 
pyrosequencing methods and those from the culture technique (Figure 1c, P<0.001, Table 1).  
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2.5 Discussion  
This study aimed to investigate the degree of correlation between culture dependent and culture 
independent methods for quantifying selected bacterial genera or families as part of the on-going 
ELDERMET study. Numbers of Bifidobacterium spp., Lactobacillus spp. and Enterobacteriaceae 
established by both methods were compared. Data from the amplicon pyrosequencing were 
assigned to genus level to determine read proportions for Bifidobacterium spp. and Lactobacillus 
spp. and to family level for the Enterobacteriaceae.   
For the culture dependent results the average Bifidobacterium count (7.8 log CFU gram
-1
 faeces) are 
comparable to that observed in other studies of elderly subjects where faecal samples were assessed 
(Hopkins et al. 2001; Guigoz et al. 2002; Bouhnik et al. 2007; Schiffrin et al. 2007). The average 
Lactobacillus spp. count recorded (6.27 log CFU gram
-1
) are comparable to counts from other 
studies of elderly subjects (Hopkins and Macfarlane 2002; Schiffrin et al. 2007; Stsepetova et al. 
2011). Additionally taxonomic proportions elucidated through pyrosequencing in this study are 
consistent with those previously reported for the intestinal microbiota (Gill et al. 2006; Ley et al. 
2006). 
In this study populations of three bacterial groups were investigated, and these were chosen due to 
their probiotic potential (Bifidobacterium spp. and Lactobacillus spp.) and possible use as indicators 
of gut health (Enterobacteriaceae). While these groups are important; they represent a small 
proportion of the intestinal microbiota. The correlation demonstrated within these groups may not 
be transferable to other bacterial groups. Additionally we investigated one culture independent 
method, pyrosequencing, and a single selective medium for each bacterial group. If other methods 
such as qPCR, FISH, and phylogenetic arrays or different selective media were chosen this 
correlation may differ. 
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There are a number of factors which may affect the ability of pyrosequencing techniques to 
efficiently detect taxa. Firstly, universal primers used to detect all bacteria have been demonstrated 
to have a bias against high GC bacteria (Farris and Olson 2007). 16S rRNA genes are chosen due to 
their ubiquitous nature; however they may not have sufficient variability to assign taxonomy to 
genus level (Juste et al. 2008). Additionally 16S rRNA genes can exist in multiple copies in bacteria 
which may affect detection levels of these bacteria (Riesenfeld et al. 2004). In the case of 
Bifidobacterium spp. there is a low mean figure of 0.005 using pyrosequencing, relative to the 
culture dependent counts; this may be due to the fact that universal primers were used, as opposed 
to Bifidobacterium spp. specific primers. As previously discussed, universal primers may be biased 
against high GC content bacteria, in particular members of the phylum Actinobacteria (Farris and 
Olson 2007).  
This investigation demonstrated that there is a correlation between culture dependent techniques 
and contemporary culture independent techniques, when enumerating Bifidobacterium spp., 
Lactobacillus spp. and Enterobacteriaceae (Spearman's rank correlation coefficients were 0.380, 
0.366 and 0.437, respectively). It is important to emphasize that for bacterial species resident in low 
numbers in the gut, pyrosequencing may not always detect these species, while selective culturing 
methods may prove useful (Riesenfeld et al. 2004). This is clearly demonstrated in our study; where 
no counts were observed from pyrosequencing, but the culture method consistently returned a count 
(illustrated in Figure 1).  Correlation will also depend on factors such as the selectivity of the 
culture medium, the ability of species to grow on the culture medium (unculturable or non-viable  
cells), and the efficiency of universal primers in identifying all members of a taxon. Whilst culture 
dependent techniques remain valuable for isolating bacterial species for further analysis (e.g. novel 
probiotic strains), the correlation between the culture dependent and independent techniques 
highlights that a single method is sufficient to enumerate selected major elements of the intestinal 
microbiota.  
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Table 1: Spearman’s rank correlation coefficient comparing culture techniques (log CFU gram-1 
faeces) and results from pyrosequencing (relative number). 
 
Group Bifidobacterium spp. Lactobacillus spp. Enterobacteriaceae No. of subjects 
Total 0.38 (<0.001)* 0.366 (<0.001) 0.437 (<0.001) 185 
*Spearman’s rank correlation coefficient with p-value in brackets.  
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Figure Legends 
Figure 1: Scatterplot of (a) Bifidobacterium spp., (b) Lactobacillus spp. and (c) Enterobacteriaceae 
counts from 185 datasets representing counts from culture methods (log CFU gram
-1
) and from 
pyrosequencing methods (relative number) (P<0.001).  
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Alterations in intestinal microbiota of elderly Irish subjects 
post-antibiotic therapy 
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2.8 Synopsis 
Objectives: The human intestinal microbiota composition alters naturally with age, but is unusually 
perturbed by antibiotic therapy. The impact of antibiotic therapy on the composition of the intestinal 
microbiota of a cross-section of elderly Irish subjects (n=185, >65 yr) was investigated, taking into 
consideration their residence location. 
Methods: Forty-two of the 185 elderly subjects were treated with at least one antibiotic within one 
month prior to faecal microbiota profiling. The residence locations of the subjects varied from long-
term nursing care and rehabilitation wards, to day hospitals and the community.  
Results: Culture-dependent methods indicated that faecal Bifidobacterium spp. numbers were 
significantly reduced following antibiotic treatment (p=0.004, 7-fold reduction), while levels of 
Lactobacillus spp. and Enterobacteriaceae were unaffected. The largest decrease in Bifidobacterium 
spp. numbers was linked to the administration of nucleic acid inhibitors (p=0.004, 23-fold 
reduction). Microbiota profiling revealed a significant compositional change across nine genera 
following antibiotic therapy, including a relative increase in Lactobacillus spp. (p=0.031), as well as 
a decrease in the number of genera identified in the antibiotic treated subjects (n=58), when 
compared to untreated subjects (n=79). More alterations in the intestinal microbiota were observed 
post nucleic acid inhibitor therapy, most notably a decrease in relative Faecalibacterium spp. 
numbers (p<0.001). 
Conclusions: The impact of antibiotic therapy on the intestinal microbiota in the elderly should be 
considered for long-term health effects, and differential susceptibility may require the development 
of products (e.g. prebiotics and probiotics) for at-risk subjects.  
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2.9 Introduction 
The human gastrointestinal tract accommodates a vast number (> 1000 species) and diverse range 
of bacteria
1-3
 which can be profiled by high throughput sequencing technologies.
4,5
 Microorganisms 
constituting the intestinal microbiota of healthy individuals are associated with numerous health 
benefits, including roles in nutrition and metabolism, conditioning of the immune system and 
protection against pathogens.
6,7
 Perturbations in the microbiota (dysbiosis) have been linked to 
adverse health conditions, such as obesity and inflammatory bowel disease.
7,8
 Changes have been 
identified in the intestinal microbiota composition with aging, even taking extensive inter-individual 
variation into account.
4,9,10
 In general, Bacteroides
11-14
 and Bifidobacterium spp.
11,15,16
 decline with 
advancing age, whilst levels of clostridia, lactobacilli, streptococci and Enterobacteriaceae were 
observed to increase. 
10,17,18
  
In addition to the natural changes that occur during the aging process, due to alterations in diet, 
lifestyle, digestive physiologies and immune function
10,16,19-21
, the composition of the intestinal 
microbiota in the elderly is impacted by antibiotic therapy. Broad spectrum antibiotic therapy 
affects not only the target pathogenic bacterium but also the entire intestinal microbiota.
22-25
 Indeed, 
recent studies confirm the short and long-term impacts of antibiotic therapy on the human intestinal 
microbiota.
23,26
 It has been demonstrated that antibiotic therapy reduces overall bacterial diversity, 
affecting up to 33% of the microbial population
5
 and that it can also have an individualised effect 
on the intestinal microbiota.
27
  More specifically, antibiotic therapy reduced Bacteroides numbers as 
well as altering the composition of the Bacteroides group
22
 and reducing Bifidobacterium spp., 
Desulfovibrio spp., Clostridium spp. and Faecalibacterium spp. populations.
13
  
Knowledge of the effect of antibiotic therapy on the composition of the intestinal microbiota of the 
elderly is fundamental to the development of targeted treatments for improved health e.g. prebiotics 
and probiotics. Previous reports on the impact of antibiotics on the gut microbiota of the elderly 
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have varied in their approach and extent; studies used a combination of culture-dependent and 
culture-independent techniques with subject numbers varying from 5
15
 to 74.
28
  In this study, the 
impact of antibiotics on the intestinal microbiota of 185 elderly Irish subjects from various 
residence locations was assessed using a combination of culture-dependent and culture-independent 
techniques. Culture-dependent methods were used to specifically enumerate viable populations of 
Bifidobacterium spp., Lactobacillus spp. and Enterobacteriaceae in faecal samples, whilst culture 
independent 16S rRNA gene amplicon sequencing was employed to investigate the global intestinal 
microbiota. Bifidobacterium spp. and Lactobacillus spp. were investigated due to their presence in 
the gastro-intestinal tract being associated with positive health effects
29-32
, and Enterobacteriaceae 
because they form a major component of the gut microbiota.
33-35
 This study demonstrated that 
antibiotic therapy resulted in significantly reduced levels of culturable Bifidobacterium spp., as well 
as perturbing the relative abundance of 9 genera, including Lactobacillus spp., in the intestine of 
older subjects. 
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2.10 Materials and Methods 
 
Subject Recruitment and Sample Collection 
Subjects aged 65 years and older were recruited and clinically examined at ELDERMET Clinics at 
two local hospitals (Cork University Hospital and St. Finbarr’s Hospital, Cork). Informed consent 
was obtained from all subjects or in cases of cognitive impairment, next of kin, in accordance with 
the local research ethics committee guidelines. This study was approved by the Clinical Research 
Ethics Committee of the Cork Teaching Hospitals. Subjects completed a validated food frequency 
questionnaire, provided a medical history, underwent a full physical examination and provided 
faecal, blood, saliva and urine samples.  
The residence locations of subjects (n=185) were defined as (i) long-term institutionalised care 
(long-stay; > 6 weeks; n=48); (ii) short-term rehabilitation hospital care (rehabilitation; stay of < 6 
weeks; n=24); (iii) occasionally attending an out-patient day hospital (day hospital; n=40) or (iv) 
community-dwelling (n=73). The mean age of the subjects (n=185) was 78 ± 7 years, with a range 
of 65–95 years. Subjects receiving antibiotics within one month prior to visiting an ELDERMET 
Clinic (n=42) were further classified as antibiotic treated. These subjects received various 
antibiotics (details for 37 of the 42 subjects are provided as Supplementary data in Table S1). The 
subjects were treated with 1 (n=25), 2 (n=10), 3 (n=1) or 4 (n=1) antibiotics. The antibiotics 
administered were grouped into nucleic acid inhibitors (n=12 subjects), cell envelope antibiotics 
(n=10), protein synthesis inhibitors (n=2) and others (n=1); a further 11 subjects received a 
combination of nucleic acid inhibitors and cell envelope antibiotics and one subject received a 
combination of protein synthesis inhibitors and cell envelope antibiotics (Table S1, available as 
Supplementary data at JAC Online). A breakdown of the subjects by residence location and 
antibiotic treatment is represented in Table S2 (provided as Supplementary data).  
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Isolation and enumeration of bacteria by culture 
Faecal samples for microbiological analysis were collected by the ELDERMET subjects into sterile 
containers and stored at 4
o
C until delivery to the laboratory. Storage times varied and were on 
average 28 h. Total culturable Bifidobacterium spp., Lactobacillus spp. and Enterobacteriaceae 
were enumerated as outlined previously.
36
 Bacterial counts were recorded as colony forming units 
(cfu) per gram of faeces and results expressed as log cfu/gram faeces. The lower limit of detection 
for the culture technique was 3.0 log cfu/gram
 
for Bifidobacterium spp. and
 
Lactobacillus spp. and 
2.0 log cfu/gram
 
for Enterobacteriaceae. 
Amplicon sequencing and bioinformatics 
DNA was extracted from faecal samples according to a standard protocol (Qiagen, West Sussex, 
UK) and subsequently the V4 region of the 16S rRNA gene was amplified and sequenced by Roche 
Diagnostics (West Sussex, UK) according to 454 protocols as previously described.
37
 Raw 
sequencing reads were quality trimmed using a locally installed version of the Ribosomal Database 
Project (RDP) Pyrosequencing Pipeline applying the following criteria: (i) exact matches to primer 
sequences and barcode tags, (ii) no ambiguous bases (Ns), and (iii) read-lengths no shorter than 150 
bp. Trimmed FASTA sequences were then BLASTed
38
 against a previously published 16S-specific 
database
39
 using default parameters. The resulting BLAST output was parsed using MEGAN.
40
 
MEGAN assigns reads to National Centre for Biotechnology Information (NCBI) taxonomies by 
employing the lowest common ancestor algorithm. Bit scores were used from within MEGAN to 
filter the results prior to tree construction and summarisation; a cut-off bit-score of 86 was 
implemented.
39
  Phylum, family and genus counts for each subject were extracted from MEGAN. 
Operational taxonomic unit assignment (OTU), chimera-checking, clustering and alpha and beta 
diversities of reads were implemented with Qiime.
41
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Statistical Methods 
Non-parametric statistical analyses (Mann Whitney, Chi-Square and Kruskal-Wallis tests) were 
applied using Minitab Release 15.1.1.0 (Minitab Inc. 2007) and SPSS PASW Statistics version 18, 
to determine the impact of antibiotic therapy and residence location of the individuals on the levels 
of bacteria recovered. Statistical significance was accepted at p<0.05. Adjustment for multiple 
testing was estimated using the q-value (genus level) and the FDR functions (phylum and family 
level) in the R statistical package (version 2.13.1) using the Benjamini & Hochberg method.
42
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2.11 Results  
 
Relationship between antibiotic therapy and residence location 
The elderly subjects were divided into four groups based on their residence location. Table S2 
(provided as Supplementary data) presents a cross tabulation of residence location by antibiotic 
therapy for these subjects and indicates (as expected) that there was a clear association between 
these two factors for the subjects (Chi-Square test statistic: 23 =13.103, p=0.004), with many more 
subjects in the long-stay (33.3%) and rehabilitation (41.7%) groups receiving antibiotic therapy than 
those in the community (12.3%) or attending a day hospital (17.5%). 
Variation in levels of culturable Bifidobacterium spp., Lactobacillus spp. and Enterobacteriaceae  
There was a large inter-individual variation in the numbers of bacteria recovered from faecal 
samples of the 185 ELDERMET subjects assessed. With respect to culturing, Bifidobacterium spp. 
counts ranged from <3.00 to 10.70
 
log cfu/gram
 
faeces for individual subjects. Lactobacillus spp. 
counts ranged from <3.00 to 9.70 log cfu/gram and Enterobacteriaceae levels similarly ranged from 
<2.00
 
to 10.00 log cfu/gram
 
(Figure S1, provided as Supplementary data).  
Levels of culturable Bifidobacterium spp., Lactobacillus spp. and Enterobacteriaceae were 
enumerated and assessed to establish whether antibiotic treatment had an effect on the numbers of 
bacteria detected (Figure S2, available as Supplementary data at JAC Online). Bifidobacterium spp. 
numbers were significantly reduced following antibiotic administration (p=0.004), with reduced 
bacterial numbers recovered from faecal samples, compared with those from non-antibiotic treated 
subjects (average of 8.00 log cfu/gram
 
reducing to 7.15 log cfu/gram; 7-fold reduction post 
antibiotic therapy). Lactobacillus spp. and Enterobacteriaceae numbers recovered from the elderly 
faecal samples were not significantly different between antibiotic treated and untreated groups 
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(Figure S2). No correlation was established between the time since cessation of antibiotic therapy 
within the one month prior to attending the ELDERMET clinic and the counts recovered for 
culturable Bifidobacterium spp., Lactobacillus spp. or Enterobacteriaceae (data not shown). The 
effect of nucleic acid inhibitors (n=12), cell envelope antibiotics (n=10) and combinations of these 2 
antibiotic types (n=11) on a selection of culturable bacteria was assessed. Subjects receiving only 
nucleic acid inhibitors had significantly lower levels of Bifidobacterium spp. (p=0.004, 23-fold 
decrease), as did subjects receiving a combination of the 2 antibiotic types (p=0.012, 13-fold 
reduction), whereas those subjects receiving only cell envelope antibiotics, had no significant 
alterations in levels of culturable Bifidobacterium spp. Subjects receiving only cell envelope 
antibiotics had significantly altered levels of Lactobacillus spp. (p=0.047, 10-fold increase). None 
of the antibiotic types or combinations affected the levels of Enterobacteriaceae compared to the 
control group. 
To further analyse the effect of antibiotic therapy on Bifidobacterium spp., Lactobacillus spp. and 
Enterobacteriaceae, the bacterial count data were considered separately by residence location and 
antibiotic use (Figure 1). Bifidobacterium spp. numbers separated by residence location and 
antibiotic treatment are represented in Figure 1a. For subjects not receiving antibiotics (first 4 box-
plots, Figure 1a), there was no significant difference between the numbers of Bifidobacterium spp. 
based on residence location. In contrast, for subjects receiving antibiotics, numbers of 
Bifidobacterium spp. varied with residence location (p=0.034). Counts of Bifidobacterium spp. were 
highest in the community-dwelling group (8.58 log cfu/gram) and lowest in the long-stay group 
(6.27 log cfu/gram) (p=0.008). Bifidobacterium numbers were significantly lower for the long-stay 
(p=0.047) and day hospital (p=0.046) subjects receiving antibiotics, compared to the equivalent 
groups not receiving antibiotics.  
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The levels of Lactobacillus spp. cultured as a function of residence location and antibiotic therapy 
are represented in Figure 1b. The levels of Lactobacillus spp. detected were not significantly related 
when all four residence locations were compared simultaneously, either in antibiotic treated or 
untreated subjects.  Pair-wise comparisons revealed that the levels of Lactobacillus spp. recovered 
from the rehabilitation subjects were significantly higher than both long-stay (p=0.015) and 
community-dwelling subjects (p=0.027) in the antibiotic untreated group. Importantly, in antibiotic 
treated subjects, the numbers of Lactobacillus spp. were not significantly different in the individual 
residence locations (p>0.05 for all).  
Recovery of Enterobacteriaceae as a function of residence location and antibiotic use is represented 
in Figure 1c. Enterobacteriaceae numbers were not significantly related to residence location, either 
in the subjects receiving antibiotics (p=0.188) or the untreated subjects (p=0.707). The numbers of 
Enterobacteriaceae did not vary significantly between the different residence locations following 
antibiotic therapy.  
Microbiota differences determined by amplicon sequencing 
Each sequence read was assigned to an operational taxonomical unit (OTU) based on 97% identity 
and further assigned taxonomy (at the phylum, family and genus level) based on the BLAST 
homology searches. To determine whether antibiotic treatment impacted on intra-subject diversity, 
we calculated five diversity measures (Shannon Diversity, Simpson Index, Chao1, Phylogenetic 
Diversity and Observed Species). While there was a decrease in the mean microbial diversity in 
antibiotic treated subjects compared to untreated subjects, both as a whole and when broken down 
by residence location, no significant changes were observed (Table S3, provided as Supplementary 
data). To investigate similarities or differences in the microbial composition between antibiotic 
treated and untreated subjects, principal coordinates analysis (PCoA) based on weighted-Unifrac 
beta diversity distance was employed. This did not reveal any difference between the antibiotic 
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treated and untreated subjects as a whole or when broken down by residence location (Figure S3, 
provided as Supplementary data), but did confirm separation of microbiota based on residence 
location
43
. Also there was no clustering of subjects based on antibiotic type (Figure S4, provided as 
Supplementary data).  Additionally, PCoA revealed no difference in the microbiota composition 
based on time since cessation of antibiotic therapy (Figure S5, provided as Supplementary data). 
Microbial composition assignment revealed a large inter-individual variability in the phylogenetic 
profile, of both antibiotic treated and untreated groups. Bacteroidetes ranged from 4% to 92% of the 
total microbiota in the untreated group and from 0.1% to 91% in the antibiotic treated group. The 
Firmicutes ranged from 8% to 96% in the untreated group and from 9% to 99% in the antibiotic 
treated group. All phyla remained at approximately equal proportions across the datasets (Figure 
2a). At the family phylogenetic level, no significant change in the microbiota of the antibiotic 
treated subjects was observed (Figure 2b). At the genus level, reads were assigned to 79 genera in 
the intestinal microbiota of the untreated group, while 58 genera were identified in the antibiotic 
treated group. Nine genera showed significant differences in abundance in the antibiotic treated 
subjects relative to the untreated subjects (Figure S6 and Table S4, both provided as Supplementary 
data). Read numbers corresponding to Lactobacillus spp. were significantly different (p=0.031), 
showing a relative increase in the antibiotic treated group (Figure 2c).   
When considering subjects on a single antibiotic only, those subjects receiving a nucleic acid 
inhibitor had significant differences in the levels of Anaerococcus (p=0.008), Denitrobacterium 
(p=0.008), Faecalibacterium (p<0.001), Lactinofactor (p<0.001) and Proteus (p=0.008), when 
compared with the antibiotic untreated subjects. Those subjects receiving a cell envelope antibiotic 
had only 2 significant differences at the phylum level, Ascomycota (p<0.001) and Elusmicrobia 
(p<0.001). However, members of these phyla were found in only one antibiotic treated subject and 
in no antibiotic untreated subject. Subjects receiving a combination of nucleic acid inhibitors and 
cell envelope antibiotics had significantly different levels of Staphylococcaceae (p<0.001) at the 
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family level and Staphylococcus (p<0.001) and Proteus (p<0.001) at the genus level. However 
again, members of these taxa were only found in one antibiotic treated subject and in no antibiotic 
untreated subject. 
In the antibiotic treated group, no significant differences were observed across residence locations. 
In antibiotic untreated subjects, there were some differences across residence locations; at the genus 
level 16 genera were significantly altered across the residence locations including Desulfovibrio 
(p=0.036), Faecalibacterium (p <0.001), Butyrvibrio (p=0.017) and Prevotella (p=0.012). The 
largest differences appeared to be between the long-stay and community groups, with 11 out of the 
16 genera being significantly different between these groups (Table S5, provided as Supplementary 
data).  
Considering the residence locations individually, most significant differences between the antibiotic 
treated and untreated populations were observed in the day-hospital population (Table 1). 
Lactobacillus spp. proportionately increased (p<0.001) in the day hospital antibiotic treated subjects 
compared to the antibiotic untreated group; in addition to alterations in seven other genera (Table 
1). In the community residence location, Bacteroidetes (p=0.020), Firmicutes (p=0.020), 
Proteobacteria (p=0.009) and Euryarchaeota (p=0.009) populations were significantly different at 
the phylum level, while Rhodocyclaceae populations (p=0.012) were proportionately increased at 
the family level in the antibiotic treated group. In the long-stay group, at the family level, 
Lachnospiraceae (p<0.001) populations were significantly reduced in the antibiotic treated subjects 
compared to the untreated subjects. There were no significant differences, across all taxonomical 
levels, in the rehabilitation group.  
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2.12 Discussion 
In this study, the impact of antibiotic therapy on the intestinal microbiota of a large cohort of elderly 
subjects was investigated, based on faecal microbiota analysis, using both culture-dependent 
(plating) and independent (compositional) approaches. The antibiotics used varied considerably 
across individuals and the inclusion criteria simply stipulated that the treatment was administered   
less than one month before sampling. Time since cessation of antibiotic therapy had no impact on 
the composition of the microbiota. The impact of residence location on the microbiota of antibiotic 
treated subjects was limited; this may be a consequence of antibiotic therapy having a blanket effect 
on the entire intestinal microbiota and not just the target pathogen.  
Overall, it was found that the culturable Bifidobacterium spp. population in faecal samples from the 
antibiotic treated group decreased 7-fold when compared to the untreated group. In this respect, 
previous studies have reported a deleterious effect on bifidobacterial populations, e.g. Bartosch et al 
reported a 2.5-fold decrease in Bifidobacterium spp. in elderly hospitalised subjects receiving 
antibiotics (n=21) compared with those not in receipt of antibiotics (n=38).
13
 Although no 
significant difference was observed in culturable Lactobacillus spp. the numbers recovered 
increased 2.6 fold in antibiotic treated subjects as a whole. Indeed, such a finding was previously 
reported by Woodmansey et al
11
, who recorded a 100-fold increase in Lactobacillus spp. levels in 
antibiotic treated subjects (n=10) compared to those not receiving antibiotics (n=6).  
The impact of the antibiotic types on the intestinal Bifidobacterium spp. revealed that the nucleic 
acid inhibitors had the most dramatic effect, with levels reduced following the administration of 
nucleic acid inhibitors (p=0.004, 23-fold decrease), and a combination of nucleic acid synthetic 
inhibitors and cell envelope antibiotics (p=0.012, 13-fold decrease). This suggests the effect of the 
antibiotic combinations was due to the nucleic acid synthetic inhibitors, as cell envelope antibiotics 
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did not impact culturable Bifidobacterium spp. numbers.  Conversely, Lactobacillus spp. levels 
were only affected by cell envelope antibiotics (p=0.047, 10-fold increase). 
Looking at the intestinal microbiota profiles, notably there was a decrease in Faecalibacterium 
populations in subjects treated with nucleic acid synthetic inhibitors only, compared to the antibiotic 
untreated group.  Faecalibacterium spp. have been associated with a protective effect against 
ulcerative colitis
44
 and colorectal cancer.
45
 A decrease in the Faecalibacterium population as 
demonstrated here precludes such positive associations occurring in antibiotic treated older subjects. 
In general, cell envelope antibiotics appeared to have less impact on specific taxa of the intestinal 
microbiota than nucleic acid inhibitors.  
The consequences of an altered intestinal microbiota post antibiotic therapy are not fully 
understood, but include increased carriage of antibiotic resistance genes
46-48
, increased susceptibility 
to antibiotic associated diarrhoea
49
, increased enteric infection
7
 and an altered inflammatory 
response.
50,51
 Therefore, while antibiotics remain an essential medical tool, more targeted anti-
microbial therapies should be explored to prevent the intestinal dysbiosis, most notably the 7-fold 
reduction in Bifidobacterium spp. numbers observed in the current study, the long-term implication 
of which remains unknown. Furthermore, these data suggest that probiotic and/or prebiotic use, in 
particular targeting the Bifidobacterium-population, may be one approach to correct the altered 
intestinal microbial composition resulting from antibiotic therapy in the elderly.  
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Table 1. Comparison of microbiota for antibiotic treated subjects versus antibiotic untreated 
subjects, grouped by residence location. Only significant differences are shown. 
Residence Location Organism Significance 
(p-value) 
Proportional change 
in antibiotic treated 
group 
Long Stay Lachnospiraceae (f) <0.001 Decrease 
Day hospital Blautia (g) <0.001 Decrease 
Day hospital Faecalibacterium (g) <0.001 Decrease 
Day hospital Lactobacillus (g) <0.001 Increase 
Day hospital Mogibacterium (g) <0.001 Increase 
Day hospital Moryella (g) <0.001 Increase 
Day hospital Peptoniphilus (g) <0.001 Increase 
Day hospital Victicallis (g) <0.001 Increase 
Day hospital Weisella (g) <0.001 Increase 
Community Bacteroidetes (p) 0.020 Increase 
Community Firmicutes (p) 0.020 Decrease 
Community Proteobacteria (p) 0.009 Decrease 
Community Euryarchaeota (p) 0.009 Increase 
Community Rhodocyclaceae (f) 0.012 Increase 
   p=phylum level, f=family level, g=genus level 
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Figure 1: Levels of (a) Bifidobacterium spp., (b) Lactobacillus spp. and (c) 
Enterobacteriaceae enumerated (log cfu/gram faeces) from faecal samples from 185 elderly 
subjects, separated by antibiotic therapy (data for untreated subjects on left of the figure and 
treated subjects on right) and residence location (long-stay (LS), n=32 and 16, light grey 
boxes; rehabilitation (RH), n=14 and 10, white boxes; day hospital (DH), n=33 and 7, white 
boxes with horizontal lines; and community (CM), n=64 and 9, dark grey boxes). Circle with 
enclosed cross = mean; letter cross = outliers; asterik = significant difference between 
residence locations.  
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Figure 2: Relative abundance in 42 antibiotic treated subjects (grey bars) and 143 antibiotic 
untreated subjects (black bars) at (a) phylum, (b) family and (c) genus level. Only major 
taxonomic groups are shown. 
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Supplementary Tables for Chapter 2B 
Table S1.  Antibiotics administered to 37 of the subjects in this study (administration details 
are unknown for 5 of the 42 subjects). Antibiotics are listed with the most recently 
administered antibiotic first, when the subject was treated with more than one antibiotic 
during this period.   
Subject Antibiotic name Antibiotic type
a
 
EM005
b
 Trimethoprim and Truoxin
c
 combination (nasi and cea) 
EM031
b
  Macrodantin
 
and Augmentin combination (nasi and cea) 
EM067  Amoxicillin   cell envelope antibiotic  
EM068
b
  Ciprofloxacin   nucleic acid synthesis inhibitor 
EM076  Augmentin  cell envelope antibiotic  
EM079  Trimethoprim nucleic acid synthesis inhibitor 
EM080  Moxifloxacin   nucleic acid synthesis inhibitor 
EM085  Augmentin duo cell envelope antibiotic   
EM101
b
 Trimethoprim and Cephradine
c
 combination (nasi and cea) 
EM103  Clarithromycin protein synthesis inhibitor 
EM108  Clonamox  cell envelope antibiotic  
EM110  Fluconazole  others 
EM111
b
 Trimethoprim nucleic acid synthesis inhibitor 
EM112
b
 Amoxicillin, Tazocin, Flagyl and Ciprofloxacin   combination (nasi and cea) 
EM114  Augmentin   cell envelope antibiotic 
EM115  Augmentin and Klacid  combination (psi and cea) 
EM117  Ciprofloxacin   nucleic acid synthesis inhibitor 
EM124
b
 Tazocin and Flagyl  combination (nasi and cea) 
EM125
b
 Augmentin   cell envelope antibiotic 
EM126
b
 Nitrofurantoin   nucleic acid synthesis inhibitor 
EM131
b
 Calvapen  cell envelope antibiotic 
EM132  Augmentin and Ciprofloxcin  combination (nasi and cea) 
EM133  Augmentin, Co-amoxicillin and Ciproxin   combination (nasi and cea) 
EM135  Moxifloxacin nucleic acid synthesis inhibitor 
EM139  Ciproxin and Augmentin  combination (nasi and cea) 
EM147  Tazocin   cell envelope antibiotic 
EM149  Flucloxacillin   cell envelope antibiotic 
EM160  Co-amoxicillin   cell envelope antibiotic 
EM163
b
  Ciproxin
 
  nucleic acid synthesis inhibitor 
EM164
b 
 Cephradine and Trimethoprim
c
 combination (nasi and cea) 
EM165  Moxifloxacin   nucleic acid synthesis inhibitor 
EM170
a
 Moxifloxacin   nucleic acid synthesis inhibitor 
EM186  Trimethoprim and Augmentin   combination (nasi and cea) 
EM200  Trimethoprim   nucleic acid synthesis inhibitor 
EM222  Klacid   protein synthesis inhibitor 
EM281  Nitrofurantoin  nucleic acid synthesis inhibitor 
EM290
b
 Trimethoprim and Cephradine
c
 combination (nasi and cea) 
aAntibiotics were classified as nucleic acid synthesis inhibitors, cell envelope antibiotics, protein synthesis 
inhibitors or others. Those on multiple antibiotics are listed as combination (nasi and cea) for those on a 
combination of .nucleic acid synthesis inhibitors and cell envelope antibiotics and combination (psi and cea) for 
those on a combination of protein synthesis inhibitors cell envelope antibiotics. 
bThese subjects were treated with antibiotics at the time of attendance at the ELDERMET Clinic (n=14).  
cThese two antibiotics were alternated on an on-going basis.  
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Table S2. 2
 
tabulation of residence location and antibiotic treatment data for elderly subjects 
studied (n=185). 
Group Antibiotic treatment
a
 Total no. of subjects 
No Yes 
Long-stay   32 (66.7%) 16 (33.3%)   48 
Rehabilitation   14 (58.3%) 10 (41.7%)   24 
Day Hospital   33 (82.5%)   7 (17.5%)   40 
Community   64 (87.7%)   9 (12.3%)   73 
Total 143 (77.3%) 42 (22.7%) 185 
a
subjects administering antibiotics within one month prior to visiting the ELDERMET Clinic. 
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Table S3. Comparison of  diversity metrics for antibiotic untreated versus treated subjects as a whole and broken down by residence location.  
The top line of each section is the p-value and the bottom line is the mean value for antibiotic untreated / antibiotic treated subjects, respectively. 
 
Diversity metric All locations Long-Stay Rehabilitation Day-Hospital Community 
Shannon 0.720 
5.051/4.861 
0.829 
5.054/4.893 
0.720 
5.056/4.79 
0.720 
4.884/4.641 
1.000 
5.146/5.052 
Simpson 0.720 
0.923/0.912 
1.000 
0.920/0.905 
0.720 
0.923/0.918 
0.750 
0.918/0.913 
1.000 
0.925/0.918 
Chao1 0.720 
384.437/363.323 
0.720 
414.965/394.812 
0.720 
380.536/337.039 
0.720 
317.335/279.883 
1.000 
404.626/380.871 
Phylogenetic diversity 0.720 
22.352/20.619 
0.720 
23.053/21.949 
0.720 
22.067/19.167 
0.720 
20.203/17.660 
1.000 
23.172/22.171 
Observed species 0.720 
326.902/304.286 
0.792 
351.281/334.438 
0.720 
332.643/282.900 
0.720 
274.848/231.286 
1.000 
340.297/331.222 
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Table S4.  Changes in the relative genus abundances in antibiotic treated versus untreated 
subjects. Only genera with significant changes are presented. 
Genus Significance  
(p-value) 
Proportional change in  
antibiotic treated group 
Acidaminococcus 0.045 decrease 
Anaerococcus
a
 0.031 increase 
Butyrvibrio 0.031 decrease 
Lachnospira 0.045 decrease 
Lactonifactor
a
 0.031 increase 
Lactobacillus 0.031 increase 
Megasphaera
a
     0.023  increase 
Penicillium
a
 0.031 increase 
Proteus
a
 0.031 increase 
a
present in low numbers of subjects. 
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Table S5. p-values from pair-wise comparison of significantly different genera broken down 
by residence location in the antibiotic untreated subjects.   
adenotes significance; g=genus level 
 
 
Microbe Long-stay vs. 
Day hospital 
Long-stay vs. 
Rehabilitation 
Long-stay vs. 
Community 
Day hospital 
vs. 
Rehabilitation 
Day hospital 
vs. 
Community 
Rehabilitation 
vs. 
Community 
Anaerofilum (g) 0.185 0.042a 0.021a 0.192 0.149 0.306 
Anaerotruncus (g) 0.201 0.007a <0.001a 0.016a <0.001a 0.017a 
Blautia (g) 0.221 0.042a 0.039a 0.192 0.194 0.333 
Butyrvibrio (g) 0.127 0.205 0.059 0.077 0.031a 0.180 
Coprobacillus (g) 0.149 0.042a 0.001a 0.333 0.062 0.042a 
Coprococcus(g) 0.115 0.049a 0.039a 0.017a 0.017 a 0.356 
Desulfovibrio (g) 0.117 0.234 0.017 a 0.192 0.326 0.043a 
Eggerthella (g) 0.228 0.031a 0.017a 0.089 0.017a 0.218 
Enterococcus (g) 0.356 0.142 0.017a 0.185 0.036a 0.142 
Faecalibacterium (g) 0.195 0.001a 0.001a 0.042a 0.078 0.142 
Oscillospira (g) 0.222 0.263 0.014a 0.142 0.017a 0.045a 
Peptococcus (g) 0.042a 0.205 0.285 0.017a 0.042a 0.142 
Porphyromonas (g) 0.234 0.132 0.089 0.080 0.050a 0.356 
Prevotella (g) 0.283 0.042a 0.356 0.062 0.285 0.059 
Spirochaeta (g) 0.248 0.039a 0.015a 0.042a 0.020a 0.201 
Synergistes (g) 0.183 0.192 0.178 0.068 0.031a 0.317 
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Supplementary Figures for Chapter 2B 
 
Figure S1.  Range of Bifidobacterium spp., Lactobacillus spp. and Enterobacteriaceae (log 
cfu/g) recovered from faecal samples of elderly human subjects (n=185; circle with enclosed 
cross = mean; cross = outlier). 
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Figure S2.  Box plot representation of the numbers of Bifidobacterium spp., Lactobacillus 
spp. and Enterobacteriaceae (log cfu/g) recovered from 185 faecal samples from subjects 
treated (n=42) and untreated (n=143) with antibiotics, independent of residence location 
(circle with enclosed cross = mean; cross = outlier).  
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Figure S3.  PCoA plots based on weighted–UniFrac distances for a) antibiotic treated (blue 
circle) and antibiotic untreated subjects (red circle), b) broken down by residence location: 
long-stay (light red circle: untreated, dark red circle: treated); rehabilitation (orange circle: 
untreated, brown circle: treated), day hospital (yellow circle: untreated, light yellow circle: 
treated) and community (dark green circle: untreated, light green circle: treated) and c) 
individual PCoA plots for each residence location (colour coding as before).  
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Figure S4.  PCoA plots based on a) bray-curtis, b) unweighted–UniFrac and c) weighted 
UniFrac distances. Antibiotics are grouped into nucleic acid synthesis inhibitors (red), cell 
envelope antibiotics (blue), protein synthesis inhibitors (orange), others (purple) and 
combination of antibiotics (green).  
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Figure S5.  PCoA plot based on weighted-Unifrac -diversity distance. Subjects are colour 
coded based on time since cessation of antibiotic therapy; currently on antibiotics (blue 
circle), ceased antibiotic therapy within: 1 week (orange circle), 2 weeks (green circle), 3 
weeks (purple circle) and 4 weeks (yellow circle). 
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Figure S6. Relative change in the abundance of selected genera in antibiotic treated subjects 
relative to untreated subjects. Only genera with significant differences in population numbers 
are illustrated.  
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CHAPTER 3 
 
 
 
 
 
TEMPORAL STABILITY OF CULTURABLE 
BIFIDOBACTERIUM SPP., LACTOBACILLUS SPP. AND 
ENTEROBACTERIACEAE IN ELDERLY IRISH SUBJECTS  
 
 
 
 
 
 
 
 
This chapter will be combined with other ELDERMET research and submitted 
to 
Letters in Applied Microbiology 
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3.1 Abstract 
The intestinal microbiota plays a pivotal role in human health and well-being, with many 
health-promoting properties being associated with this community. Factors such as antibiotic 
therapy, aging and disease can negatively impact on this bacterial population. The temporal 
stability of this microbiota is thought to be of importance to host health and consequently 
maintenance of the balance of this bacterial community is desirable. Probiotic 
supplementation is one strategy commonly employed to contribute to a healthy intestinal 
environment. It is well known that ingestion of probiotic preparations consisting of 
bifidobacteria and/or lactobacilli have been associated with a number of positive health 
effects. For this reason, the temporal stability of culturable Bifidobacterium spp. and 
Lactobacillus spp. in faecal samples from 65 elderly subjects was monitored over a 6 month 
period. The levels of another important intestinal group, Enterobacteriaceae were also 
monitored over this period. The impact of probiotic intake, antibiotic therapy and residence 
location on these inhabitants of the GIT were also determined over time. Contrary to data that 
indicates that the microbiota of the elderly can be easily perturbed by extrinsic factors, this 
study demonstrates that the levels of the 3 bacterial groups analysed remained relatively 
stable over the 6 month period. Surprisingly, antibiotic administration did not result in 
perturbations in the counts of the 3 bacterial groups. Regular probiotic consumption resulted 
in a significant increase in Bifidobacterium spp. counts by month 6, while there were no 
alterations in the other two bacterial groups studied.  
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3.2 Introduction 
The gastrointestinal tract (GIT) is inhabited by a complex microbial community known as the 
gut microbiota that is thought to have a profound impact on host health, immunity and 
nutrition (Guarner & Malagelada 2003; Sekirov et al. 2010; Tiihonen et al. 2010). At birth 
the GIT is initially sterile and is then rapidly colonised by bacteria of maternal origin and 
from environmental exposure (Palmer et al. 2007). Then, an ecological succession takes 
place within the human intestinal microbiota over the first few years of life, which after a 
period of relative flux converges into a complex adult pattern (Favier et al. 2002; Palmer et 
al. 2007; Koenig et al. 2011). Studies on the human gut microbiota have suggested that in the 
absence of perturbations, the microbial communities are relatively stable during adulthood 
(Zoetendal et al. 1998; Vanhoutte et al. 2004; Costello et al. 2009), yet the bacterial profiles 
are unique in that there is a lot of inter-individual variation (McCartney et al. 1996; Eckburg 
et al. 2005). Variations in the composition of the gut microbiota have been linked to the aging 
process (Hopkins et al. 2001; Woodmansey et al. 2004; Biagi et al. 2010). Indeed a number 
of extrinsic factors such as diet (De Filippo et al. 2010; Wu et al. 2011), geographic origin 
(Mueller et al. 2006; De Filippo et al. 2010), living environment (Bartosch et al. 2004; 
Claesson et al. 2012), antibiotic therapy  and health conditions such as inflammatory bowel 
disease, obesity and colon cancer (Ley et al. 2006; Jernberg et al. 2007; Scanlan et al. 2008; 
Jeffery et al. 2012) can contribute to significant changes in the faecal bacterial communities 
in the elderly. Age-related changes in the gut microbiota composition include decreased 
species diversity and a decline in the abundance of intestinal Bifidobacterium spp. (Hopkins 
et al. 2001; Woodmansey 2007; Biagi et al. 2010; Claesson et al. 2012). In contrast, the 
population of Lactobacillus spp. remain stable or increase (Mitsuoka 1992; Hayashi et al. 
2003; Mariat et al. 2009; Claesson et al. 2012). 
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Antibiotic use is often associated with adverse GI symptoms and can induce disturbances in 
the intestinal microbiota especially in hospitalized subjects (Bartosch et al. 2004; Young & 
Schmidt 2004; O'Sullivan et al. 2013). The impact of antibiotic treatment is also a factor in 
the prevalence of pathogenic bacteria such as Clostridium difficile (Rea et al. 2012). Recent 
studies have revealed that short and long term antibiotic administration can lead to ecological 
disturbances of the gut microbiota that can persist for up to two years (Jakobsson et al. 2010; 
Jernberg et al. 2010). 
The balance and composition of the intestinal microbiota is important for the well-being of 
the host. Attempts to increase the natural resistance of the host to infection and minimize 
alterations in the bacterial community include the consumption of probiotics. Both 
Lactobacillus spp. and Bifidobacterium spp. are the key components of the gut microbiota 
and have received attention due to their associated health-promoting properties (Salminen et 
al. 1998; Rastall 2004; O'Flaherty & Klaenhammer 2010). They are commonly used as 
probiotic supplements and in that capacity they may restore the microbial balance that is 
negatively affected by aging. As such they may be considered as potential modulators of the 
gut microbiota and may be particularly effective in elderly populations (Ouwehand et al. 
2002; Lahtinen et al. 2009; Guillemard et al. 2010; Namba et al. 2010). 
The stability of the gut microbiota is known to change at certain key times in life such as 
early and late life, infection and inflammation. The temporal stability of this gut microbiota 
has been evaluated by repeated sampling of faecal communities over time, which suggests 
that the predominant bacterial community remains relatively stable and unique in healthy 
individuals over a prolonged period of time (Zoetendal et al. 1998; Vanhoutte et al. 2004). 
Culture independent methods during initial ELDERMET studies demonstrated temporal 
stability of the faecal microbiota at 3 months for the majority of subjects (85 %), while there 
was substantial inter-individual variation (Claesson et al. 2011). Using culture dependent 
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methods, this study aimed to investigate the temporal dynamics (0, 3 and 6 months) of a 
selection of bacteria (Bifidobacterium spp., Lactobacillus spp. and Enterobacteriaceae) in 
faecal samples from elderly Irish subjects (n=65) as impacted by antibiotic therapy, residence 
location and probiotic intake. Extremes of residence location (long-stay versus community) 
and probiotic intake (regular versus none) were compared. Some subjects ceased antibiotic 
therapy during the 6 month period and the impact of this on the 3 bacterial groups was also 
determined. 
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3.3 Materials and Methods 
 
Subject recruitment and sample collection  
Subjects aged 65 yr and older were recruited and examined at ELDERMET Clinics at two 
local hospitals (Cork University Hospital and St. Finbarr’s Hospital, Cork) as previously 
outlined (Claesson et al. 2011). This study determined the levels of culturable 
Bifidobacterium spp., Lactobacillus spp. and Enterobacteriaceae at month 0, 3 and 6 (T0, T3 
and T6) for 65 of these elderly subjects. Subjects were recruited from long-term 
institutionalised care (long-stay; more than 6 wk), short-term rehabilitation centers (rehab; 
under 6 wk stay), out-patient day hospitals and from the general elderly community. 
Residence locations and details of antibiotic therapy by the subjects are outlined in Table 1. 
Subjects receiving antibiotics within one month prior to visiting an ELDERMET Clinic were 
classified as antibiotic treated. In total 20 subjects received antibiotics at 1, 2 or all 3 time 
points. These subject were divided into 4 groups based on the type of antibiotic administered: 
Group 1 (cell envelope inhibitors (CE) at 1 time point), Group 2 (protein synthesis inhibitors 
(PSI) at 1 time point), Group 3 (nucleic acid synthesis inhibitors (NAI) at 1 or 2 time points) 
and Group 4 (combinations of antibiotics at 1 to 3 time points) (Table 2).  Probiotic intake 
varied among the 65 subjects and details were unavailable for 20 subjects.  Frequency of 
probiotic consumption was graded from never, to infrequent (max. 1 portion per month), to 
irregular (1 to 2 portions per week) and regular probiotic intake (from 0.7 to 2 portions per 
day) (Table 3).   
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Isolation and enumeration of bacteria by culture dependent methods  
Stool samples were collected into sterile containers and stored at 5
o
C until transported to the 
laboratory. Bifidobacterium spp., Lactobacillus spp. and Enterobacteriaceae  were 
enumerated as outlined previously (O’Sullivan et al. 2011). Bacterial counts were recorded as 
colony forming units (CFU) per gram of faeces and results expressed as log CFU gram
-1
 
faeces. The lower limit of detection for the culture technique was 3.0 log CFU gram
-1 
for 
Bifidobacterium spp. and 
 
Lactobacillus spp. and 2.0 log CFU gram
-1 
for Enterobacteriaceae.  
Statistical Methods 
Non-parametric statistical analyses (Mann Whitney, Chi-Square and Kruskal-Wallis tests) 
were applied using Minitab Release 15.1.1.0 (Minitab Inc. 2007), to determine the impact of 
time, antibiotic therapy or residence location of the individuals on the levels of bacteria 
recovered. Statistical significance was accepted at P<0.05.  
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3.4 Results and Discussion 
During this study the effect of external factors such as antibiotic therapy, residence location 
and probiotic intake on the levels of culturable Bifidobacterium spp., Lactobacillus spp. and 
Enterobacteriaceae recovered from faecal samples of 65 elderly human subjects were 
assessed. We focused on these subjects as the bacterial counts were available at 3 times 
points over a 6 month period.  
Temporal stability of Bifidobacterium spp., Lactobacillus spp. and Enterobacteriaceae   
Compositional alterations that disturb the normal balance of the intestinal microbiota 
(dysbiosis) are partly considered responsible for adverse health conditions (Sekirov et al. 
2010). Hence, ensuring appropriate balance and stability of the intestinal microbiota is 
considered an effective means of maintaining host health. In this study, we concentrated on 
Bifidobacterium spp. and Lactobacillus spp. as they are autochthonous members of the 
human gut microbiota and have been positively associated with a range of health-promoting 
effects (Kleerebezem & Vaughan 2009). Enterobacteriaceae were also investigated as they 
form a major component of gut microbiota and are used as indicators of hygiene and health 
(Lupp et al. 2007; Al-Mutairi 2011). 
Culturable Bifidobacterium spp., Lactobacillus spp. and Enterobacteriaceae recovered from 
the faecal samples of elderly human subjects over time are presented in Figure 1.  These 
bacterial counts are presented irrespective of residence location, antibiotic therapy or 
probiotic intake. There was a large inter-individual variation in the numbers of bacteria 
recovered from the 65 subjects. Bifidobacterium spp. counts ranged from <3.0 to 10.7
 
log 
CFU gram
-1 
faeces for individual subjects; Lactobacillus spp. counts ranged from <3.0 to 9.7 
log CFU gram
-1 
and Enterobacteriaceae  levels ranged from 2.3
 
to 10.0 log CFU gram
-1 
(Figure 1).  
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The numbers of Bifidobacterium spp., Lactobacillus spp. and Enterobacteriaceae remained 
stable over the 6 month period, with no significant difference observed between the counts at 
the 3 time points (P values for comparison of T0, T3 and T6 in Figure 1). Furthermore no 
significant differences were observed when 2 individual time points were compared (e.g. T0 
compared to T3, T0 compared to T6, etc). This result reinforces a previous ELDERMET 
study, where Claesson et al observed using compositional sequencing that the faecal 
microbiota of elderly individuals was relatively stable over a 3 month period in the majority 
of the subjects. In this case it was noted that the microbiota composition of the elderly was 
characterised by higher inter-individual variation when compared to younger control subjects 
(Claesson et al. 2011).  
Effect of antibiotic therapy on the temporal stability of Bifidobacterium spp., Lactobacillus 
spp. and Enterobacteriaceae   
Antibiotic therapy is of fundamental importance to modern medicine and is pivotal in treating 
many infectious diseases. Both molecular and culture based techniques have revealed the 
perturbations and resilience of gut microbiota following antibiotic administration (De La 
Cochetiere et al. 2005; Jernberg et al. 2007; Dethlefsen & Relman 2011). In this study, no 
significant difference was observed between the levels of Bifidobacterium spp., Lactobacillus 
spp. or Enterobacteriaceae over the 6 month period when the impact of antibiotic therapy was 
considered i.e. in the antibiotic treated group or in the untreated group (sees Figure 2). In 
addition, there was no significant difference between the levels of Bifidobacterium spp., 
Lactobacillus spp. or Enterobacteriaceae between the antibiotic treated and untreated subjects 
at the corresponding time points. However, in a previous ELDERMET study, we observed 
that the Bifidobacterium spp. numbers were significantly reduced following antibiotic therapy 
(P=0.004) (O'Sullivan et al. 2013) . This difference may be due to a larger subject number in 
the initial study and thus more subjects on antibiotic therapy (42 of 185 subjects on 
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antibiotics (23 %) versus 7 to 9 of 65 subjects (average 12 %) on antibiotics). Even though 
there was no significant difference observed in the three bacterial groups studied, the levels 
of Bifidobacterium spp. and Lactobacillus spp. tended to be lower (albeit not significantly) 
for the subjects on antibiotic therapy compared to antibiotic untreated subjects (Figure 2). 
Alterations to and recovery of the bacterial groups post antibiotic therapy 
Even though antibiotic therapy as a whole did not affect the temporal stability of the 3 
bacterial groups, the elderly subjects receiving antibiotics (n=20) were individually assessed 
based on antibiotic type (group 1 to 4) and antibiotic combination. In this study, 19 subjects 
were treated with various antibiotics and antibiotic combinations at 1 or 2 time points. Only 
one subject received antibiotics at all 3 time-points (EM101, Table 2). Antibiotic types and 
combinations included cell envelope inhibitors (Group 1; n=5), protein synthesis inhibitors 
(Group 2; n=4), nucleic acid synthesis inhibitors (Group 3; n=2) and combination of 
antibiotics (Group 4; n=7). 
Figure 3(a) represents the subjects receiving only cell envelope inhibitors (Group 1). Subjects 
EM085 and EM185 were on antibiotic therapy prior to the study and at T0, but had ceased by 
month 3. In these cases, Bifidobacterium spp. levels increased slightly following completion 
of antibiotic therapy (0.5 log by month 3 for EM185 and 1 log by month 6 for EM085). 
Enterobacteriaceae levels increased by 0.5 log in both subjects when antibiotic treatment 
ceased (T3) but returned to the original level by T6. In subject EM085, the levels of 
Lactobacillus spp. decreased when antibiotic therapy ceased (2 log decrease by T3 and 
another 2 log decrease by T6) (Figure 3(a)). This reflects the observation that Lactobacillus 
spp. can increase with antibiotic therapy (O'Sullivan et al. 2013). In contrast, for subject 
EM137, when antibiotics were introduced at T3, the Lactobacillus spp. levels declined by 1 
log and then increased again when antibiotic therapy ceased (T6).  Levels of Bifidobacterium 
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spp. and Enterobacteriaceae in faecal microbiota of subject EM137 were not impacted 
immediately by antibiotic therapy, but levels had dropped by over 1 log by T6. Introducing 
antibiotics at T6 for subject EM096 did not impact levels of Bifidobacterium spp. and 
Lactobacillus spp.; however, Enterobacteriaceae declined by 2 logs. All bacterial groups 
assessed in subject EM181 decreased by the introduction of antibiotics at T6, with levels 
dropping over 100 fold in all cases.  
In subjects on protein synthesis inhibitor therapy (PSI, Group 2) there was no major impact 
on the three bacterial groups, with the exception of subject EM059, where the counts of 
Bifidobacterium spp. decreased by up to 6 log following commencement of antibiotic therapy 
just prior to T3.  Bifidobacterium spp. levels had increased slightly by T6 once antibiotic 
therapy ceased (Figure 3(b); Group 2). Of the two elderly subjects receiving nucleic acid 
inhibitors (Group 3), subject EM200 received antibiotics at only T0, whereas subject EM090 
received antibiotics at T3 and T6. There was no noticeable impact of antibiotics on the 
bacterial classes in subject EM090 over time. However, for subject EM200, the levels of 
Bifidobacterium spp. and Lactobacillus spp. initially increased at T3 but then decreased by 1 
to 2 log by T6 (Figure 3(c); Group 3). The impact of the combination of antibiotics (Group 4) 
was limited; of the 7 subjects, only 2 showed a 1 to 2 log decrease in bacterial counts, which 
eventually recovered ((Figure 3(d); Group 4). 
Overall, in some subjects there was still an effect on bacterial counts up to 3 and 6 months 
following therapy, re-enforcing the long-term impact of antibiotics on the gut microbiota 
observed in other studies (Jernberg et al. 2007; Hussey et al. 2010). In some subjects, the 
recovery of the microbiota was slow and in some subjects it stabilized relatively quickly, 
suggesting that the resilience of the gut microbiota to antibiotic treatments varies 
considerably between individuals. Studies have reported bacterial resilience following 
antibiotic treatment (Dethlefsen et al. 2008; Antonopoulos et al. 2009; Jakobsson et al. 
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2010). A recent study by Dethlefsen et al outlined the response of distal gut communities to 
antibiotic administration across three individuals, where the gut community returned to a 
stable state similar, yet distinct to the pre-treatment state (Dethlefsen & Relman 2011). 
Similarly, our results suggest that the resilience of the microbiota can vary considerably 
across individuals and between the antibiotic treatment periods in the same individual.  
Impact of residence location on the temporal stability of Bifidobacterium spp., 
Lactobacillus spp. and Enterobacteriaceae  
The 65 elderly subjects resided in 4 different living environments and we compared the 2 
more diverse residence locations (long-stay versus community). The long-stay subjects were 
resident in institutionalised care for greater than 6 weeks (n=21 at all-time points) and the 
community subjects were members of the general public living in the community (n=35, 36 
and 36 at T0, T3 and T6, respectively). To analyse the effect of residence location on 
Bifidobacterium spp., Lactobacillus spp. and Enterobacteriaceae, the bacterial counts were 
also divided based on antibiotic therapy, as it was demonstrated previously that the levels of 
culturable Bifidobacterium spp. are affected by antibiotic therapy (O'Sullivan et al. 2013).  
Statistical analysis was not carried out on the antibiotic treated group as the sample numbers 
were limited (n=4, 5 and 2 for the for long-stay subjects at T0, T3 and T6 respectively and 
n=3 for community subjects at all time-points). However, the culture results for these 
antibiotic treated subjects are graphically represented in Figure 4(b), (d) and (f).  
Enterobacteriaceae and Bifidobacterium spp. levels were maintained over 6 months in the 
long-stay and community groups on antibiotic therapy, but levels of  Lactobacillus spp. were 
found to decline as time progressed (in both stratifications).  
The levels of Bifidobacterium spp., Lactobacillus spp. and Enterobacteriaceae in the 
antibiotic untreated groups in both residence locations were maintained over the 6 month 
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period (P values detailed in Figure 4(a), (c) and (e)). When the residence locations were 
compared at the individual time-points, Bifidobacterium spp. were significantly higher in the 
community compared to the long-stay residence location at T0 (P=0.047). This significant 
difference was maintained at T3 (P=0.020) and T6 (P=0.002). This result was in agreement 
with Bartosch et al., 2004 who reported that the elderly living in the community had higher 
levels of faecal Bifidobacterium spp. than hospitalised subjects (Bartosch et al. 2004). 
Lactobacillus spp. and Enterobacteriaceae levels were not significantly different at any time 
point, when the two residence locations were compared.  
Effect of probiotic intake on the temporal stability of Bifidobacterium spp., Lactobacillus 
spp. and Enterobacteriaceae   
The evidence for the use of probiotics to maintain health and well-being in the elderly is 
growing and has been shown to cover a wide range of diseases and ailments (Fujimura et al. 
2010; Aureli et al. 2011; Gerritsen et al. 2011). The health benefits derived by the 
consumption of foods containing probiotic bacteria are well documented (Gill et al. 2001; 
Ahmed et al. 2007), and most probiotics belong to the two genera Bifidobacterium spp. and 
Lactobacillus spp., which are generally regarded as safe (Ventura et al. 2008; Kleerebezem & 
Vaughan 2009; Kim et al. 2013). In the last 10 years, there has been an increasing interest in 
the consumption of probiotics and functional foods. Probiotic bacteria are known to suppress 
potentially pathogenic microorganisms in the gastrointestinal tract and enhance the 
population of beneficial microorganisms (Culligan et al. 2009; Gerritsen et al. 2011). 
Levels of culturable Bifidobacterium spp., Lactobacillus spp. and Enterobacteriaceae were 
enumerated to establish whether regular probiotic intake had an effect on the numbers of 
bacteria detected in faecal samples from elderly subjects. The food frequency questionnaire 
(FFQ) enabled the elderly subjects to document whether they consumed a probiotic-based 
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drink or food. Details were unavailable for some of the 65 elderly subjects in this study 
(Table 3). Levels of culturable Bifidobacterium spp., Lactobacillus spp. and 
Enterobacteriaceae in faecal samples from subjects that regularly consumed a probiotics-
based product at all 3 time points (T0, T3 and T6; n=5) were compared to subjects that did 
not consume probiotics at any time point (n=26).  Statistical analysis (P>0.05 for T0, T3 and 
T6 on Figure 5) indicated no significant difference between the subject groups. When the 
levels of the three bacterial groups were compared  with respect to probiotic intake, only 
Bifidobacterium spp. numbers at month 6 were significantly higher (P=0.012) in the group 
with regular probiotic consumption (8.85 compared to 7.58 log CFU gram
-1
). Although 
statistically there was no difference in the count of Bifidobacterium spp. observed at T0, 
(P=0.248) and T3 (P=0.126), an increase in counts was observed (Figure 5(a)). Similarly, the 
average numbers of culturable Lactobacillus spp. in the subjects on probiotics were higher 
than the subjects not on probiotics, but there was no statistical difference (P>0.05).   
The study showed that the bacterial counts remained stable over the 6 month period for the 
groups assessed in all subjects, irrespective of probiotic intake. This stability of the gut 
microbiota was in contrast to the observed response of the gut microbiota of both elderly and 
infants fed with probiotics, in which the gut microbiota composition was considerably 
affected by probiotics administration (Lahtinen et al. 2009; Cox et al. 2010). Indeed, in a 
short-term dietary intervention study, controlled feeding of the probiotic diet over 10 days 
also showed a rapid and marked change in the microbiome composition within a day of the 
intervention (Wu et al. 2011). 
Overall, monitoring the stability of specific key members of the human gut bacterial 
community from 65 elderly subjects over a 6 month time period demonstrated the temporal 
stability of 3 bacterial groups (Bifidobacterium spp., Lactobacillus spp. and 
Enterobacteriaceae). The population of these bacterial communities fluctuated unpredictably 
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with antibiotic usage, wherein the microbiota of some subjects recovered slowly and others 
reached a stable state relatively quick, suggesting that the resilience of the gut microbiota 
varied among the subjects. Studies have examined variations in the faecal microbiota using 
high-throughput sequencing technologies (Caporaso et al. 2010; Dethlefsen & Relman 2011) 
and have shown that despite fluctuations in the microbiota composition over time and shifts 
due to disturbances, the overall bacterial community is maintained in the longer term 
(Turnbaugh et al. 2008; Dethlefsen & Relman 2011).  
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3.5 Conclusion 
The ability of the human gut microbiota to remain stable is thought to be an important factor 
to maintain the host health. In this respect, it was found that microbial diversity was inversely 
related to health, based on a number of physiological and biological parameters. In this study, 
we monitored the stability of specific key members of the human gut bacterial community 
(Bifidobacterium spp., Lactobacillus spp. and Enterobacteriaceae) from 65 elderly subjects 
over a 6 month time period and demonstrated the temporal stability of these 3 bacterial 
groups. The administration of antibiotics did not significantly alter the temporal stability of 
the bacterial communities. However, the population of these bacterial communities fluctuated 
unpredictably with the use of different antibiotic types and the resilience of the gut 
microbiota varied between subjects. Regular probiotic intake by the elderly subjects 
demonstrated a significant increase in the counts of Bifidobacterium spp. at only one time 
point (month 6).  In contrast, there was no significant effect on culturable Lactobacillus spp. 
and Enterobacteriaceae due to regular probiotic consumption. One of the major limitations of 
this study was the lack of molecular characterisation of the isolates to strain level, where 
undoubtedly even larger changes in the microbial population could have occurred. Further 
longitudinal studies assessing the bacterial species composition and diversity, and function of 
the gut microbiota in these elderly subjects may help to better understand the activity and the 
contribution of the microbiota to human health and well-being.  
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Table 1:  Residence location and details of antibiotic therapy for 65 elderly subjects at month 
0, 3 and 6 
 Residence location Time (month) 
 0 3 6 
Long-stay 21 (4)* 21 (5) 21 (2) 
Rehab 4 (2) 5 (1) 4 (2) 
Day Hospital  5 (0) 3 (0) 4 (0) 
Community  35 (3) 36 (3) 36 (3) 
Total   65 (9) 65 (9) 65 (7) 
*number of subjects on antibiotic therapy in each residence location is outlined in brackets.  
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 Table 2:  Antibiotics administered to 20 elderly subjects in this study.
 
Antibiotics were 
classified as nucleic acid inhibitors (NAI), cell envelope antibiotics (CE), protein synthesis 
inhibitors (PSI) or others. Groups were defined by the type of antibiotic administered - Group 
1: CE at 1 time point; Group 2: PSI at 1 time point; Group 3: NAI at 1 or 2 time points and 
Group 4: combination of antibiotics at 1, 2 or 3 time points.  
Subject Group  T0 T3 T6 
EM085  1 CE none none 
EM096 1 none none CE 
EM137 1 none CE none 
EM181 1 none none CE 
EM185  1 CE none none 
EM047 2 none PSI none 
EM053  2 none PSI none 
EM059  2 none PSI none 
EM118  2 none none PSI 
EM090 3 none NAI NAI 
EM200  3 NAI none none 
EM101 4 CE, NAI & CE CE & NAI CE & NAI 
EM110 4 CE, NAI, PSI & others none none 
EM126  4 NAI none CE 
EM133  4 CE, CE & NAI none none 
EM135  4 NAI, NAI & CE none none 
EM166 4 CE, CE, NAI, CE & NAI none none 
EM169 4 none NAI & CE NAI 
EM159 NA* none others none 
EM168  NA none others  none 
*NA – not applicable. 
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Table 3:  Probiotic intake by 65 elderly subjects over time.   
 
Frequency of probiotic consumption Time (month) 
0 3 6 
Never 31 40 38 
Infrequent (max. 1 portion/month) 9 13 10 
Irregular (1- 2 portions/week) 2 3 4 
Regular (0.7-2 portions/day) 6 8 9 
Data not available 17 1 4 
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Figure 1:  Culturable Bifidobacterium spp., Lactobacillus spp. and Enterobacteriaceae (log 
CFU gram
-1
) recovered from faecal samples from elderly subjects over time (0 (), 3 () 
and 6 () months) (n=65;  = mean; × = outliers).  
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Figure 2:  Box plot representation of the numbers of (a) Bifidobacterium spp., (b) 
Lactobacillus spp. and (c) Enterobacteriaceae (log CFU gram
-1
) recovered from faecal 
samples from 65 elderly subjects treated and untreated with antibiotics at T0 (; n=9 and 
n=56, respectively),  T3 (; n=9 and n=56, respectively) and T6 (; n=7 and n=58, 
respectively), independent of residence location ( = mean; × = outliers).  
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 Figure 3:  Levels of Bifidobacterium spp. (B), Lactobacillus spp. (L) and Enterobacteriaceae 
(E) in faecal samples from elderly subjects on antibiotic therapy at one or more time point. 
Subjects are divided into (a) Group 1: treatment with cell envelope (CE) antibiotics at one 
time point (EM085 at T0, EM185 at T0, EM137 at T3, EM096 at T6 and EM181 at T6);  (b) 
Group 2: treatment with protein synthesis inhibitors (PSI) at one time point (EM047 at T3, 
EM053 at T3, EM059 at T3 and EM118 at T6); (c) Group 3: treatment with nucleic acid 
synthesis inhibitors (NAI) at one or two time points (EM200 at T0 and EM090 at T3 and T6) 
and (d) Group 4: treatment with a combination of antibiotics at one or more time points 
(EM110 at T0, EM133 at T0, EM135 at T0, EM166 at T0, EM126 at T0 and T6, EM169 at 
T3 and T6 and EM101 at T0, T3 and T6). Counts were recorded at month 0 (), month 3 
() and month 6 ().  
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(c) Group 3 
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Figure 4: Levels of culturable Bifidobacterium spp., Lactobacillus spp. and 
Enterobacteriaceae (log CFU gram
-1
 faeces) in faecal samples from 65 elderly subjects 
separated by antibiotic therapy and residence location. Figures 4(a), 4(c) and 4(e) represent 
levels of Bifidobacterium spp., Lactobacillus spp. and Enterobacteriaceae, respectively, in the 
antibiotic untreated subjects from the long-stay (n=17 (T0), 16 (T3) and 19 (T6)) and 
community (n=32 (T0), 33 (T3) and 33 (T6)) residence locations. Figures 4(b), 4(d) and 4(f) 
represent levels of Bifidobacterium spp., Lactobacillus spp. and Enterobacteriaceae, 
respectively, in the antibiotic treated subjects from the long-stay (n=4 (T0), 5 (T3) and 2 
(T6)) and community (n=3 (T0), 3 (T3) and 3 (T6)) residence locations. ( = mean; × = 
outliers).  
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Figure 5:  Levels of culturable (a) Bifidobacterium spp., (b) Lactobacillus spp. and (c) 
Enterobacteriaceae in faecal samples from elderly subjects. Subjects were assessed based on 
probiotic intake, where no probiotic intake at any time point (n=26) was compared to regular 
probiotic intake at all 3 time points (n=5). Counts were recorded at 0 (), 3 () and 6 () 
months.  
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4.1 Abstract 
 
Aims: To isolate and characterize bacteriocins produced by predominant species of lactic 
acid bacteria (LAB) from faeces of elderly subjects.  
Methods and Results: Screening over 70,000 colonies, from faecal samples collected from 
266 subjects, using the indicator organisms Lactobacillus bulgaricus LMG 6901 and Listeria 
innocua DPC 3572, identified 55 antimicrobial-producing bacteria. Genomic fingerprinting 
following ApaI digestion revealed 15 distinct strains. The antimicrobial activities associated 
with 13 of the 15 strains were sensitive to protease treatment. The predominant antimicrobial-
producing species were identified as Lactobacillus salivarius, Lactobacillus gasseri, 
Lactobacillus acidophilus, Lactobacillus crispatus and Enterococcus spp. A number of 
previously characterized bacteriocins, including ABP-118 and salivaricin B (from Lb. 
salivarius), Enterocin B (Ent. faecium), Lactacin B (Lb. acidophilus), Gassericin T and a 
variant of Gassericin A (Lb. gasseri), were identified. Interestingly, two antimicrobial-
producing species, not generally associated with intestinally-derived microorganisms were 
also isolated: Lactococcus lactis producing Nisin Z and Streptococcus mutans producing 
Mutacin II.  
Conclusion: These data suggest that bacteriocin production by intestinal isolates against our 
chosen targets under the screening conditions used was not frequent (0.08%).  
Significance and Impact of the Study: The results presented are important due to growing 
evidence indicating bacteriocin production as a potential probiotic trait by virtue of strain 
dominance and/or pathogen inhibition in the mammalian intestine.  
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4.2 Introduction 
Bacteriocins produced by lactic acid bacteria (LAB) are ribosomally synthesised peptides, 
which generally have inhibitory action against closely related organisms and to which the 
producing strain is immune (Cotter et al. 2005; De Vuyst and Vandamme 1994). A number 
of bacteriocins produced by LAB have potential as novel antimicrobial agents in various 
practical applications from food to medicine (De Martinis et al. 2002; Joerger 2003; 
Klaenhammer et al. 2005; O'Sullivan et al. 2002; Todorov and Dicks 2007).  Many LAB 
have been proven to function as probiotics, which are of benefit to human health when 
ingested in sufficient quantities. The isolation of potential bacteriocin-producing strains from 
the intestinal microbiota (comprising both Gram-negative and Gram-positive bacteria) has 
been previously reported (Gordon and O'Brien 2006; O'Shea et al. 2009). A diverse range of 
Gram-positive bacteriocin producers including lactobacilli, enterococci and streptococci were 
isolated in the latter study, with a high incidence (up to 70%) of repeated isolation for some 
bacteriocin producers. With respect to Gram-negative bacteria, the frequency of production 
of bacteriocins (such as colicins and microcins) by the E. coli population component of the 
microbiota can vary from 10-80% (Gordon and O'Brien 2006).  
Bacteriocin production may confer a significant advantage to the producing strain by 
allowing it to dominate complex microbial populations (O'Shea et al. 2009). The added 
advantage of using bacteriocin-producing probiotics over bacteriocins themselves is that in 
situ production potentially overcomes the adverse effect of proteolysis of the released peptide 
during gastric transit. A number of studies have demonstrated the potential use of 
bacteriocins in the control of important gastric pathogens including Salmonella spp. (Casey et 
al. 2004), Campylobacter jejuni (Stern et al. 2006; Svetoch et al. 2011), Listeria 
monocytogenes (Allende et al. 2007; Corr et al. 2007), Escherichia coli O157:H7 (Brashears 
et al. 2003) and Clostridium difficile (Rea et al. 2007). With regard to the latter, Rea et al. 
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demonstrated the potential of a narrow spectrum bacteriocin to control C. difficile in a human 
colon model, without causing collateral damage to the surrounding microbiota (Rea et al. 
2011).  
The intestinal microbiota is considered a rich source of potential probiotic bacteria 
and there is an increasing interest in the isolation of new bacteriocin-producing strains of 
human origin. Indeed, intestinal source has been reported as one of the primary criteria in 
selecting probiotic strains, as these strains may function better in an environment similar to 
its origin (Saarela et al. 2000). While, there has been considerable research on LAB 
bacteriocins to date, there are few studies on the screening for bacteriocin-producing LAB 
from the human intestinal tract (Birri et al. 2010; Flynn et al. 2002; Verdenelli et al. 2009). 
The increasing interest in the isolation of bacteriocin-producing LAB of human intestinal 
origin that could be evaluated for probiotic effects was one of the motivating factors for this 
research. 
The ELDERMET consortium was established in 2008 (http://eldermet.ucc.ie), and 
aims to determine the intestinal microbiota of 500 elderly (>65 yr) Irish people. To date, this 
project has elucidated links between microbiota composition, diet and health (Claesson et al. 
2011; Claesson et al. 2012), and has generated a large collection of intestinal isolates 
(including bifidobacteria and lactobacilli), suitable for screening for use as probiotics for the 
elderly population. The aim of this present study was to isolate and characterize bacteriocin-
producing isolates from the ELDERMET biobank that may have potential applications for 
improving gut health in the elderly. Bacteriocin-like substances were characterized based on 
their spectrum of inhibition and identified by DNA sequencing and Matrix-assisted laser 
desorption ionization-time of flight (MALDI-TOF) mass spectrometry (MS) with a view to 
determining their potential for probiotic applications. 
143  
4.3 Materials and Methods 
 
Subject recruitment and sample collection 
Subjects aged 65 yr and older were recruited and examined at ELDERMET Clinics at two 
local hospitals (Cork University Hospital and St. Finbarr’s Hospital, Cork) as previously 
outlined (Claesson et al. 2011). The subjects included patients in long-term institutional care, 
rehabilitation centres, out-patient day hospitals, people being treated with antibiotics and a 
group of comparatively healthy elderly individuals. A total of 410 faecal samples from 266 
elderly subjects were assessed. In addition to the initial sample (T0), faecal samples were also 
collected from some subjects at 3 (T3) and 6 months (T6). Stool samples were collected into 
a sterile container, stored at 5
o
C until transported on ice to the laboratory.  
Bacterial strains, media and growth conditions 
LAB strains were grown anaerobically at 37
o
C for 24 to 48 h on de Man, Rogosa, Sharpe 
(MRS, Difco Laboratories, Detroit, MI, USA) agar supplemented with 0.05% (w/v) L-
cysteine hydrochloride (Sigma Chemical Co., St. Louis, MO, USA) (denoted mMRS agar).  
All other bacterial strains were cultivated in Brain Heart Infusion (BHI) medium and were 
grown aerobically at 37
o
C.  Where solid media was required, 1.5% agar (w/v) (Oxoid Ltd., 
Basingstoke, Hampshire, UK) was added and for softer overlay medium, 0.8% (w/v) agar 
was added. 
Enumeration of culturable bacteriocin-producing strains from faecal samples  
One gram of the faecal sample was mixed with 9 ml maximum recovery diluent (MRD, 
Oxoid) in a Seward stomacher bag and subsequently diluted 10-fold as outlined previously 
(O’Sullivan et al. 2011). To enumerate total culturable LAB strains, the dilutions were spread 
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plated (100 μl) onto mMRS agar.  Agar plates were incubated anaerobically at 37oC for 48 h. 
Bacterial counts were recorded as colony forming units (CFU) per gram of faeces and counts 
were expressed as log CFU g
-1
 faeces. These plates were overlaid with the indicator strains 
and were incubated at 37
o
C for 24 h. The indicator strains used were Lactobacillus 
delbrueckii subsp. bulgaricus LMG 6901 (for all samples) (BCCM/LMG Culture Collection, 
Gent, Belgium), Bifidobacterium breve NCIMB 8807 (for 228 samples) (National Collection 
of Industrial, Marine and Food Bacteria, Aberdeen, Scotland), Bifidobacterium lactis Bb12 
(for 30 samples) (Chr. Hansen, Little Island, Cork, Ireland), Escherichia coli O157:H7 NCTC 
12900 (for 11 samples) (National Collection of Type Cultures, Central Public Health 
Laboratory, London, UK) and Listeria innocua DPC 3572 (for 123 samples) (Teagasc Food 
Research Centre, Moorepark, Fermoy, Co. Cork, Ireland).  Bacterial colonies generating a 
zone of inhibition against the indicator strain on the agar plates were selected and cultured in 
mMRS broth for 24 h at 37
o
C. These isolates were stocked in the ELDERMET Culture 
Collection for further characterization. 
Antimicrobial activity assay 
The antimicrobial activity of the cell-free supernatant (CFS) of the bacteriocin-producing 
strains was determined by the agar well diffusion method (Ryan et al. 1996). To eliminate the 
possibility of a zone of inhibition due to acid production, all culture supernatants were 
adjusted to pH 6.5 with 1 N NaOH and filter-sterilised (0.45 µm). Antimicrobial activity was 
assessed against a selection of Gram-positive and Gram-negative strains (Lb. bulgaricus 
LMG 6901, L. innocua DPC 3572, L. monocytogenes DPC 3785, Staphylococcus aureus 
DPC 5245, Salmonella typhi DPC 6452, S. typhi DPC 6046, E. coli DPC 6239 and 
Cronobacter sakazakii DPC 6440). All agar plates were examined for a zone of inhibition 
following overnight incubation. 
145  
Influence of heat treatment and enzymes on antimicrobial activity 
To evaluate the heat stability of the bacteriocins, the neutralised supernatants from the 
bacteriocin-producing strains were heated to 100
o
C for 30 min. The untreated bacteriocin was 
used as a positive control. All culture supernatants were adjusted to pH 6.5 with 1 N NaOH 
and were mixed with an equal volume of each of the enzymes proteinase K, pepsin and 
catalase (25 mg ml
-1
; Sigma) and incubated at 37
o
C for 3 h. Following enzyme and heat 
treatment, the residual antimicrobial activity in the treated supernatant was assessed using the 
agar-well diffusion assay with the indicator strain Lb. bulgaricus LMG 6901, in comparison 
with the untreated sample. 
Genetic characterization of bacterial isolates 
Genomic DNA was extracted as outlined previously (Coakley et al. 1996), and RNAse (0.75 
μl, Sigma) was added to the extracted DNA, incubated for 1 h at 37oC and then denatured at 
65
o
C for 15 min. Bacterial isolates were identified by amplification of the 16S rRNA gene 
using the 16S Eubacterial primers CO1 and CO2 (Table 1; Simpson et al. 2003) and the 
complete sequence of the 16S rRNA gene  was determined by Sanger sequencing (Beckman 
Coulter Genomics). The species was determined by nucleotide alignments (>98%) with 
deposited species in the NCBI database (http://blast.ncbi.nlm.nih.gov) and using the 
Ribosomal Database Project (RDP) (http://rdp.cme.msu.edu/). For Enterococcus isolates 
further PCR analysis was used to distinguish the species present using previously published 
species-specific primers (Jackson et al. 2004). Primers specific to structural genes of known 
bacteriocins were also used (Table 1).  All PCR reactions were performed in a G-Storm PCR 
machine (Gene Technologies, Essex, UK) and PCR products sequenced by Beckman Coulter 
Genomics. Sequences were aligned to the structural bacteriocin genes using the Lasergene 6 
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software programme and subsequently analysed by BlastP analysis 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi). 
Pulsed-field gel electrophoresis (PFGE) of bacterial isolates  
PFGE of isolates demonstrating antimicrobial activity in the CFS was performed as 
previously described (Simpson et al. 2002) using the ApaI restriction endonuclease. A low 
range molecular weight DNA marker (9.42–194.0 Kb; New England Biolabs, Beverly, MA, 
USA) was used to determine the band size. Electrophoresis was performed using the Biorad 
Chef-DR II instrument (Biorad, USA). For each PFGE pattern obtained, one strain was 
selected for further characterization. 
Purification and identification of bacteriocins 
Purification of antimicrobial peptides was performed by reverse-phase high-performance 
liquid chromatography (RP-HPLC). The bacteriocins were purified from an overnight culture 
of the producing strain in mMRS broth. Bacterial cells were harvested by centrifugation and 
resuspended in 70% (v/v) propan-2-ol and 0.1% (v/v) trifluoroacetic acid (TFA) and mixed at 
room temperature for 3-4 h. Following removal of the propan-2-ol by rotary evaporation, 20 
ml of the sample was applied to a 5 g STRATA C18-E SPE column (Phenomenex, Cheshire, 
UK) which was pre-equilibrated with methanol and water. The column was washed with 20 
ml 40% (v/v) ethanol and the bacteriocin activity was eluted with 70% (w/v) propan-2-ol. 
Following removal of the propan-2-ol from the preparation, aliquots were applied to a semi-
preparative Proteo Jupiter (4 u Proteo, 90 Å, 250 x 10 mm) RP HPLC column, previously 
equilibrated with 30% propan-2-ol containing 0.1% TFA. The column was subsequently 
developed in a gradient of 30% (v/v) propan-2-ol, containing 0.1% (v/v) TFA to 60% (v/v) 
propan-2-ol, containing 0.1% (v/v) TFA over 40 min. Bioactive fractions were collected at 1 
min intervals and bacteriocin activity was monitored by the well diffusion assay. For some 
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strains, the supernatant of the overnight culture was used to determine the bacteriocin 
activity. MALDI-TOF mass spectrometry was performed on HPLC fractions as described 
previously (Cotter et al. 2006). 
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4.4 Results  
 
Screening and isolation of bacteriocin-producing bacteria 
Screening of over 70,000 colonies from 410 faecal samples (from 266 elderly subjects) 
resulted in the detection of 276 colonies exhibiting antimicrobial activity against Lb. 
bulgaricus LMG 6901 (273 colonies) and L. innocua DPC 3572 (3 colonies), representing an 
isolation frequency of 0.4% in the initial screening. Despite exhaustive parallel screening, 
colonies showing inhibitory activity against Bif. breve NCIMB 8807, Bif. lactis Bb12 and    
E. coli strains were not detected in this study.  The lack of activity against the indicator strain 
E. coli was not surprising due to the protective nature of the cell membrane in Gram-negative 
bacteria against the action antimicrobial compounds (Gao et al. 1999). In addition, the culture 
conditions in this study focused mainly on the isolation of LAB bacteria which generally kill 
or inhibit closely related Gram-positive strains (Klaenhammer 1988; Riley and Wertz 2002). 
The 276 inhibitory isolates were subsequently reduced in number to 55 isolates (from 
32 subjects) following neutralization of the CFS, representing a frequency of successful 
probable bacteriocin isolation of 0.08%.  Further analysis of the 55 isolates by PFGE resulted 
in 15 individual strains (from 14 subjects) with distinct PFGE profiles (Figure 1), 
corresponding to a probable bacteriocin detection frequency of 0.02%. Strains with similar 
PFGE patterns were isolated from multiple subjects, as shown in Table 2. A high incidence of 
repeated isolation was observed for Lb. gasseri (12), Lb. crispatus (15) and Ent. durans (6). 
Strains with identical PFGE patterns were confirmed to produce the same/similar bacteriocin 
by cross-sensitivity assays, since each isolate was cross-immune to the antimicrobial 
compound produced by the other (data not shown).  
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Species identification of bacterial strains 
The 16S rDNA gene sequences of the isolates were determined and compared with the 
available 16S rDNA sequences in the NCBI database. One of the most predominant species 
isolated in this study was Lb. gasseri. Other organisms identified included Lb. salivarius, Lb. 
acidophilus, Strep. mutans, L. lactis and Enterococcus spp. (Table 3). In addition to 16S 
rDNA gene sequencing, the identified enterococcal isolates were further typed using species-
specific PCR primer sets for sequence variations in manganese dependent superoxide 
dismutase genes of Enterococcus, as previously described (Jackson et al. 2004). Based on 
this method, two of the enterococcal strains (EM342-BC-1 and EM297-BC-T6-1) were 
determined to be Ent. faecium and EM133-BC-1 to be Ent. durans.  
Inhibitory spectrum 
The 15 antimicrobial-producing strains with distinct PFGE patterns were selected for further 
characterization. The inhibitory spectra of the strains using a range of indicator organisms 
were investigated and revealed a strain-dependent variation (Table 4). All the strains 
exhibited zones of inhibition against Lb. bulgaricus and other strains including Lb. salivarius, 
L. lactis and Enterococcus spp. also exhibited relatively wide spectra of activity, inhibiting L. 
innocua and Staph. aureus. As expected, none of the strains tested exhibited antimicrobial 
activity against the Gram-negative indicator organisms, including strains of S. typhi, C. 
sakazakii or E. coli.  
Enzyme and heat sensitivity 
The isolated crude bacteriocins exhibited stability at 100
o
C for 30 min, with the exception of 
bacteriocins from the Lb. crispatus strains. None of the inhibitory zones were affected by 
catalase, indicating that hydrogen peroxide was not involved in the inhibitory action. In 
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contrast, the antimicrobial activity associated with 13 of the 15 strains was found to be 
sensitive to proteinase K, indicating the presence of antimicrobial compound of a protein 
nature in these cases (Table 3). The two Lb. crispatus strains were again exceptions, as their 
culture supernatants demonstrated antimicrobial activity even after proteinase K treatment.  
Identification and purification of bacteriocins  
Following species identification of the bacteriocin-producing isolates, primers specific to 
known bacteriocin structural genes from the isolated bacterial species were employed in test 
amplifications (Table 1). PCR analysis and subsequent DNA sequencing were used as an 
initial method to identify the putative bacteriocin structural genes present in each strain. This 
resulted in identification of ten different putative bacteriocins from the selected 15 isolates 
(Table 3). In parallel, the bacteriocins produced by these strains were purified by RP HPLC, 
and the molecular mass of the peptides was determined using MALDI-TOF MS. Precise 
matching of these peptide masses to the theoretical masses was taken as evidence that the 
identified bacteriocin structural genes encoded the active bacteriocin. Certain bacteriocin 
producers were selected for further characterization based either on their unusual presence in 
the human intestinal microbiota (L. lactis EM089-BC-T6-1 and Strep. mutans EM315-BC-
T3-2), on their broad inhibitory spectra (Lb. salivarius EM100-BC-T3-1 and EM253-BC-T6-
2), or due to the production of multiple bacteriocins (Ent. faecium EM297-BC-T6-1).  
PCR and amplicon sequence analysis of Lb. salivarius EM100-BC-T3-1 and EM253-
BC-T6-2 confirmed the presence of the three bacteriocin structural genes; these encoded 
salivaricin B and both peptides of the ABP-118 bacteriocin (α and β) in all strains. MALDI-
TOF MS of the pure peptides, following RP-HPLC purification, confirmed molecular masses 
of 4,096 and 4,332 Da (Figures 2a and 2b), which correspond to the previously characterized 
ABP-118α and ABP-118β peptides of the ABP-118 bacteriocin, respectively (Flynn et al. 
151  
2002). This was in accordance with the PCR and sequence analysis, which indicated the 
presence of the structural genes (100% identity) for this two-peptide bacteriocin within the 
strain. In addition, MS analysis also confirmed the presence of another previously 
characterized peptide, salivaricin B (Cataloluk 2001) showing a corresponding mass of 4,433 
Da (Figure 2c). However, this peptide neither inhibited the indicator strain Lb. bulgaricus nor 
displayed anti-listerial activity, which confirmed recent findings in our laboratory.  
PCR analysis and DNA sequencing data for Ent. faecium EM342-BC-1 confirmed the 
presence of the Enterocin B gene, a previously characterized class IIc bacteriocin (Casaus et 
al. 1997). Interestingly, another Ent. faecium strain EM297-BC-T6-1, was confirmed to 
harbour the structural genes for a recently identified bacteriocin, Enterocin M (Marekova et 
al. 2007) and also the genes for the two-component bacteriocin Enterocin 62-6, which is 
closely related to Enterocins L50A and L50B (Dezwaan et al. 2007). MS analysis of the 
bacteriocins from Ent. faecium EM297-BC-T6-1 identified proteins of two different masses 
corresponding to two putative bacteriocins. A peptide of 4,628 Da was identified 
corresponding to Enterocin M, which is an anti-listerial class IIa pediocin-like bacteriocin 
(Figure 2f) and a second bacteriocin consisted of two peptides (5,206 and 5,219 Da), 
corresponding to the two-peptide class IIc bacteriocins produced by a vaginal isolate of Ent. 
faecium 62-6 (Figure 2g).  
The sequence of the amplified PCR product from the L. lactis isolates revealed 100% 
amino acid identity to the translated structural gene of the well characterized lantibiotic, Nisin 
Z (Mulders et al. 1991) and was further investigated. MS analysis of bioactive RP-HPLC 
fractions purified from L. lactis EM089-BC-T6-1 revealed a peptide with a molecular mass of 
3,332 Da, which corresponds exactly to the peptide mass value expected for the nisin variant, 
Nisin Z (Figure 2d). 16S rDNA sequencing identified the ELDERMET isolate EM315-BC-
T3-2 as Strep. mutans. PCR and sequence analysis indicated the presence of the structural 
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gene for the bacteriocin, Mutacin II, whose expression was verified by MS analysis of the 
bacteriocin. The purified peptide (3,244 Da) from this isolate corresponded to the mass of the 
lanthionine-containing mutacin peptide, Mutacin II (Novak et al. 1994) (Figure 2e).  
In this study, three Lb. gasseri strains were shown to produce bacteriocins; Lb. gasseri 
EM081-BC-T3-1, EM315-BC-T6-1 and EM301-BC-T3-1 (Table 3). Of the three strains, Lb. 
gasseri EM081-BC-T3-1 generated the expected-sized PCR product when amplified with 
Gassericin T primers, which was confirmed by DNA sequencing. The other two strains were 
initially screened for the presence of the Acidocin B and Gassericin A structural genes using 
specific primers (Table 1). Due to the high similarity (>95% amino acid identity) between 
these two bacteriocins (Kawai et al. 1998b), both PCRs successfully generated a product in 
all strains. However, subsequent sequence analysis confirmed the presence of a structural 
gene with 98% amino acid identity to both Acidocin B and Gassericin A, indicating a new 
variant of this family of bacteriocins (Figure 3). MS analysis of the purified antimicrobial 
peptides revealed molecular mass of 5,683 Da, inferring the protein to be a variant of 
Gassericin A, a previously characterized class IIc bacteriocin (Kawai et al. 1998b) (Figure 
2h). PCR amplification of DNA from Lb. acidophilus EM066-BC-T3-3 confirmed the 
presence of the structural gene for Lactacin B and the protein alignments indicated 100% 
amino acid identity with the Lactacin B structural gene product, identified previously in Lb. 
acidophilus La-5 (Tabasco et al. 2009). The strain isolated from this study, demonstrated a 
narrow inhibitory spectrum, inhibiting only Lb. bulgaricus, which is similar to the Lactacin B 
bacteriocin (Barefoot and Klaenhammer 1983).  
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4.5 Discussion  
As intestinal origin is generally considered a desirable attribute for probiotic strains for 
human consumption, this screening study was undertaken to isolate human intestinally-
derived bacteria with antimicrobial activity. The availability of a large number of faecal 
samples from older subjects recruited in the ELDERMET study enabled a comprehensive 
screening for such strains specifically associated with the intestinal niche of older subjects of 
different health states, and resulted in the successful isolation of a broad range of bacteriocin 
producers of human intestinal origin. The initial activity screening of 70,000 colonies against 
Lb. bulgaricus LMG6901 resulted in the isolation of 273 isolates (representing an isolation 
frequency of 0.4%), which were subsequently reduced to 15 distinct strains through further 
characterization.   
  The bacteriocinogenic isolates were identified from the total bacterial count (on 
mMRS agar incubated anaerobically) ranging between log 10
6
 to log 10
9 
CFU per gram 
faeces. The isolation frequency of the bacteriocinogenic isolates was found to be low than 
expected (0.4% from total culturable bacteria) and did not represent a major part of bacteria 
culturable by the above methods. Due to the high number of colonies screened, the number of 
indicator organisms was restricted in this study.  In addition, it does have to be noted that 
conventional culture methods can limit a screening study to the ‘easy to culture’ organisms 
from the intestine. However, it has also been widely documented that the elderly intestinal 
microbiota differs from younger adults (Biagi et al. 2011; Claesson et al. 2011) and that the 
compromised stability of the intestinal microbiota in the elderly (Biagi et al. 2012; Mueller et 
al. 2006) may have resulted in the lower isolation of bacteriocin-producing strains.  
The majority of bacteriocin producers isolated in this study were Lactobacillus spp., 
with Lb. gasseri being the predominant species isolated.  This is in agreement with previous 
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studies which consider Lb. gasseri to be one of the most commonly detected LAB in the 
human intestinal tract (Reuter 2001; Wall et al. 2007). Other bacteriocin producers identified 
included Lb. crispatus, a common vaginal isolate (Pavlova et al. 2002), Lb. salivarius, 
Enterococcus spp., Strep. mutans and L. lactis. All the isolated bacteriocins exhibited 
stability at 100
o
C for 30 min and were sensitive to proteases with the exception of 
bacteriocins from the Lb. crispatus strains. Further analysis is required to determine the 
nature of the antimicrobial compound produced by these strains. 
Certain bacteriocin producers were selected for further characterization, including L. 
lactis EM089-BC-T6-1, Lb. salivarius EM100-BC-T3-1, Lb. salivarius EM253-BC-T6-2, 
Ent. faecium EM297-BC-T6-1 and Strep. mutans EM315-BC-T3-2. All four of the Lb. 
salivarius isolates (Table 3) from different ELDERMET subjects demonstrated inhibitory 
activity against Lb. bulgaricus LMG 6901, L. innocua DPC 3572 and the pathogenic L. 
monocytogenes DPC 3785 (Table 4). The presence of the three peptides ABP-118α, ABP-
118β and salivaricin B were confirmed in these Lb. salivarius isolates. ABP-118 is a well 
characterized two-component Class II heat-stable bacteriocin, produced by Lb. salivarius 
subsp. salivarius UCC118 (Flynn et al. 2002) that inhibits the food-borne pathogen L. 
monocytogenes (Corr et al. 2007). In contrast to the ABP-118α and ABP-118β peptides, the 
salivaricin B did not exhibit anti-listerial activity, which is in agreement with a recent study 
concerning another Lb. salivarius strain (O'Shea et al. 2011). These results demonstrate that 
the production of a two-component class II bacteriocin may be a common feature among 
intestinal Lb. salivarius strains.  
Bacteriocin-producing species not commonly isolated from the human intestine, 
including L. lactis and Strep. mutans, were identified in this screening study.  The bacteriocin 
produced by L. lactis EM089-BC-T6-1 (Nisin Z) exhibited broad spectrum inhibitory activity 
against the indicator strains Lb. bulgaricus LMG 6901, L. innocua DPC 3572, L. 
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monocytogenes DPC 3785 and Staph. aureus DPC 5245. Although it is well documented that 
nisin is anti-listerial (Cai et al. 1997), the first human-derived nisin reported previously 
(Millette et al. 2007) did not show activity against Listeria spp. and was sensitive to 
temperatures greater than 70
o
C. This outcome was explained by the fact that the nisin 
concentration produced by the strain was insufficient to inhibit the food pathogen (Millette et 
al. 2008). Further studies on this human-derived Nisin Z from L. lactis EM089-BC-T6-1 
isolate are necessary to determine its efficacy. Additionally, further characterization of 
bacteriocin production by the Lb. crispatus and Ent. durans isolated in this study is also 
required, as limited information is available on bacteriocin production by these strains (Hu et 
al. 2008; Tahara and Kanatani 1997; Yanagida et al. 2005). 
Strep. mutans is one of the principal aetiological agents of dental caries (Kamiya et al. 
2005) and although the presence of Strep. mutans in the human intestine has already been 
reported (Hamada and Slade 1980), to our knowledge this is the first time a bacteriocin-
producing Strep. mutans (producing Mutacin II) has been identified from a human intestinal 
source. In this respect, it is noteworthy that mutacin production has been shown to be a 
colonization factor in the human oral cavity (Hillman et al. 1987). 
Both the Ent. faecium bacterial isolates, EM342-BC-1 and EM297-BC-T6-1, 
exhibited inhibitory activity against Lb. bulgaricus LMG 6901, L. innocua DPC 3572 and L. 
monocytogenes DPC 3785. MS analysis of the purified antimicrobial peptides produced by 
Ent. faecium EM297-BC-T6-1 confirmed molecular masses for two putative bacteriocins. 
While it is characteristic of enterococci to produce different types of bacteriocins (Franz et al. 
2007), little has been reported about the production of bacteriocins by enterococci of human 
intestinal origin (Moon et al. 2000). Enterocin producers are being characterized as novel 
probiotics and have been studied for their antagonistic nature against major food pathogens 
such as L. monocytogenes (Achemchem et al. 2005; Franz et al. 1999; Kang and Lee 2005; 
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Renye et al. 2009). The present study reports the characterization of two active bacteriocins 
exhibiting anti-listerial activity and suggests the need to assess such strains for their 
beneficial effect on the gastrointestinal microbiota.  
The bacteriocins produced by the Lb. gasseri isolated in this study exhibited a narrow 
spectrum of activity, inhibiting just the Lb. bulgaricus assessed (Table 4). Sequence analysis 
identified Gassericin bacteriocins, Gassericin T and a new variant of Gassericin A, in 
agreement with the MS data. In general, Lb. gasseri is considered one of the most 
predominant and commonly detected species of Lactobacillus in the human gastrointestinal 
tract (Reuter 2001) and is commonly associated with bacteriocin production (Kawai et al. 
1998a). It was recently demonstrated that the combined effect of both Gassericin A and 
Gassericin T along with glycine could be used as a preservative for the  food industry 
(Arakawa et al. 2009). Similarly, the Gassericin producing strains isolated in this study may 
be of benefit for the food industry. 
Bacteriocin production can confer a competitive advantage to the producing strain, 
enhancing its dominance over other species in an ecological niche. To date, only a limited 
number of studies relating to bacteriocin production by strains of human intestinal origin 
have been performed. This study has highlighted the diverse range of bacteriocinogenic 
strains present in the human intestinal environment, which may help these strains to 
predominate in the bacterial population. Overall, following preliminary characterization, 
genotyping of all of the 55 bacteriocin-producing strains isolated revealed 15 different 
individual strains indicating a higher incidence of repeated isolation of similar strains. In 
addition to the known predominant species of the human intestinal environment, including 
Lb. gasseri and Enterococcus spp., this study has highlighted the isolation of unexpected 
species such as L. lactis and Strep. mutans. This screening has resulted in the isolation of a 
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panel of bacteriocin-producing human strains with the potential to alter the gut microbiota 
when introduced as probiotic cultures. 
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Table 1  Primers used in this study 
 
Primers Sequence (5’-3’) Annealing 
Temp. (
o
C) 
Amplicon 
size (bp) 
Reference 
CO1-Forward  
CO2-Reverse 
AGTTTGATCCTGGCTCAG 
TACCTTGTTAC GACT 
50 1500 (Simpson et al. 2003) 
118α-For 
118im-Rev 
ATGATGAAGGAATTTACA G 
CCACGCTCTCACATAAC 
50 700 (Barrett et al. 2007) 
salivaricin B-For 
salivaricin B-Rev 
AGCGGACAGTTTGGTTATGA 
TTCAGCACATAGAACACATCCTC 
55 900 (O'Shea et al. 2011) 
Lactacin B-For 
Lactacin B-Rev 
TTGAGTTATGTAATTGGTGGAG 
CTGCTGAGCCTTTGATAACG 
60 181 (Tabasco et al. 2009) 
Acidocin-B-For 
Acidocin B-Rev 
GTTGGAATAGTATGGTTTTCG 
ATTCATATCCGGCACCAACG 
58 700 This study 
Gassericin A-For 
Gassericin A-Rev 
CACTCGTAATGGATTTCCTA 
GCCTTT TTTGAATACTCTATTC 
55 350 (Kawai et al. 2001) 
Gassericin T-For 
Gassericin T-Rev 
TGGATTTAAATTGCCTGAAAC 
CATTCCCCCACTTGTTTCC 
58 645 This study 
Nisin Z-For 
Nisin Z-Rev 
AACGGCTCTGATTAAATTC 
CTATTTAGCAACCCTAAATAAC 
50 215 This study 
Enterocin B-For 
Enterocin B-Rev 
GAAAATGATCACAGAATGCCTA 
GTTGCATTTAGAGTATACATTTG 
58 159 (Toit et al. 2000) 
Enterocin 62-6-For 
Enterocin 62-6-Rev 
GTGGAAAGCTAGTATTTGCAAC 
AGCGTTAAGCCGAATGTTTACAC 
49 511 (Dezwaan et al. 
2007) 
Mutacin II-For 
Mutacin II-Rev 
AACGCAGTAGTTTCTTTGAA 
TTCCGGTAAGTACATAGTGC 
52 444 (Kamiya et al. 2005) 
Enterolysin A-For 
Enterolysin A-Rev 
GGACAACAATTCGGGAACACT 
GCCAAGTAAAGGTAGAATAAA 
55 1007 (Nigutova et al. 
2007) 
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Table 2  Diversity of bacteriocin-producing strains among individual elderly subjects  
 
Strains Number of 
isolates 
Number of 
subjects 
Number of 
pulsotypes 
PFGE profile 
Lb. gasseri 12 6 3 A, B & C 
Lb. salivarius 5 3 4 D, E, F & G 
Lb. acidophilus 9 7 1 H 
Ent. faecium 4 2 2 I & J 
L. lactis 3 2 1 K 
Strep. mutans 1 1 1 L 
Lb. crispatus 15 7 2 M & N 
Ent. durans 6 4 1 O 
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Table 3  Predicted bacteriocins and their enzyme sensitivity 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*  ND Not determined  
+ Sensitive to enzyme  
- Resistant to enzyme 
† Amino acid alignments of the sequenced structural genes of strains identified in this study with structural genes from characterised bacteriocins (NCBI). 
 
 
 
 
 
 
 
 
 
 
 
 
Strains identified 
through 16S rDNA 
sequencing 
Strain ID PFGE 
profile 
Predicted bacteriocin 
†
Amino acid 
identity (%) 
Proteinase K  Pepsin 
Lb. gasseri EM081-BC-T3-1 
EM301-BC-T3-1 
EM315-BC-T6-1 
A 
B 
C 
Gassericin T 
Acidocin B 
Acidocin B 
99 
100 
100 
+ 
+ 
+ 
+ 
+ 
+ 
Lb. salivarius EM100-BC-T3-1 
EM253-BC-T6-2 
EM347-BC-T3-1 
EM351-BC-5 
D 
E 
F 
G 
ABP-118 & Salivaricin B 
ABP-118 & Salivaricin B 
ABP-118 & Salivaricin B 
ABP-118 & Salivaricin B 
100 
100 
100 
100 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
Lb. acidophilus EM066-BC-T3-3 H Lactacin B 98 + + 
Ent. faecium EM342-BC-1
 
EM297-BC-T6-1 
I 
J 
Enterocin B 
Enterocin 62-6 & Enterocin M 
100 
100 
+ 
+ 
+ 
+ 
L. lactis EM089-BC-T6-1 K Nisin Z 100 + + 
Strep.  mutans EM315-BC-T3-2 L Mutacin II 100 + + 
Lb. crispatus EM047-BC-T6-4 
EM200-BC-T3-1 
M 
N 
 ND* 
ND 
ND 
ND 
- 
- 
- 
- 
Ent. durans EM133-BC-1 O ND ND + + 
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Table 4  Inhibitory spectrum of ELDERMET isolates 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
+ Strains exhibiting antimicrobial activity against indicator organism 
- Strains not exhibiting antimicrobial activity against indicator organisms. No antimicrobial activity was observed against S. typhi, C. sakazakii and E. coli 
 
 
 
 
 
 
 
 
 
 
 
ELDERMET 
isolates 
Indicator organism 
Lb. bulgaricus 
LMG 6901 
L. monocytogene 
 DPC  3785 
L. innocua 
DPC 3572 
S. aureus  
DPC 5245 
    
Lb. gasseri + - - -     
Lb. crispatus + - - -     
Lb. acidophilus + - - -     
Lb. salivarius + + + +     
Ent. durans + - - -     
Ent. faecium + + + -     
L.  lactis + + + +     
Strep. mutans 
+ - - -     
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Figure 1 Grouping of the macro-restriction patterns of the bacteriocin-producing strains 
generated 15 PFGE pulsotypes; termed A to O, on digestion of chromosomal DNA with ApaI 
restriction enzyme (Lane 1 is the marker (Ma)). 
 
 
 
 
 
 
 
 
 
 
 
 
 
kb 
194.0 
145.5 
9.42 
23.1 
48.5 
97.0 
6.55 
4.36 
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Figure 2  RP-HPLC chromatograms and MALDI-TOF MS data (inserted panel) of (a) S1n1 
produced by Lb. salivarius EM100-BC-T3-1, (b) S1n2 produced by Lb. salivarius EM100-
BC-T3-1, (c) Salivaricin B produced by Lb. salivarius EM100-BC-T3-1, (d) Nisin Z 
produced by L. lactis EM089-BC-T6-1, (e) Mutacin II produced by Strep. mutans EM315-
BC-T3-2, (f) Enterocin M produced by Ent. faecium EM297-BC-T6-1, (g) Enterocin 62-6 
produced by Ent. faecium EM297-BC-T6-1 and (h) a variant of Gassericin A produced by 
EM301-BC-T3-1. Arrows indicate location of the antimicrobial peptides. 
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Figure 3  Comparison of amino acid sequences of Gassericin A (mature peptide) and variant 
produced by Lb. gasseri EM301-BC-T3-1 and Lb. gasseri EM315-BC-T6-1. Amino acid 
differences are bold and underlined. 
 
 
Gassericin A       : MASGASLGTAFAAILGVTLPAWALAAAGALGATAA    Mass: 5,652 Da  
                               
EM301-BC-T3-1: MASGASLGTAFATILGVTLPAWALAAAGALGATAA     Mass: 5,683 Da 
 
EM315-BC-T6-1: MASGASLGTAFATILGVTLPAWALAAAGALGATAA     Mass: 5,683 Da 
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5.1 Abstract 
The aim of this study was to investigate the diversity and composition of the intestinal 
microbiota of elderly subjects using a combination of culture dependent techniques and 16S 
rRNA gene amplicon sequencing. The study was performed as part of the ELDERMET project, 
in which 368 faecal samples were assessed for viable numbers of Bifidobacterium spp., 
Lactobacillus spp. and Enterobacteriaceae on selective agar. However, the Bifidobacterium 
selective medium (BSM) also supported the growth of Clostridium perfringens, which 
appeared as distinct colonies and were subsequently characterised phenotypically and 
genotypically. All the isolates were confirmed as toxin biotype A producers. In addition, three 
isolates tested also had the genetic determinants for the beta-2 (β2) toxin. Of the 368 faecal 
samples assessed, C. perfringens was detected in 28 samples (7.6%). Moreover, C. perfringens 
was observed in samples from subjects in all the residence locations assessed; but was most 
prevalent in subjects from longstay residential care, with 71.4% of the samples (63.2% of the 
subjects) being from this residence location, and with a shedding level in excess of 10
6 
c.f.u. g
-1
 
faeces. Microbiota profiling revealed some significant compositional changes across both the 
family and genus taxonomic levels between the C. perfringens positive and negative data-sets. 
Levels of culturable Bifidobacterium spp. and Lactobacillus spp. were significantly (P<0.05) 
lower in the C. perfringens positive samples. Sequence based methods also confirmed a 
significant difference in the Bifidobacterium spp. level (P<0.05) between both the datasets. 
Taken together, these data suggest that a high viable count (in excess of 10
6 
c.f.u. g
-1
 faeces) of 
C. perfringens in stool samples may be indicative of a less healthy microbiota in the intestine 
of elderly people in longstay residential care. 
 175 
5.2  Introduction 
Although the composition of the intestinal microbiota can vary greatly between individuals, the 
dominant population in the adult intestinal microbiota has been shown to be relatively stable 
over time (Zoetendal et al., 1998). However, it is known that ageing impacts the composition 
of the gut microbiota (Biagi et al., 2010; Claesson et al., 2011). Recently, it has been shown 
that variations in the dietary pattern and health parameters also impact the gut microbiota of 
elderly individuals (Claesson et al., 2012).  
Previous studies have demonstrated modulations in the elderly gut microbiota, with a decline in 
the population of bifidobacteria and lactobacilli (Mitsuoka 1992; Hopkins & Macfarlane 2002; 
Woodmansey 2007) and an increase in the populations of Enterobacteriaceae (Hopkins et al., 
2002) and obligate anaerobes such as clostridia (Guigoz et al., 2008). Despite being a normal 
constituent of the intestinal flora, when overpopulated the Clostridium spp. may be responsible 
for serious infections including mild to severe diarrhoea and pseudomembranous colitis caused 
by Clostridium difficile (Rupnik et al., 2009) or food borne illnesses caused by C. perfringens 
enterotoxin (Sparks et al., 2001).  
The ELDERMET project (http://eldermet.ucc.ie) aims to elucidate the intestinal microbiota of 
500 elderly (65 yr) Irish subjects. Work to date has revealed a core gut microbiota rich in 
Bacteroidetes and Firmicutes with large inter-individual variability (n=161) (Claesson et al., 
2011) and with a distinctive pattern when compared to the younger Irish population (Claesson 
et al., 2009; Claesson et al., 2010). In parallel to the sequence based methods, culture 
dependent techniques enumerated levels of Bifidobacterium spp., Lactobacillus spp. and 
Enterobacteriaceae in the faecal samples (O’Sullivan et al., 2011; O'Sullivan et al., 2012). 
This study mainly focuses on Bifidobacterium spp. and Lactobacillus spp. among other human 
intestinal microbiota because of their potential probiotic role (Aureli et al., 2011; Turroni et al., 
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2008).In this respect, several selective media have been previously recommended for the 
isolation of Bifidobacterium spp. (Beerens 1990; Nebra & Blanch 1999; Rada & Petr 2000; 
Mikkelsen et al., 2003; Simpson et al., 2004; Thitaram et al., 2005; Ferraris et al., 2010) from 
various sample types (dairy products, faeces, intestinal samples, animal feed). In this study, de 
Man, Rogosa, Sharpe (MRS) medium supplemented with L-cysteine hydrochloride and 
mupirocin, termed Bifidobacterium selective medium (BSM) was used. This medium was 
previously used for the growth and enumeration of Bifidobacterium spp. from human faecal 
samples (Rosberg-Cody et al., 2004; Wall et al., 2008).  
While one aim of the ELDERMET project was to enumerate bifidobacteria from faecal 
samples of elderly subjects, the fortuitous isolation of the clinically significant C. perfringens 
at high levels from a sub-set of these elderly subjects motivated the current study. Culture 
independent techniques were used to compare the microbiota of the C. perfringens positive 
subjects and negative subjects, to determine whether the presence of C. perfringens had an 
impact on the intestinal microbiota as a whole.  
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5.3 Materials and Methods 
 
Subject recruitment and sample collection 
Subjects aged 65 yr and older, were recruited and examined at ELDERMET Clinics at two 
local hospitals (Cork University Hospital and St. Finbarr’s Hospital, Cork) as previously 
outlined (Claesson et al., 2011). Residence locations of the subjects were defined as long-term 
residential care (longstay, >6 weeks), short-term rehabilitation centres (rehab, <6 weeks), out-
patient in day hospitals and community dwelling. A sub-set of these subjects were undergoing 
antibiotic therapy within the month prior to faecal sampling. All subjects were screened for the 
presence of C. difficile. Informed consent was obtained from all subjects, or in cases of 
cognitive impairment, from next of kin in accordance with the local Clinical Research Ethics 
Committee guidelines. This study was approved by the Clinical Research Ethics Committee of 
the Cork Teaching Hospitals. Faecal samples were collected from some subjects at two further 
time points (at month 3 (T3) and month 6 (T6)). Stool samples were collected in a sterile 
container, stored at 5 
o
C until transported on ice packs to the laboratory. Storage time varied 
with a mean time of 28 h.  
Bacterial strains, media and growth conditions 
Bifidobacterium breve NCIMB 8807 from the (National Collection of Industrial, Marine and 
Food Bacteria, Aberdeen, Scotland), B. bifidum NCIMB 700795, Lactobacillus delbrueckii 
subsp. bulgaricus LMG 6901 from the (BCCM/LMG Culture Collection, Gent, Belgium), C. 
perfringens NCTC 8239 from the (National Collection of Type Cultures (NCTC), PHLS 
Central Public Health Laboratory, UK), C. perfringens LMG 10468, C. perfringens LMG 
11264, a selection of C. perfringens strains (n=10) from (Alimentary Health Limited, based at 
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University College Cork, Ireland; isolated as described previously (Pruteanu et al., 2011)), 
Listeria innocua DPC 3572 from (Teagasc Food Research Centre), C. perfringens WIT 495 
(Waterford Institute of Technology, Waterford, Ireland) and Streptococcus agalactiae LMG 
14694 were used in this study. Bifidobacterium spp. and Lactobacillus spp. were grown 
anaerobically at 37 
o
C for 24 to 48 h on de Man, Rogosa, Sharpe (MRS, Difco Laboratories, 
Detroit, MI, USA) agar supplemented with 0.05% (w/v) L-cysteine hydrochloride (Sigma 
Chemical Co., St. Louis, MO, USA) (denoted mMRS agar). Where solid medium was required, 
1.5% agar (w/v) (Oxoid Ltd., Basingstoke, Hampshire, UK) was added. To encourage 
selectivity for Bifidobacterium spp. from the faecal samples, the medium was supplemented 
with 100 µg mupirocin ml
-1
 (Oxoid) as outlined previously (Rosberg-Cody et al., 2004; Wall et 
al., 2008). The antifungal agent nystatin (50 Units ml
-1
, Sigma) was also included. All the 
Clostridium strains were grown anaerobically at 37 
o
C for 24 to 48 h in Trypticase Soy agar 
(Merck, Germany) containing 7% sheep blood (TCS Biosciences Ltd, Buckingham, UK). All 
other bacterial strains were cultivated in Brain Heart Infusion (BHI) medium and were grown 
aerobically at 37 
o
C. 
Isolation and enumeration of Bifidobacterium spp. and Lactobacillus spp.  
Total culturable Bifidobacterium spp. and Lactobacillus spp. were enumerated as outlined 
previously (O’Sullivan et al., 2011). The agar plates were incubated anaerobically for 3 or 5 
days at 37 °C for Bifidobacterium spp. or Lactobacillus spp., respectively. Bacterial counts 
were recorded as c.f.u. g
-1
 of faeces and results expressed as log c.f.u. g
-1
 of faeces. 
Phenotypic characterization of putative C. perfringens isolates 
 
Fructose 6-phosphoketolase assay 
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A fructose 6-phosphoketolase (F-6-PPK) assay was performed as previously described 
(Bibiloni et al., 2000). B. breve NCIMB 8807 and Lb. bulgaricus DPC 6901 were used as 
positive and negative controls, respectively. A positive reaction, which is typical of 
Bifidobacterium spp., resulted in the development of a red-violet colour. 
Stormy Clot assay 
 C. perfringens was inoculated at 1% (v/v) into 10 ml reconstituted skim-milk in a test tube, 
which was then plugged with 2% agar and incubated at 37 °C overnight. Coagulation of the 
milk resulting in a stormy clot was indicative of C. perfringens (Mac Faddin 1976). 
Reverse CAMP test  
C. perfringens cultures were streaked at right angles to within 1-2 mm of a β-haemolytic group 
B Streptococcus (S. agalactiae LMG 14694) on sheep blood agar plates. The agar plates were 
incubated anaerobically for 18-24 h. A positive reverse CAMP test was indicated by the 
formation of a bow-tie or reverse arrow pattern of haemolysis at the junction of the two 
cultures (Buchanan 1982). 
Mupirocin resistance of C. perfringens 
To assess the sensitivity of a selection of C. perfringens strains to mupirocin, the putative C. 
perfringens ELDERMET isolates and the C. perfringens strains from Alimentary Health Ltd 
(n=10), together with C. perfringens NCTC 8239, C. perfringens WIT 495, C. perfringens 
LMG 10468 and C. perfringens LMG 11264 were streaked onto agar plates with increasing 
concentrations of mupirocin (from 100 μg ml-1 to 500 µg ml-1). B. breve NCIMB 8807 and B. 
bifidum NCIMB 795 were used as positive controls. Lb. bulgaricus LMG 6901 and L. innocua 
DPC 3572 were used as negative controls.  
Genotypic characterization 
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Isolation of genomic DNA  
Genomic DNA was extracted as outlined previously (Coakley et al., 1996). RNAse (0.75 μl, 
Sigma) was added to the extracted DNA, incubated for 1 h at 37 
o
C, and denatured at 65 
o
C for 
15 min. The DNA was stored at -20 
o
C. 
16S rRNA gene sequence analysis to identify bacterial isolates 
The full length 16S rRNA gene was amplified from genomic DNA of each strain using 16S 
Eubacterial primers (Simpson et al., 2003). The complete sequence of the 16S region was 
determined by Sanger sequencing (Beckman Coulter Genomics). The species was identified by 
nucleotide alignments (>98% identity cut-off) with deposited species in the NCBI database and 
using RDP classifier (Wang et al., 2007). 
PFGE 
Following overnight incubation, 200 μl of each culture was inoculated into 10 ml of BHI broth 
(Merck, Darmstadt, Germany), which had previously been boiled and cooled under anaerobic 
conditions, and grown for 5 h at 37 ºC. Genomic DNA was prepared in agarose plugs, lyzed 
and subsequently digested with Sma1 as described previously (Lukinmaa et al., 2002). 
Electrophoresis was performed using the Biorad Chef-DR II instrument for 20 h at 5.5 Vcm
-1
 
with initial and final pulse times of 0.5 s to 40 s respectively. A lambda ladder PFG marker 
(New England BioLabs Inc., UK) ranging from 48.5 to 727.5 kb was used as the molecular 
weight marker and DNA macro-restriction profiles visualised using the Alpha Imaging system. 
The DNA banding patterns were analysed with Bionumerics software version 6.5 (Applied 
Maths). The Dice coefficient of similarity was calculated and the unweighted pair group 
method with arithmetic averages (UPGMA) was used for cluster analysis with optimisation and 
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position tolerance set at 1.5%. A cut-off at 90% similarity of the Dice co-efficient was used to 
indicate identical PFGE patterns.  
Assessment of toxin production by the C. perfringens isolates 
 
 Detection of the cpe enterotoxin gene 
PCR was used to detect the presence of the cpe enterotoxin gene in the C. perfringens isolates 
as outlined by Lukinmaa et al. (Lukinmaa et al., 2002). C. perfringens NCTC 8239 was used as 
a positive control. Presence of the cpe enterotoxin gene was indicated by the amplification of a 
933 bp fragment.  
Enterotoxin immunoassay 
Prior to the entertoxin test, all isolates were grown in modified Duncan-Strong sporulation 
medium (Duncan & Strong 1968) to promote enterotoxin production. Enterotoxin production 
was assessed with the reverse passive latex agglutination kit (PET_RPLA kit, Oxoid). 
Detection of other toxin genes 
Primers corresponding to the alpha toxin (cpa), beta toxin (cpb) or epsilon toxin (etx) genes 
were used as previously described (Wu et al., 2009) to assess the C. perfringens isolates for 
toxin production capability. In addition, production of the β2 toxin, encoded by cpb2 gene was 
assessed as previously outlined (Greco et al., 2005).  
Amplicon sequencing and bioinformatics 
DNA was extracted from faecal samples according to a standard protocol (Qiagen, West 
Sussex, UK). Pyrosequencing yielded an average of 32,677 reads per sample. Amplicon 
sequencing analysis was performed as previously outlined (Claesson et al., 2011). Trimmed 
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FASTA sequences were then RDP classified from phylum down to genus level (Wang et al., 
2007) using Bergey’s taxonomy (Garrity et al., 2004). Species level data was generated using a 
combination of the Qiime package (http://qiime.org/) and BLAST. First, individual reads were 
grouped into operational taxonomic units (OTUs) at 97% sequence similarity using UCLUST, 
and then a representative sequence was chosen from each OTU using the default method. 
These representative sequences were analysed using BLASTed against a custom-made species 
database to identify species from the genus Clostridium and any other species of interest. OTU 
assignment, clustering, correspondence analysis were implemented with Qiime. The data 
generated from BLAST and the RDP Classifier were stored in a MYSQL database.  
Statistical Methods 
Statistical analysis for the bacteriological culture data was performed using Minitab Release 
15.1.1.0 (Minitab Inc. 2007). Significance was calculated with the Mann-Whitney test and 
statistical significance was accepted at P<0.05. The R statistical software version 2.13.1 was 
used for the amplicon sequencing statistical analyses. For each subject, all reads at phylum, 
family and genus level were converted to percentage values of the total number of reads. The 
Mann-Whitney U test was used to test for statistical differences between the C. perfringens 
positive data-set (n=27) and the C. perfringens negative data-set (n=254) for each taxon in the 
phylum, family and genus level data-sets. The P-values were adjusted to account for multiple 
testing. Two related methods were used – estimation of q-values using the FDR (false 
discovery rate) function in R for genus level and Benjamini and Hochberg correction for 
phylum and family levels (Benjamini & Hochberg 1995). 
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5.4 Results and Discussion 
 
Prevalence of C. perfringens in the faecal microbiota of older subjects 
Of 368 faecal samples analysed (from 184 elderly subjects at T0, T3 and/or T6) during this 
study, 28 samples (7.6% of samples from 19 subjects; Table 1) upon culture, yielded colonies 
that were atypical of Bifidobacterium spp. on the Bifidobacterium selective medium (BSM). 
These atypical colonies were translucent, irregular shaped (4-5 mm diameter), yellow colonies 
with a distinct odour; as opposed to typical bifidobacterial colonies, which were white/cream, 
convex and circular in shape (2-3 mm diameter). From these 19 subjects, atypical colonies 
were observed at two time points for 5 subjects and at all three time points for 2 subjects, 
indicating the stability of the presence of this bacterium over time in the intestinal environment 
of some subjects. In some cases (n=15), these isolates grew on the selective medium in 
conjunction with the Bifidobacterium spp., but in other cases (n=13) only these unusual 
colonies were observed. However, they were reliably distinguishable from bifidobacteria both 
macroscopically and microscopically (larger box-car shaped rods). Moreover, these isolates 
tested negative in a fructose-6-phosphate phosphoketolase assay (a positive result is indicative 
of Bifidobacterium spp.) demonstrating that they were not bifidobacteria. 
Phenotypic and genotypic characterisation of C. perfringens  
Approximately 3 to 4 colonies per sample were taken for further characterisation. All of the 
atypical isolates demonstrated phenotypic traits characteristic of C. perfringens such as the 
stormy clot formation when grown in 10% skim-milk and an arrow-head shaped haemolytic 
pattern in the reverse CAMP test. All isolates were subsequently confirmed as C. perfringens 
using 16S rRNA sequencing. C. perfringens isolates that have the potential to cause C. 
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perfringens associated diarrhoea, by the production of an enterotoxin, are normally identified 
by confirming the presence of the cpe gene. However none of the isolates from this study were 
positive for the cpe gene, indicating that all were non-enterotoxigenic. This was further 
confirmed by testing all the isolates for enterotoxin production using a RPLA kit, which 
demonstrated that none produced enterotoxin. It is reported that CPE-producing C. perfringens 
are only occasionally isolated, representing < 5% of all C. perfringens isolates (Smedley III & 
McClane 2004). 
Genotyping of toxin produced by C. perfringens 
In general, all C. perfringens types produce α toxin; additionally, type B C. perfringens 
produce β and ε toxins, type C produce β toxin, type D produce ε toxin and type E produce ι 
toxin (Petit et al., 1999). Type A C. perfringens has been shown to predominate in the 
environment and can cause gas gangrene in humans, while the other types (B-E) are usually 
restricted to animals. As type E strains rarely cause disease in humans (Petit et al., 1999; 
Smedley III & McClane 2004), none of the C. perfringens isolates from this study were tested 
for this toxin. The cpa gene, encoding α toxin, was detected by PCR in all of the isolates, but 
none of the other genes, including the cpb gene (encoding β toxin in types B and C), or the etx 
gene (encoding ε toxin in types B and D) were detected. This confirms that all the isolates 
belonged to C. perfringens type A. In addition to the α toxin, three of the isolates (EM156-T6, 
EM177-T0, and EM200-T6) produced β2 toxin and were then classified as C. perfringens type 
A and β2 toxin positive. PCR and sequence analysis revealed 100% amino acid identity to the 
cpb2 structural gene of the previously characterised β2 toxin (Shimizu et al., 2002) indicating 
the presence of this toxin in all three isolates. Although the β2 toxin positive C. perfringens 
have been linked with intestinal disorders in animals (Waters et al., 2003) and humans (Fisher 
et al., 2005), their presence does not always result in an adverse effect on the intestine (Lebrun 
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et al., 2007; Carman et al., 2008). In this respect, the impact of the β2 toxin appears to be 
subject dependent and circumstance related. 
Relatedness and stability of C. perfringens isolates 
Genomic fingerprinting by PFGE is a valuable tool when establishing strain similarities and 
has been used for strain identification in C. perfringens related diarrhoeal outbreak situations 
(Lukinmaa et al., 2002). Diversity among the C. perfringens isolates from this study was 
observed, as they were resolved into 17 distinct strains (A-Q) using the Dice coefficient (≥90 
% similarity). This diversity is noteworthy because these strains were isolated from 19 C. 
perfringens positive subjects residing in different residence locations.  
The C. perfringens PFGE profiles from four subjects - EM156-T0, EM165-T0, EM168-T3 and 
EM169-T0 were confirmed as being 100% identical (Fig. 1). Even though these subjects were 
sampled over a 9 month period, all were from the same residence location (long-term 
residential care) and even the same ward. Similarly, the profiles from subjects EM186-T0 and 
EM200-T0 were 100% identical. Interestingly at the time of sampling these two subjects were 
residing on the same ward and were sampled within 15 days of each other.  
In some cases, the persistence of the C. perfringens strains was confirmed by isolating similar 
pulsotypes from the same subject at multiple time points as recorded for EM082 (T3 and T6), 
EM151 (T0, T3 and T6), EM156 (T0 and T6), EM168 (T3 and T6) and in EM182 (T3 and T6), 
indicating their stability of colonization over time. However, diversity among the strains was 
observed over time in a few subjects. For instance, the faecal samples collected at all three time 
points for EM159, showed strains with two distinct PFGE patterns (one at T0 and another at 
each of T3 and T6). In EM200, where two distinct strains of C. perfringens were observed at 
T0 and T6, C. perfringens was not detected at the intermediate time (T3). This subject was on 
the same ward at all time-points but was receiving antibiotics at T0 and T6 (Fig 1); the time-
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points where C. perfringens was detected. Overall, the PFGE analysis revealed a diverse range 
of pulsotypes from the different residence locations.  
Mupirocin resistance of C. perfringens isolates and co-association with bifidobacteria 
In general, supplementation of selective media with mupirocin enables the recovery of 
Bifidobacterium spp. from faecal samples. However, in this study C. perfringens was isolated 
on the BSM despite using a high concentration of mupirocin (100 μg ml-1). The growth of these 
isolates on this selective medium was reasonably distinguishable, both macroscopically and 
microscopically. To assess the resistance of C. perfringens in general to mupirocin, a number 
of strains including C. perfringens NCTC 8239, C. perfringens LMG 10468, C. perfringens 
LMG 11264, a selection of C. perfringens strains (n=10) and C. perfringens WIT 495 were 
grown on agar plates with varying concentrations of mupirocin. All the C. perfringens isolates 
assessed grew at all mupirocin concentrations up to 500 μg ml-1, indicating a high level of 
resistance (Table 2). This high level of mupirocin resistance may provide an opportunity to 
exploit the antibiotic as a selective agent for C. perfringens. However, this study does point to 
the limitations of using mupirocin as a selective agent for Bifidobacterium spp.  
During the broader ELDERMET study, BSM has been used to enumerate Bifidobacterium spp. 
from 366 faecal samples (O'Sullivan et al., 2012). The levels of Bifidobacterium spp. were 
below the limit of detection (<3.0 log c.f.u. g
-1
) in 5.2% of these faecal samples. When 
analysing the samples, where C. perfringens was detected on BSM (n=28), Bifidobacterium 
spp. were below the limit of detection for 46.0% of these samples. This indicates that the 
presence of the C. perfringens in the elderly is inversely associated with the numbers of 
Bifidobacterium spp. recovered. In addition, when the levels of culturable Bifidobacterium spp. 
and Lactobacillus spp. were compared in the C. perfringens positive and C. perfringens 
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negative groups, significantly lower levels (P<0.05) of both species were observed in the C. 
perfringens positive group.  
Prevalence of C. perfringens as a function of subject health status 
C. perfringens was detected in subjects from all of the residence locations assessed (longstay, 
rehabilitation, day hospital and community) and at varying levels (4.0 to 9.5 log c.f.u.g
-1
 
faeces; Table 1). However, the longstay subjects accounted for 71.4% of the samples where C. 
perfringens was detected. This is in agreement with the study by Stringer et al. (1985), 
reporting high numbers of C. perfringens in elderly hospitalized patients (Yamagishi et al., 
1976; Stringer et al., 1985). It has also been reported that the carriage rate of C. perfringens 
was significantly higher in the elderly (Benno et al., 1989). C. perfringens type A food 
poisoning outbreaks are usually reported in institutionalised settings involving larger numbers 
of elderly patients (Smith 1998; Lund et al., 2000).  
Microbiota alterations and C. perfringens culture status  
Microbiota composition analysis by amplicon sequencing was used to determine whether the 
presence of C. perfringens was associated with an altered intestinal microbiota. 
Pyrosequencing data were available for 27 C. perfringens positive samples and 254 C. 
perfringens negative samples. The taxonomical profile of each sample was elucidated using a 
combination of BLAST and RDP classifier and resulting taxa were compared at the phylum, 
family and genus levels. While there were some observed differences at the phylum level, none 
of these were statistically significant. The major observed differences were; Bacteroidetes and 
Proteobacteria proportions of 52.2% and 2.7%, respectively in the C. perfringens negative 
data-set compared to 48.4% and 1.5% in the C. perfringens positive data-set, whilst Firmicutes 
were higher at 44.0% in the negative population compared to 48.6% in the positive population. 
At the family level, some significant changes in compositional data were observed; Members 
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of the families Clostridiaceae (P=0.0003), Eubacteriaceae (P=0.0033), Coriobacteriaceae 
(P=0.0103), Enterobacteriaceae (P=0.0337), Desulfovibrionaceae (P=0.0374) and 
Porphyromonadaceae (P=0.0383) were higher in the C. perfringens positive data-set compared 
to the negative data-set. Members of the families Lachnospiraceae (P=0.0011) and 
Veillonellaceae (P=0.0383) were lower in the C. perfringens positive subject microbiota when 
compared to the negative subjects (Fig. 2 and Table 3).  
There were many significant differences in the proportions of individual genera between the C. 
perfringens positive and negative data-sets; 10 genera appeared to be higher in the C. 
perfringens positive population including Clostridium spp. (P<0.0001), Eubacterium 
(P=0.0022), Parabacteroides (P=0.0084). In contrast, Coprococcus (P=0.0233), Roseburia 
(P=0.0006), Catenibacterium (P=0.0363) and Bifidobacterium (P=0.0363) were lower in the 
positive group (Fig. 3 and Table 3).  
Levels of Bifidobacterium spp. were significantly lower in the C. perfringens positive 
population (P=0.0363; Table 3), which is in agreement with the culture-based techniques as 
discussed above. In contrast to the culture results, no significant difference was observed in 
levels of Lactobacillus spp. (P=0.9375). To establish the similarities in the total microbial 
composition between the C. perfringens positive and negative samples, correspondence 
analysis on the proportions at phylum, family and genus level was employed. This failed to 
show any major differences in the microbiota composition between these two groups (Fig. S1-
provided as Supplementary data). 
In conclusion, this study focuses on the isolation of high levels of C. perfringens from faecal 
samples of elderly Irish subjects, on a selective medium aimed at isolating Bifidobacterium 
spp. The subjects were from different residence locations with the isolation of C. perfringens 
being more frequent in subjects in long-term residential care and having a higher shedding 
 189 
level (up to 10
9 
c.f.u.
 
g
-1
). The isolation of similar C. perfringens strains from individual 
subjects located in the same residence location suggests horizontal transmission within the 
hospital. The presence of C. perfringens negatively correlated with the numbers of 
Bifidobacterium spp. recovered, suggesting that Bifidobacterium spp. replacement warrants 
investigation as a possible means of reducing C. perfringens carriage. However, overall, there 
was no significant diversity among the microbial community between the C. perfringens 
positive and negative subjects.  
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Table 1. Data on the 28 ELDERMET samples from which C. perfringens was cultured on BSM 
 
No. Subject Time  
(month*) 
Residence location Antibiotic 
therapy
†
 
Bifidobacterium spp. 
(log c.f.u. gram
-1
) 
Lactobacillus spp. 
(log c.f.u. gram
-1
) 
C. perfringens 
(log c.f.u. gram
-1
) 
C. perfringens 
Pulsotypes 
1 EM059-T3 T3 day hospital yes <3.00‡ 5.45 6.15 A 
2 EM063-T6 T6 community no <3.00 6.00 6.30 B 
3 EM082-T3 T3 community no 6.30 7.42 6.18 C 
4 EM082-T6 T6 community no 5.70 7.87 6.85 C 
5 EM095-T0 T0 community no <3.00 4.77 5.11 D 
6 EM124-T3 T3 longstay (CD+)§ no <3.00 <3.00 5.79 E 
7 EM133-T0 T0 rehab yes 7.78 6.64 8.15 F 
8 EM144-T6 T6 longstay no 4.60 4.23 7.10 G 
9 EM151-T0 T0 longstay no 8.41 7.07 9.46 H 
10 EM151-T3 T3 longstay no <3.00 4.86 8.32 H 
11 EM151-T6 T6 longstay no 6.60 5.54 7.59 H 
12 EM156-T0 T0 longstay (CD+) no 5.81 5.83 6.13 I 
13 EM156-T6 T6 longstay (CD+) no 8.11 7.09 8.69 I 
14 EM159-T0 T0 longstay no <3.00 <3.00 7.81 J 
15 EM159-T3 T3 longstay no <3.00 <3.00 4.53 K 
16 EM159-T6 T6 longstay no 4.77 <3.00 5.73 K 
17 EM165-T0 T0 longstay yes <3.00 5.43 6.62 I 
18 EM168-T3 T3 longstay no <3.00 5.08 8.26 I 
19 EM168-T6 T6 longstay no 7.89 4.99 7.57 I 
20 EM169-T0 T0 longstay no <3.00 <3.00 8.15 I 
21 EM177-T0 T0 community no 5.48 5.83 6.61 L 
22 EM182-T3 T3 longstay no 7.60 <3.00 7.60 M 
23 EM182-T6 T6 longstay no 7.03 3.00 5.90 M 
24 EM186-T0 T0 longstay (CD+) no <3.00 7.61 6.73 N 
25 EM200-T0 T0 longstay yes 5.45 4.64 5.36 N 
26 EM200-T6 T6 longstay no 3.00 3.00 4.00 O 
27 EM297-T0 T0 longstay yes <3.00 - 6.92 P 
28 EM322-T0 T0 rehab No <3.00 - 7.18 Q 
*T0=Month 0, T3=Month 3 and T6=Month 6; †on antibiotics within 1 month of attending the ELDERMET Clinic; ‡<3.00 indicates the lower limit of detection; §CD+ C. difficile detected in the faecal sample. 
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Table 2. Details of C. perfringens strains with resistance to 500 µg mupirocin ml
-1
.  
 
No. C. perfringens  
strain ID 
Source 
1 UC 3.1 subject with ulcerative colitis, UC3 
2 UC 8.1 subject with ulcerative colitis, UC8 
3 UC 18 subject with ulcerative colitis, UC18 
4 CD 19.1 sub ect with Crohn’s disease, CD19 
5 AH 36.1 healthy volunteer, AH36 
6 AH 36.2 healthy volunteer, AH36 
7 AH 55.1 healthy volunteer, AH55 
8 AH 55.2 healthy volunteer, AH55 
9 AH 95.2 healthy volunteer, AH95 
10 AH 95.3 healthy volunteer, AH95 
11 NCTC 8239 unknown 
12 LMG 10468 lamb, intestinal contents 
13 LMG 11264 bovine 
14 WIT 495 pig manure composite 
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Table 3. Significant differences in faecal microbiota abundance between the C. perfringens 
positive and C. perfringens negative subjects. Only taxa with significant differences are shown. 
  P-value* Observation in C. perfringens 
positive data-set† 
Family   
Clostridiaceae 0.0003 increase 
Lachnospiraceae 0.0011 decrease 
Eubacteriaceae 0.0033 increase 
Coriobacteriaceae 0.0103 increase 
Enterobacteriaceae 0.0337 increase 
Desulfovibrionaceae 0.0374 increase 
Porphyromonadaceae 0.0383 increase 
Veillonellaceae 0.0383 decrease 
Genus    
Clostridium 0.0000 increase 
Acetanaerobacterium 0.0005 increase 
Butyricicoccus 0.0005 decrease 
Roseburia 0.0006 decrease 
Anaerostipes 0.0018 increase 
Eubacterium 0.0022 increase 
Lactonifactor 0.0033 increase 
Anaerotruncus 0.0070 increase 
Parabacteroides 0.0084 increase 
Coprobacillus 0.0116 increase 
Ethanoligenens 0.0233 increase 
Escherichia 0.0233 increase 
Coprococcus 0.0233 decrease 
Parasporobacterium 0.0233 decrease 
Bifidobacterium 0.0363 decrease 
Anaerosporobacter 0.0363 decrease 
Catenibacterium 0.0363 decrease 
*<0.05 is considered a significant result; †compared to the C. perfringens negative data-set.  
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Figure 1. Dendographic analysis of PFGE profiles of C. perfringens from elderly Irish subjects 
and their pulsotypes. 
 
                                                                                                                                Sample ID        Pulsotypes 
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Figure 2. Family level composition of the faecal microbiota from (a) C. perfringens positive 
subjects (aggregated) and (b) the C. perfringens negative subjects (aggregated). 
(a) 
 
 
(b) 
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Figure 3. Genus level composition of the faecal microbiota of the (a) C. perfringens positive 
subjects compared to the (b) C. perfringens negative subjects, expressed as percentage reads. 
(a) 
 
 
(b) 
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Supplementary Figures for Chapter 5 
Supplementary Figure S1. Correspondence analysis of the proportions of (a) phylum, (b) 
family and (c) genus level of C. perfringens positive () and C. perfringens negative groups 
(). 
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CHAPTER 6 
 
 
 
 
 
ISOLATION AND MOLECULAR CHATACTERIZATION OF 
CIPROFLOXACIN RESISTANT LACTIC ACID BACTERIA 
FROM EDERLY IRISH SUBJECTS  
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6.1 Abstract:  
Lactic acid bacteria (LAB) isolated from over one hundred faecal samples from elderly Irish 
subjects as a part of ELDERMET project (http://eldermet.ucc.ie) were investigated for their 
resistance against the clinically important antibiotics, ciprofloxacin and amoxicillin. 
Ciprofloxacin represents the widely used members of the fluoroquinolone family. Screening over 
25,000 colonies identified 21 LAB isolates with increased ciprofloxacin resistance; however, 
none of the isolates screened exhibited resistance against amoxicillin. The predominant isolates 
with increased ciprofloxacin resistance were identified by 16S rRNA sequencing as 
Lactobacillus gasseri, Enterococcus and Pediococcus spp. The minimum inhibitory 
concentrations (MIC) values for all of the isolates exhibiting ciprofloxacin resistance ranged 
between 90-300 µg/ml. The parC and gyrA genes of the quinolone resistance determining region 
(QRDR) for the isolates with increased ciprofloxacin resistance were analyzed using PCR 
primers specific for the respective genes. We found no typical mutations in the amino acid 
codons of quinolone-resistance determining regions of the genes encoding gyrA. However, in 
parC, a single amino acid change related with the substitution of Ser at position 80 to isoleucine 
was determined. These resistant strains could potentially be co-administered with ciprofloxacin 
to maintain a positive microbiota which reduces the gastrointestinal side effects in the elderly 
subjects, being treated with antibiotics.  
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6.2 Introduction: 
Lactic Acid Bacteria (LAB) are a heterogeneous group of bacteria found widely in nature. 
Indeed, they are commonly found among the resident microbiota of the gastrointestinal tract 
(GIT) of humans and animals. Members of LAB have been exploited for millennia in the 
production of fermented foods and beverages (Leroy & De Vuyst 2004). In addition, LAB have 
been used as probiotic bacterial cultures (Collins et al. 1998), which are intentionally added to 
the diet to positively influence human health and have been shown to have a number of health 
benefits associated with ingestion of particular strains. However, concerns have been raised in 
relation to LAB being a potential source for transferring antibiotic resistance to other bacterial 
strains including pathogenic microorganisms (Danielsen & Wind 2003; Mathur & Singh 2005; 
Gevers et al. 2006). Henceforth, evaluating potentially probiotic strains for the presence of 
transmissible antibiotic resistance genes is an important safety measure. 
In recent years, researchers have focused on characterizing the presence of antibiotic resistance 
in LAB of different origin (Axelsson et al. 1988; Scott et al. 2000; Delgado et al. 2005; Belletti 
et al. 2009). Among the LAB, the subject of intense study is the antibiotic resistance among 
enterococci, as they play a major role in imparting serious infections in humans such as urinary 
tract infections (Petersen & Jensen 2006; Hummel et al. 2007a; Sood et al. 2008; Ribeiro et al. 
2011; Chang et al. 2012). The molecular determinants underlying antibiotic resistance among 
lactobacilli is of growing interest (Hummel et al. 2007b; Fukao et al. 2009).  
Bacterial resistance to antibiotics can either be natural (intrinsic or innate), acquired (through the 
acquisition of exogenous DNA) or mutational (mutation of indigenous genes) (Ashraf & Shah 
2011). Intrinsic resistance is an inherent trait of bacteria and can be due to a number of 
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mechanisms including reduced permeability of certain antibiotics across the bacterial cell wall, 
absence of the antibiotic affinity targets (Džidić et al. 2008). Intrinsic resistance to antibiotics is 
generally not horizontally transferable as it is chromosomally encoded. In contrast, a bacterial 
strain can acquire resistance either by mutation in genes or by the uptake of resistance genes by 
horizontal transfer from other bacteria (Egervärn et al. 2009).  
Although LAB have a long history of safe use and have acquired the ‘generally recognized as 
safe  (GRAS) status, some LAB have demonstrated intrinsic or acquired antibiotic resistance 
(Levy 1997; Delgado, Flórez et al. 2005; Kastner et al. 2006; Ouoba et al. 2008). For example, 
many lactobacilli seem to be intrinsically resistant to quinolones, for example, ciprofloxacin and 
nalidixic acid, by an unidentified resistance mechanism (Hummel, Hertel et al. 2007b).  
Fluoroquinolones have been used for antibacterial therapy for almost two decades. Of these, 
ciprofloxacin, gatifloxacin, ofloxacin and moxifloxacin represent the widely used members of 
the family (Stahlmann & Lode 2010). Ciprofloxacin is a second generation fluoroquinolone, that 
inhibits the activity of the bacterial enzymes DNA gyrase (encoded by gyrA and gyrB) and DNA 
topoisomerase (encoded by parC and parE - referred to as grlA and grlB respectively in 
Staphylococcus aureus), which are essential for DNA replication (Cambaul & Gurmannz 1993; 
Blanche et al. 1996). DNA gyrase and topoisomerase IV share extensive amino acid sequence 
homology, including highly conserved regions in both subunits A and B (Bagel et al. 1999). 
Interestingly, the quinolone target varies in gram positive and gram negative microorganisms, 
being primarily DNA gyrase for gram negative bacteria, and  topoisomerase IV in gram positive 
bacteria (Ruiz 2003).  
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Ciprofloxacin, being one of the most important member of the quinolone family have been 
tremendously used in the treatment of urinary, respiratory, gastrointestinal and skin infections 
(Dalhoff 2012). They are particularly effective, given their broad spectrum activity against 
different microbes, and for their use as both oral and parenteral preparations and for their relative 
safety (Rodríguez-Julbe et al. 2010). However, resistance to fluoroquinolone has emerged 
relatively rapid among almost all gram positive and gram negative species. The most common 
mode of resistance to quinolones is through mutations in the genes, gyrA and parC, which 
encode for subunit A of the DNA gyrase and topoisomerase IV, respectively. These regions are 
referred to collectively as the Quinolone Resistance Determining Region (QRDR).  
The ELDERMET consortium (http://eldermet.ucc.ie) was established in 2008 and aims to 
explicate the intestinal microbiota of 500 elderly Irish subjects. Work to date has revealed links 
between the microbial composition, health and diet of the elderly Irish population (Claesson et 
al. 2011; Claesson et al. 2012). In addition, investigating the impact of antibiotic therapy on the 
composition of the intestinal microbiota of elderly Irish subjects (n=185) revealed a notable 
reduction in the numbers of Bifidobacterium spp., emphasizing the potential need of probiotics or 
prebiotics to rectify this aspect of the intestinal microbial composition (O'Sullivan et al. 2013). 
The objective of this study was not only to screen and isolate lactic acid bacterial strains from 
elderly Irish subjects with increased resistance to clinically important antibiotics, including 
ciprofloxacin and amoxicillin, but to also elucidate the underlying genetic mechanism. These 
antibiotics were chosen for this study mainly because of their intensive use in the elderly in 
treating a wide range of infections. 
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6.3 Materials and Methods 
Subject recruitment and sample collection 
Subjects aged ≥ 65 years were recruited and examined at ELDERMET clinics at two local 
hospitals (Cork University Hospital, Cork, Ireland and St. Finbarr’s Hospital, Cork, Ireland) as 
outlined previously (Claesson, Cusack et al. 2011). The subjects included patients in long-term 
institutional care (long-stay, >6 weeks), short-term rehabilitation centers (rehab, <6 weeks), 
outpatient day hospitals and community dwelling subjects. A subset of these subjects was 
undergoing antibiotic therapy within the month prior to faecal sampling. A total of 107 samples 
from 91 elderly subjects were assessed. In addition to the initial sample (T0), faecal samples 
were collected from some subjects at two further time points - at month 3 (T3) and month 6 (T6). 
Stool samples were collected in a sterile container and stored at 5
o
C until transported on ice to 
the laboratory.  
Isolation and enumeration of bacterial isolates from faecal samples 
All of the faecal samples were processed as outlined previously (O’Sullivan et al. 2011). To 
enumerate total culturable LAB strains, the dilutions were spread plated (100µl) onto de Man, 
Rogosa, Sharpe agar supplemented with 0.05% L-cysteine hydrochloride (Sigma Chemical Co., 
St Louis, MO, USA) (denoted mMRS agar). For the enumeration of bifidobacteria, the dilutions 
were spread plated (100µl) onto mMRS agar supplemented with mupirocin (Oxoid) at a 
concentration used in our earlier study (O’Sullivan, Coakley et al. 2011). mMRS medium 
incorporating the antibiotics of interest were used to isolate antibiotic resistant strains. The 
antibiotics, Ciprofloxacin and Amoxicillin (Sigma) were added to the selective medium at a 
concentration of 75µg ml
-1
, following an initial screening, where several samples were assessed 
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on mMRS agar with a range of antibiotic concentrations (25µg ml
-1
 to 150µg ml
-1
). The 
concentration of 75µg ml
-1 
was then chosen as the
 
optimum concentration for both antibiotics, as 
this concentration yielded a considerable number of amoxicillin and ciprofloxacin resistant 
isolates. The agar plates were incubated anaerobically at 37
o
C for 3 or 5 days for 
Bifidobacterium spp. and Lactobacillus spp. respectively. Bacterial counts were recorded as 
colony forming units (CFU) per gram of faeces and the results expressed as log CFU g
-1
 faeces. 
Bacterial colonies that grew on the mMRS agar supplemented with the antibiotics were selected 
and cultured in mMRS broth for 24 hr at 37
o
C. These isolates were then stocked in the 
ELDERMET Culture Collection for further characterization. 
Genetic characterization of bacterial isolates 
Genomic DNA was extracted as outlined previously (Coakley et al. 1996). RNase (0.75µl; 
Sigma) was added to the extracted DNA, incubated for 1 hr at 37
o
C and denatured at 65
o
C for 15 
min. Bacterial isolates were identified by amplifying the full-length 16S rRNA gene using the 
16S eubacterial primers (Simpson et al. 2003). The complete sequence of the 16S rRNA gene 
region was determined by Sanger sequencing (Beckman Coulter, Essex, UK). The resulting 
sequences were compared with the deposited GenBank database using the BLAST program and 
the identity of the isolates was determined on the basis of the highest scores (>98%). The 
presence of antibiotic resistance genes for ciprofloxacin (gyrA and parC) were amplified by PCR 
using previously designed primers (Hummel, Hertel et al. 2007b). PCR products and the deduced 
amino acid sequences were aligned with those retrieved from the GenBank database using the 
Lasergene 6 software program. 
Minimum inhibitory concentration (MIC) assays 
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MIC determinations were carried out in triplicate in 96 well micro-titer plates. For preparation of 
antibiotic stock solutions, ciprofloxacin was dissolved in 0.01M HCl and amoxicillin in water to 
a concentration of 30mg ml
-1
. Fresh overnight bacterial strains were diluted to a final 
concentration of 10
6
 CFU ml
-1
. A further (1:1000) dilution was made into double strength 
mMRS broth, and a 0.1 ml inoculum was added into each well containing the serially diluted 
antibiotics. Positive (mMRS medium with bacterial culture) and negative (mMRS medium 
without bacterial culture) controls were included in the micro-titer plates. The 96 well plates 
were incubated in an anaerobic chamber at 37°C, with the exception of Enterococcus spp., which 
were incubated aerobically at 37°C. MIC was interpreted as the minimum concentration of 
antibiotic required for total inhibition of visible bacterial growth after incubation for 48 hr. 
Pulsed-field gel electrophoresis (PFGE) of bacterial isolates 
Pulsed-field gel electrophoresis of the resistant isolates was performed as previously described 
(Simpson et al. 2002) using the Apa1 restriction endonuclease. A low-range molecular weight 
DNA marker (New England Biolabs; 4.36-194.0 Kb) was used to determine band size, and the 
DNA macro restriction profiles were visualized using the Alpha Imaging System. For each 
PFGE pattern observed, one strain with a high MIC for ciprofloxacin was selected for further 
characterization. 
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6.4 Results and Discussion 
The emergence of bacterial resistance to antibiotics presents a serious public health threat. 
Resistance can be an inherent property of the bacteria themselves or it can be acquired. Acquired 
bacterial antibiotic resistance can be caused by gene mutation or acquisition of foreign resistance 
genes or by both mechanisms. A variety of genes can be involved in antibiotic resistance as there 
are several targets or pathways for the antibiotic entry into the bacterial cell and each access 
point requires expression of several genes (Džidić, Šušković et al. 2008). Ciprofloxacin and 
other quinolones are considered the most important antibiotics mainly because of their low level 
resistance (Cirz et al. 2005). However, resistance to these antibiotics is evolving at an alarming 
rate due to alterations in the targets of quinolones through mutations in gyrase or topoisomerase 
IV and/or an over expression of the efflux system (Džidić, Šušković et al. 2008). Both of these 
mechanisms are chromosomally mediated. It has been documented that intrinsic resistance and 
resistance by mutations in the chromosomal genes presents a low risk of horizontal 
dissemination (Ammor et al. 2007). 
Isolation and species identification of antibiotic resistant bacteria 
Initial screening over 25,000 isolates from 107 faecal samples (from 91 elderly subjects) resulted 
in the detection of 21 isolates (from 15 subjects) with increased antibiotic resistance to 
ciprofloxacin, representing an isolation frequency of (0.08% from total culturable bacteria). 
Further analysis of the 21 isolates by PFGE resulted in five individual strains (from five different 
subjects) with distinct PFGE profiles (Figure 1), corresponding to ciprofloxacin resistance 
frequency of 0.02%. None of these five subjects were on ciprofloxacin or amoxicillin. Strains 
showing similar PFGE profile were isolated from multiple subjects, as shown in Table 1. Of the 
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bacterial strains detected with increased ciprofloxacin resistance, Lactobacillus gasseri was the 
most predominant species in this study (Table 1), suggesting that this trait is more common 
among isolates of these species (Wall et al. 2007; Lakshminarayanan et al. 2013). Other bacterial 
strains identified included Enterococcus faecalis, Pediococcus spp. and Lb. casei (Table 1). 
Despite intense parallel screening, no bacterial isolates exhibiting resistance against amoxicillin 
were detected in this study. Other studies have also demonstrated the susceptibility of lactic acid 
bacteria to the β-lactam group of antibiotic, which includes penicillin, amoxicillin and ampicillin 
(Liasi et al. 2009; Sieladie et al. 2011).  
Determination of MIC and identification of antibiotic resistant determinants 
The MIC value for ciprofloxacin for the strains was assessed and is summarized in Table 2, 
which ranged from 90-300µg ml
-1 
in our strains. The MIC values obtained in this study were 
found to be comparatively higher than the results shown in recent studies, which assessed 
ciprofloxacin resistance in different Lactobacillus spp., Pediococcus spp., and Enterococcus spp. 
(Rojo-Bezares et al. 2006; Hammad & Shimamoto 2010; Chang, Wang et al. 2012). The five 
individual strains exhibiting high levels of resistance to ciprofloxacin were then further selected 
for molecular analysis of the gyrA and parC genes in the QRDR.  
Fluoroquinolone resistance in Gram-positive bacteria has been associated with mutations in the 
QRDR of the gyrA or parC genes, resulting in alterations in the amino acid sequences. 
(Kanematsu et al. 1998; Schmitz et al. 1998; Hooper 2002; Kawamura et al. 2003; Petersen & 
Jensen 2006; Hummel, Hertel et al. 2007b). The presence of point mutations in the QRDR of 
both gyrA and parC regions were investigated and the deduced amino acid sequences of both 
genes are presented (Table 3).  
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It is postulated that high level resistance to quinolones in Gram-positive bacteria is linked to a 
substitution in the gyrA QRDR sequence of Ser83 to Arg and/or Glu87 to Gly or Lys (Petersen & 
Jensen 2006). The mutation in this region of the gyrA gene alters the structure of the gyrase 
protein near its active site. Although this typical substitution could not be observed for any of the 
ciprofloxacin resistant isolates obtained in this study, an amino acid variation of Glu87 to Leu 
was detected in Lb. gasseri and Ent. faecalis isolates (Table3). This kind of substitution was 
previously identified in Lb. acidophilus BFE 7429, however this substitution has not yet been 
reported to be associated with increase in quinolone resistance (Hummel, Hertel et al. 2007b).  
It is postulated that other variations in the QRDR of the ParC subunit of topoisomerase IV, such 
as substitution of Ser80 with Leucine or Isoleucine can also be responsible for high level 
resistance to quinolone (Petersen & Jensen 2006) (Table 3). Interestingly, the substitution of 
Ser80 to Isoleucine was observed in all the resistant strains isolated in this study (Table 3). 
Similar alterations (Ser to Arg/Ile) in Ent. faecalis have been reported earlier (Kanematsu, 
Deguchi et al. 1998). Although mutations in the parC gene are shown to confer resistance to 
quinolones, it should be noted that previous studies have suggested that mutations in 
topoisomerase IV may simply be a contributor to high level resistance along with other 
mechanisms such as reduced permeability of quinolones across the cell membrane (Kumagai et 
al. 1996; Lee et al. 2005). Further work would be required to confirm the role of parC in 
quinolone resistance observed in our isolates.  
In the recent decade, increased usage of antibiotics has been implicated as a major cause of the 
emergence of antibiotic resistant strains. Knowledge on the antibiotic resistance of LAB is still 
limited. Since LAB are naturally present in fermented food and are also used as probiotic 
bacteria in the food industries, concerns have been raised about the antibiotic resistance in these 
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beneficial bacterial strains. In contrast where LAB is present in the gastrointestinal tract in large 
amounts, their resistant to certain antibiotics could potentially benefit the host organism, in cases, 
where other beneficial microbes are killed. This study opens up the possibility for using 
antibiotic resistant probiotics to offset the problems which antibiotics cause to the gut flora.  
Such strains could be particularly effective to treat people on long term antibiotic treatment such 
as cystic fibrosis sufferers. Of course, this hypothesis would need to be tested in rigorous human 
clinical studies where readouts would include both health and microbial measurements. 
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Table 1:  Diversity of antibiotic resistant strains among individual elderly subjects  
 
Strains Number of  
isolates 
Number of 
subjects 
Number of  
isolates 
Number of 
subjects 
L. gasseri 8 5 1 A 
L. casei 3 2 1 B 
Ent. faecalis 4 2 1 C 
Pediococcus pentosaceus 3 3 1 D 
P. acidilactici 3 3 1 E 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2:  Minimum inhibitory concentrations of ciprofloxacin (µg ml
-1
)
 
of all bacterial strains 
isolated from this study 
Bacterial strains MIC 
(µg/ml) 
Ent. faecalis EM358-1 
L. gasseri EM296-T6-1 
L. casei EM324-1 
P. pentosaceus EM350-1 
P. acidilactici EM341-1 
150 
200 
200 
250 
250 
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Table 3:  Amino acid alignments of partially sequenced parC (codons 74-92) and gyrA (codons 
73-87) genes in the quinolone resistance determining regions (QRDRs) are presented 
Bacterial strains Resistance 
phenotype
a
 
Partial amino acid sequence
b
 Source or reference 
GyrA 
Ent. faecalis ATCC 19433 
Ent. faecalis E52 
Ent. faecalis E82 
L. acidophilus BFE 7429 
Ent. faecalis EM358-1 
L. gasseri EM296-T6-1 
L. casei EM324-1 
P. pentosaceus EM350-1 
P. acidilactici EM341-1 
 
 
S 
R 
R 
R 
R 
R 
R 
R 
R 
 
 
VMGKYHPHGDSAIYE 
VMGKYHPHGDSAIYG 
VMGKYHPHGDSAIYG 
VMGKFHPHGDSSIYL 
VMGKFHPHGDSSIYL 
VMGKFHPHGDSSIYL 
VMGKFHPHGDSSIYL 
VMGKYHPHGDSSIYE 
VMGKYHPHGDSSIYE 
 
(Petersen & Jensen 2006) 
(Petersen & Jensen 2006) 
(Petersen & Jensen 2006) 
(Hummel, Hertel et al. 
2007b) 
This study 
This study 
This study 
This study 
 
ParC 
Ent. faecalis ATCC 19433 
Ent. faecalis E52 
Ent. faecalis E82 
Ent. faecalis EM358-1 
L. gasseri EM296-T6-1 
L. casei EM324-1 
P. pentosaceus EM350-1 
P. acidilactici EM341-1 
 
 
S 
R 
R 
R 
R 
R 
R 
R 
 
 
YHPHGDSSIYEAMVRLSQD 
YHPHGDISIYEAMVRLSQD 
YHPHGDISIYEAMVRLSQD 
YHPHGDISIYEAMVRLSQD 
YHPHGDISIYEAMVRLSQD 
YHPHGDISIYEAMVRLSQD 
YHPHGDISIYEAMVRLSQD 
YHPHGDISIYEAMVRLSQD 
 
 
(Petersen & Jensen 2006) 
(Petersen & Jensen 2006) 
(Petersen & Jensen 2006) 
This study 
This study 
This study 
This study 
This study 
 
a 
R, resistant; S, sensitive 
b 
Amino acid substitutions resulting in resistant phenotype are bold and underlined. 
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Figure 1 Grouping of the macro-restriction patterns of the antibiotic resistant strains generated 5 
PFGE pulsotypes; termed A to E, on digestion of chromosomal DNA with ApaI restriction 
enzyme (Lane 1 is the marker (Ma)). 
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Discussion 
The ageing population is dramatically changing with a constant increase in the proportion of 
elderly people globally. At the global level, the number of those over the age of 60 is projected 
by the UN Population Division to increase from just fewer than 800 million (representing 11% of 
world population) to just over 2 billion in 2050 (representing 22% of world population). The 
world population is projected to increase 3.7 times from 1950 to 2050, but the number of those 
aged 60 and over will increase by a factor of nearly 10 (Bloom et al. 2011). Therefore it is not 
surprising that understanding the gastrointestinal microbiota of the elderly has received increased 
attention in recent years (Tiihonen et al. 2010; Forssten et al. 2011; Biagi et al. 2012b). 
ELDERMET (http://eldermet.ucc.ie) is an innovative project based at University College Cork 
(UCC), Cork area hospitals and Teagasc Food Research Centre, Fermoy, Co. Cork focuses on 
the elderly. This project aimed to determine the baseline composition of the faecal microbiota of 
the elderly Irish population and how it is influenced by both intrinsic and extrinsic factors. The 
project demonstrated that diverse dietary patterns may be responsible for the intestinal 
microbiota variation between community-dwellers and individuals in long-term residential care. 
This indicates a strong role for diet-driven microbiota towards health and in the progression of 
disease and frailty in older people (Claesson et al. 2012). The research in this thesis focused on 
selected culturable bacteria (Bifidobacterium spp., Lactobacillus spp. and Enterobacteriaceae) in 
faecal samples from elderly Irish subjects. We decided to focus on these three bacterial groups 
because of their probiotic potential (Bifidobacterium spp. and Lactobacillus spp.) and possible 
use as indicators of intestinal health (Enterobacteriaceae) (Lupp et al. 2007; Turroni et al. 2008; 
O'Flaherty & Klaenhammer 2010; Aureli et al. 2011).  
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The human gastrointestinal tract (GIT) is a complex ecosystem housing a dynamic and diverse 
microbial consortium estimated at up to 100 trillion (10
14
) bacterial cells (Clemente et al. 2012). 
The consequences of disturbances in the microbiota may sometimes result in the pathogenesis of 
chronic gastrointestinal disease including IBD, colon cancer, allergy and obesity (Aspinall & 
Meddings 2003; Ley et al. 2006; Mongan et al. 2010). Chapter 1 reviewed the current literature 
regarding the baseline composition and function of the gut microbiota along with the changes it 
undergoes and the therapeutic strategies employed to counteract these alterations. Novel 
sequencing technologies such as pyrosequencing have provided more in-depth analysis of the 
biodiversity of the intestinal microbiota (Claesson et al. 2010). The exploration of the human gut 
microbiota will possibly lead in the long-term to the identification of novel probiotics that 
possess more health benefits but more importantly to dietary strategies to modulate the 
composition of the microbiota in a positive direction.  
Culture dependent techniques had been the traditional method of exploration of the human gut 
microbiota up until relatively recently. Indeed, they have been extensively used to quantify lactic 
acid bacteria (LAB) from faecal material (Wall et al. 2007; O'Shea et al. 2008; Birri et al. 2010). 
The great advantage with cultivation is that isolates can be recovered and further characterised in 
detail including analysis of their antibiotic susceptibility pattern and bacteriocin production. 
However, molecular methods are now increasingly being applied since they give a truer 
representation of the entire microbiota including the uncultivable bacteria (Amor et al. 2007). In 
Chapter 2a we investigated the degree of correlation between the culture dependent and culture 
independent methods for quantifying selected bacterial genera or families including 
Bifidobacterium spp., Lactobacillus spp. and Enterobacteriaceae. The result showed a large 
variation in the levels of Bifidobacterium spp., Lactobacillus spp. and Enterobacteriaceae among 
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the subjects studied (n=185). The range of counts varied from <3.0 log (limit of detection) to 
10.7
 
log c.f.u. g
-1 
faeces for total bifidobacteria; from <3.0 log to 9.74 log c.f.u. g
-1
 faeces for 
total lactobacilli and from <2.0 log (limit of detection) to 10.0 log c.f.u. g
-1
 faeces for total 
Enterobacteriaceae. This investigation demonstrated that there is a correlation between culture 
dependent techniques and contemporary culture independent techniques, when enumerating 
Bifidobacterium spp., Lactobacillus spp. and Enterobacteriaceae (Spearman's rank correlation 
coefficients were 0.380, 0.366 and 0.437, respectively).  
While these bacterial groups are important, they represent only a small proportion of the overall 
intestinal microbiota. The correlation demonstrated within these groups may not be transferable 
to other bacterial groups as these groups are generally cultivable unlike many of the other 
intestinal inhabitants. It is also important to emphasize that for bacterial species resident in low 
numbers in the gut, pyrosequencing with general bacterial primers is not useful (Riesenfeld et al. 
2004). This is clearly demonstrated in our studies, where on some occasions no counts were 
observed from pyrosequencing (due to lack of sequencing depth); however, the culture method 
returned a count (albeit low). Correlation also depend on factors such as the selectivity of the 
culture medium, the ability of species to grow on the culture medium (uncultivable or non-viable 
cells), and the efficiency of universal primers in identifying all members of a taxon. Whilst 
culture dependent techniques remain valuable for isolating bacterial species for further analysis 
(e.g. novel probiotic strains), the correlation between the culture dependent and independent 
techniques highlights that a single method is sufficient to enumerate some selected major 
elements of the intestinal microbiota. However, both methods have advantages that justify their 
use in tandem. This was the first extensive study that compared the bacterial counts using both 
culture dependent methodologies and next generation sequencing technologies. 
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The balance and composition of the intestinal microbiota is important for the well-being of the 
host. In this respect, the ability of the human gut microbiota to remain stable in the face of 
continuous and potentially disruptive perturbations (such as antibiotic exposure, infection and 
inflammation) is thought to be highly important for health (Bäckhed et al. 2012). Hence, the 
temporal stability of the three groups of intestinal bacteria (Bifidobacterium spp., Lactobacillus 
spp. and Enterobacteriaceae) in faecal samples from 65 elderly subjects was monitored over a 6 
month period (Chapter 3). Contrary to data that indicate that the microbiota of the elderly can be 
easily perturbed by extrinsic factors (Jakobsson et al. 2010; Jernberg et al. 2010; Rea et al. 2012; 
O'Sullivan et al. 2013), this study demonstrated that the levels of the 3 bacterial groups analysed 
remained stable over the 6 month period reinforcing previous observations from pyrosequencing 
results (Claesson et al. 2011). Antibiotic administration did not significantly alter the temporal 
stability of the bacterial communities, however, the levels of Bifidobacterium spp. and 
Lactobacillus spp. tended to be lower (albeit not significantly) for the subjects on antibiotic 
therapy compared to antibiotic-untreated subjects. A recent study by Dethlefsen et al outlined the 
response of distal gut communities to antibiotic administration across three individuals, and 
found that the gut community returned to a stable state similar, yet distinct to the pre-treatment 
state (Dethlefsen & Relman 2011). Similarly, the population of the bacterial groups in our study 
fluctuated unpredictably with the use of different antibiotic types and treatment periods 
suggesting that the resilience of the gut microbiota varied between subjects. Regular probiotic 
consumption resulted in a significant increase in Bifidobacterium spp. by month 6, while there 
were no alterations in the other two bacterial groups studied. One of the major limitations of this 
study was the lack of molecular characterisation of the isolates to strain level, where undoubtedly 
even larger changes in the microbial population could have occurred. 
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The production of antimicrobials including organic acids, fatty acids and bacteriocins are often 
considered an important probiotic trait. In the last few decades much research has been 
undertaken to characterize the antimicrobial nature of many bacteriocins produced by LAB 
(Millette et al. 2007; O'Shea et al. 2008). Bacteriocins are a diverse group of ribosomally-
synthesized antimicrobial peptides against which the producing strains possess specific immunity 
(Cotter et al. 2005). The ability of bacteriocin producers to inhibit pathogens and protect the host 
against infections has been well documented (Corr et al. 2007; Millette et al. 2008). Chapter 4 
involved the isolation and characterization of bacteriocin-producing LAB of human intestinal 
origin. Faecal samples from subjects from diverse residence locations, including community and 
long-stay nursing homes were analysed. The predominant antimicrobial-producing species were 
identified as Lactobacillus salivarius, Lb. gasseri, Lb. acidophilus,   Lb. crispatus and 
Enterococcus spp. A number of previously characterized bacteriocins, including ABP-118 and 
salivaricin B (from Lb. salivarius), Enterocin B (Ent. faecium), Lactacin B (Lb. acidophilus), 
Gassericin T and a variant of Gassericin A (Lb. gasseri), were identified. Interestingly, two 
antimicrobial-producing species, not generally associated with intestinally-derived 
microorganisms were also isolated: Lactococcus lactis producing Nisin Z and Streptococcus 
mutans producing Mutacin II. The isolation frequency of the bacteriocinogenic isolates was 
found to be lower than expected (0.4% from total culturable bacteria) and did not represent a 
major part of bacteria culturable by the method employed in the study. It has also been widely 
documented that the elderly intestinal microbiota differs from younger adults (Biagi et al. 2011; 
Claesson et al. 2011) and that the compromised stability of the intestinal microbiota in the 
elderly (Mueller et al. 2006; Biagi et al. 2012a) may have resulted in the lower isolation of 
bacteriocin-producing strains. However, this study has resulted in the isolation of a panel of 
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bacteriocin producers with the potential to alter the gut microbiota when introduced as probiotic 
cultures.  
An unusual aspect of this thesis work was the isolation of the clinically significant Clostridium 
perfringens at high levels from a subset of these subjects (Chapter 5). Of the 368 faecal samples 
analysed, 28 samples (7.6% of samples) from 19 subjects yielded colonies that were atypical of 
Bifidobacterium spp. on Bifidobacterium selective medium, which were subsequently confirmed 
as C. perfringens. Interestingly, the isolation of similar C. perfringens strains from subjects 
residing in the same residence location suggested horizontal transmission within the hospital 
environment. The shedding level of C. perfringens in elderly hospitalized patients was in 
agreement with the previous studies (Yamagishi et al. 1976; Stringer et al. 1985; Benno et al. 
1989), where a high count was reported (in excess of 10
6 
c.f.u. g
-1
 faeces). The results suggest 
that such a high viable count (in excess of 10
6 
c.f.u. g
-1
 faeces) may be indicative of a less 
healthy microbiota in the intestine since elderly people residing in long-stay residential care were 
more frequent shedders. Microbiota composition analysis by amplicon sequencing was used to 
determine if the presence of C. perfringens was associated with an altered intestinal microbiota. 
There were many significant differences in the proportions of individual genera between the C. 
perfringens positive and negative subjects. A significant higher level of Clostridium spp. 
(P<0.0001) and significant lower level of Bifidobacterium (P=0.0363) were observed in the 
positive group. Furthermore isolation of all the C. perfringens strains from medium with higher 
concentration of mupirocin (up to 500 μg ml-1) suggests the limitation of using this antibiotic as a 
selective agent for Bifidobacterium spp.  
The discovery of antibiotics has revolutionized the treatment of infections and diseases and is 
one of the primary factors associated with extended life expectancy of humans. Knowledge of 
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the effect of antibiotic therapy on the composition of the intestinal microbiota is fundamental to 
the development of targeted treatments for improved health. Chapter 2b of this thesis assessed 
the impact of antibiotic therapy on the intestinal microbiota of 185 elderly Irish subjects from 
various residence locations using a combination of culture dependent and culture independent 
approaches. Echoing previous studies (Bartosch et al. 2004; Woodmansey et al. 2004) antibiotic 
therapy had a deleterious effect on Bifidobacterium spp. populations (a 7 fold decrease). In 
contrast, increased the levels of culturable lactobacilli populations (a 2.6 fold increase) were 
reported following antibiotic therapy. Assessment of the different antibiotic types revealed that 
the nucleic acid synthesis inhibitors had the most dramatic effect on Bifidobacterium spp. 
resulting in a 23 fold decrease. In contrast, the cell envelope antibiotics demonstrated a 10 fold 
increase in the Lactobacillus spp. levels. The consequences of an altered intestinal microbiota 
due to antibiotic therapy are not fully understood, but could include increased carriage of 
antibiotic resistance genes (Salyers et al. 2004; Jernberg et al. 2010). The selection pressure 
applied on the bacterial population during antibiotic usage is undoubtedly the driving force for 
the emergence of resistant bacteria (Levy & Marshall 2004).  
 
As mentioned by Felix Marti-Ibanez (1955) 
“Antibiotic therapy, if indiscriminately used, may turn out to be a medicinal flood that 
temporarily cleans and heals, but ultimately destroys life itself”.  
Since LAB are present in the GI tract in large amounts, there is growing interest in the possible 
role of LAB acting as reservoirs of antibiotic resistance genes (Mathur & Singh 2005). In 
addition to the properties that define a bacterial strain as being “probiotic”, the antibiotic 
resistance and the ability to act as a donor of antibiotic resistance genes must also be assessed. 
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Thus, the combination of antibiotic and probiotic intake can provide a potential advantage in the 
treatment of bacterial disorders by aiding the recovery of intestinal microbial imbalance. Thus 
the objective of Chapter 6 was to isolate and characterize LAB with increased resistance to 
clinically important antibiotics including ciprofloxacin and amoxicillin and also elucidate the 
molecular determinants underlying the resistance. The gyrA genes of the quinolone resistance 
determining region (QRDR) for the isolates with increased ciprofloxacin resistance showed no 
typical mutations in the amino acid codons. However, in parC, a single amino acid change was 
discovered, suggesting that mutation in topoisomerase IV may simply be a contributor to high 
level resistance along with other mechanisms such as reduced permeability of quinolones across 
the cell membrane (Kumagai et al. 1996; Lee et al. 2005). Further work would be required to 
confirm the role of parC in quinolone resistance observed in our isolates. This study opens up the 
possibility of using antibiotic resistant probiotics to offset the problems which antibiotics cause 
to the gut microbiota. Such strains could be particularly effective to treat people on long term 
antibiotic treatment such as cystic fibrosis sufferers. Of course, this hypothesis would need to be 
assessed in rigorous human clinical studies.  
Culture collection and gene banks are at the very heart of efforts to conserve bacterial diversity. 
One of the major parts of thesis work was the generation of a large bank of selected beneficial 
gut bacteria (lactobacilli and bifidobacteria) from hundreds of elderly subjects. This 
ELDERMET Culture Collection (EMCC) will be screened for potential probiotics and can be 
used to develop the next generation of functional foods for the elderly. A total of 6,500 bacterial 
isolates are currently stored in the ELERMET culture collection, which constitutes an invaluable 
bank of bacterial cultures for future characterization and exploitation.  
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Overall Conclusions 
The adaptation of the gut microbiota to our changing life-style is probably the reason for the 
large inter-individual variation observed among different people. Since the gut microbiota plays 
an essential role in interactions with host metabolism, it is of utmost importance to explore this 
relationship. The elderly intestinal microbiota has been the subject of a number of studies in 
recent years. The results presented in this thesis have further contributed to the expansion of 
knowledge related to gut microbiota research highlighting the combined effect of culture based 
and molecular methods as powerful tools for understanding the true impact of microbes. 
Bacteriocins have shown great promise as alternatives to traditional antibiotics. In this respect, 
the isolation and characterisation of bacteriocinogenic and antibiotic resistant strains can be 
exploited for their potential as possible agents in the control of infections and to improve the 
intestinal microbial environment. Future work is required to explore the culture collection 
housing thousands of bacterial isolates as a valuable source of potential probiotics for use for the 
elderly Irish community. 
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